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Abstract  
Nuclear envelope spectrin repeat proteins, or Nesprins, are a novel 
family of nuclear and cytoskeletal proteins with rapidly expanding roles as 
intracellular scaffolds and linkers.  Nesprins are characterized by a central 
spectrin repeat (SR) rod domain and a C-terminal KASH domain, which acts 
as a nuclear envelope (NE) targeting motif.  At the NE, via interactions with 
the Sun domain family of proteins and the nuclear lamina, nesprins on both 
the inner and outer nuclear membranes form the linker of the nucleoskeleton 
and cytoskeleton (LINC) complex.  This complex requires the giant nesprin-1 
and nesprin-2 isoforms, which possess a pair of N-terminal calponin 
homology domains that bind directly to Filamentous-actin. However, via 
alternative promoter usage and alternative 3’ end processing, the  nesprins 
are able to generate multiple mRNA transcripts, leading to the production of 
diverse tissue specific isoforms with potential roles beyond the NE.   
To explore further the capacity of nesprin-1 to generate alternative 
transcripts, 5’ and 3’ RACE was performed to identify cDNA ends which 
represent novel 5’ and 3’ untranslated regions (UTRs) respectively.  By 
alternatively combining the differential 5’ and 3’ UTRs, multiple tissue specific 
nesprin-1 variants could be generated.  Transfection of tagged constructs 
showed localizations to multiple sub-cellular compartments such as the 
nucleolus, focal adhesions, actin stress fibres and cytoplasmic particles, 
supporting the notion that nesprins are more than NE-cytoskeletal couplers.  
 One of these novel nesprin-1 variants, p50Nesp1, was found to localize 
to cytoplasmic RNA granules called mRNA processing bodies (P-bodies).  
Using GST pull-downs and co-immunoprecipitations (co-IPs), p50Nesp1 was 
found to complex with mRNA decapping factors and translational repressors.  
Furthermore, p50Nesp1 was required for the efficient silencing function of 
miRNAs, shown using luciferase reporter constructs.  More importantly, 
p50Nesp1 associated strongly with microtubules, both in vitro and in vivo, and 
was required for scaffolding P-body complexes to microtubules.  By disrupting 
P-body-microtubule association with a dominant negative p50Nesp1 construct, 
time-lapse microscopy demonstrated impairment of fluorescently-labelled P-
body proteins.  Furthermore, this disruption resulted in P-bodies failing to 
	   10 
associate with RNA stress granules and transferring β-globin mRNA reporter 
transcripts between compartments during the stress response.      
Further co-IP experiments identified a host of mRNA processing 
proteins that also associated with nesprin-1, including Matrin-3; an abundant 
nuclear matrix protein involved in a number of key nuclear processes.  A 
novel isoform of matrin-3 localized to P-bodies and was required for miRNA-
mediated translational repression.  By identifying and tethering matrin-3 P-
body localizing domains to a luciferase reporter construct, it was also found 
that matrin-3 could induce translational repression, which was significantly 
hampered when a single point mutation (S85C), previously described in a 
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Chapter 1: Introduction 
The eukaryotic cytoplasm contains three major types of cytoskeletal 
filaments: Filamentous-actin (F-actin), microtubules and intermediate 
filaments.  These components provide cells with internal scaffolds which 
regulate cell shape, cell polarity, cell adhesion and migration, cytokinesis, 
inter- and intracellular communication, and intracellular trafficking of cellular 
organelles, vesicles, proteins and RNA [2,3].   
 Spectrin repeat (SR) containing proteins have been identified as key 
cytoskeletal scaffolds and linkers [4].  SR proteins not only cross link different 
components of the cytoskeleton but also scaffold protein complexes and 
organelles, allowing cells to undergo dynamic re-modelling in response to 
altered mechanical cues.   
  Nuclear envelope spectrin repeat proteins, or Nesprins, are the latest 
family of SR proteins associated with nuclear and cytoplasmic signalling and 
scaffolding events [5,6].  In this chapter, I will comprehensively review the 
structural properties that distinguish nesprins from other SR proteins, their 
rapidly expanding roles in cellular signalling and scaffolding processes, and 
diseases associated with nesprin mutations.   
1.1 Spectrin Repeat super family      
The SR super family is composed of a number of SR proteins including 
α-actinins, α/β spectrins, dystrophins, spectraplakins and the nesprins.  All the 
family members are typically characterized by an N-terminal calponin 
homology domain (CHD) which binds F-actin, and a rod domain composed of 
multiple SRs.  The SR superfamily are generally distinguished by their C-
terminal domains which give the individual proteins a specialized function 
(Figure 1.1) [4].  Mutations in SR proteins lead to a wide range of diseases, 
emphasizing their functional importance in multiple tissues (Table 1.1).      
1.1.1 α-Actinin 
 In humans, α-actinin-1, α-actinin-2, α-actinin-3 and α-actinin-4 are 
encoded by four separate genes [7,8,9].  α-actinins consist of an N-terminal 
CHD, a central rod composed of four SRs and two C-terminal EF- hands, a 12  
	   21   
	   22 






























































































	   23 
residue helix-loop-helix Ca2+ binding domain (Figure 1.1) [23,24].  The α-
actinin SRs facilitate their anti-parallel homodimerization, bringing the CHD in 
close proximity to the EF hands, which may convey calcium-sensitivity to 
CHD-mediated interactions.  α-actinins cross-link actin fibres to the plasma 
membrane, facilitate cellular migration and are also key structural components 
of contractile apparatuses in striated muscle sarcomere and smooth muscle 
dense bodies [25,26,27,28].  Of the SR super family, α-actinins are one of the 
simplest SR proteins and are believed to be the early evolutionary precursors 
[29,30,31]. 
1.1.2 α- and β-Spectrins  
 As signalling pathways and cellular architecture became increasingly 
complex, SR proteins evolved into larger, more diverse scaffolds.  αI-spectrin  
and βI-spectrin are the primary components of the human erythrocyte 
cytoskeleton [32,33,34]. Mutations in these proteins distort red blood cell 
morphology, leading to a wide range of haematologic disorders.  Non-
erythrocytic family members αII-spectrin, βII-spectrin, βIII-spectrin, βIV-
spectrin, and βV-spectrin provide structural support for the plasma membrane 
as well as intracellular membranous organelles, such as the Golgi and 
trafficking vesicles [35,36,37,38]. Both α- and β-spectrins contain a central SR 
rod, however α-spectrins usually possess two C-terminal EF hands while β-
spectrins are characterized by an N–terminal CHD and a C-terminal pleckstrin 
homology domain (PHD) which facilitates membrane association [39,40].  The 
α-spectrins are also characterized by a src homology-3 (SH3) motif which 
serves as a cytoskeletal and signalling protein docking site (Figure 1.1). 
[41,42]. Similar to the α-actinins, α- and β-spectrins can form anti-parallel 
heterodimers, which then couple end-to-end to form an actin cross-linking 
heterotetramer [43,44].  
1.1.3 Dystrophins and Utrophins 
Dystrophin, and the closely related homologue utrophin are larger SR 
scaffolds which link the cytoskeleton to the extra-cellular matrix (ECM).  The 
~430 kDa dystrophin connects the skeletal muscle sarcolemma to the actin 
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cytoskeleton, sarcomere and basement membrane via interactions with β-
dystroglycan, a plasma transmembrane glycoprotein which forms a complex 
with extracellular laminin-binding α-dystroglycan [45,46].  Utrophin is a 
ubiquitously expressed dystrophin which can partially compensate for the loss 
of dystrophin expression [47,48,49].  The two proteins have similar overall 
structures, with dystrophin containing a greater number of SRs [50] (Figure 
1.1).  
Unlike the α-actinins and α/β spectrins, the divergent SRs of the 
dystrophin family do not facilitate dimerization in vitro and therefore the 
dystrophins are not believed to promote actin cross-linking.  Instead, the 
dystrophins anchor the dystrophin-glycoprotein complex (DGC) to actin via 
their N-terminal CHDs and unique C-terminal WW and Zn-finger motifs.  The 
WW domain consists of two Tryptophan residues separated by 21 amino 
acids that binds to a conserved PPPY sequence in the cytoplasmic C-terminal 
portion of β-dystroglycan.  The Zn-finger and EF hands, both located within a 
cysteine-rich domain, stabilize the WW interaction with β-dystroglycan (Figure 
1.1).  The SR rod of dystrophin, but not utrophin, can also directly interact with 
actin and provides an alternative CHD-independent connection to the 
cytoskeleton [51,52,53].   
1.1.4 Spectraplakins 
Spectraplakins were named based on their shared features of both the 
SR and plakin super families.  Members of the plakin super family were 
originally identified as proteins of the epithelium, which secured keratin based 
intermediate filaments to desmosomes and hemidesmosomes.  The two 
major spectraplakins in humans are the bullous pemphigoid antigen 1 
(BPAG1) and microtubule-actin cross-linking factor 1 (MACF1) [54]. 
 Spectraplakins contain several distinct motifs in addition to the SR rod, 
CHD and EF hands.  A plakin domain (PD) proximal to the N-terminus, 
contains of four divergent SRs interrupted by an SH3 domain and is 
necessary for targeting to the hemidesmosome [55,56,57].  Because the 
majority of plakin superfamily members, such as desmoplakin, envoplakin, 
plectin, and peri-plakin also contain PDs, they can be considered close 
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relatives of the SR protein superfamily [57,58].  Plakin repeats, 38 aa motifs 
organized into a β-hairpin and two anti-parallel α-helices, convey intermediate 
filament binding to spectraplakins and are also capable of binding to other 
cytoskeletal proteins such as peri-phillin [59,60,61,62].  Finally, a C-terminal 
growth arrest specific-2 (GAS2)-related (GAR) domain, which is absent from 
other plakins and SR proteins, facilitates microtubule bundling (Figure 1.1). 
[63,64,65].  These domains make spectraplakins master cytoskeletal cross-
linkers of microtubules, actin and intermediate filaments.   
 The dystrophins and spectraplakins were once the largest scaffolding 
protein family encoded by the human genome, but have now been replaced 
by the relatively newly identified Nesprins. 
1.2 Nesprins  
 To date, four nesprin genes have been identified in vertebrates;  
nesprin-1 on chromosome 6q25, nesprin-2 on chromosome 14q23, nesprin-3 
on chromosome 14q32.13 and nesprin-4 on chromosome 19q13.12.  Full 
length nesprin-1 and nesprin-2 are giant proteins with molecular weights of 
~1000 kDa and ~800 kDa respectively, making them the two largest SR 
proteins.  Nesprin-3 and nesprin-4 are of a more modest size, with molecular 
weights of ~110 kDa and ~42 kDa respectively [66,67,68,69].  
 Nesprins differ from other SR proteins as they localize to the nuclear 
envelope (NE) via their unique C-terminal Klarsicht, ANC-1 and Syne 
homology (KASH) domains.  The N-terminal domains of the nesprins interact 
with various components of the cytoskeleton and molecular motors, 
suggesting the primary function of nesprins is to act as a cytoskeletal-NE 
scaffold [6].  As with the other SR family members, nesprin-1 and nesprin-2 
associate with F-actin through a pair of N-terminal CHDs [67].  Nesprin-3 and 
nesprin-4 differ in their N-terminal domains with nesprin-3 possessing a 
plectin binding domain which links the NE to the intermediate filament network, 
while nesprin-4 has a kinesin-1 binding domain which links the NE to the 
microtubule network [68,69] (Figure 1.1). 
 Nesprins have been described as multi-isomeric proteins that can 
generate truncated KASH variants that have the ability to localize on both the 
inner and outer NE membranes.  Furthermore, KASH-less nesprin variants 
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have been described which localize to sub-cellular compartments beyond the 
NE, suggesting nesprins are SR proteins with global cellular localizations and 
functions.  The multi-isomeric nature of nesprins will be described throughout 
the latter sections of this thesis chapter.          
1.2.1 Nesprin cytoskeletal binding domains  
1.2.1.1 Calponin homology domain      
 A pair of N-terminal CHDs are present in multiple SR proteins, 
including those described so far.  The CHD is composed of ~100 amino acids 
that form four α-helices connected by interspersed loops [70,71].  Nesprins 
and other SR proteins possess two CHDs, designated CHD1 for the most N-
terminal motif and CHD2 for the adjacent motif.  The tandem arrangements of 
the two motifs bind F-actin with high affinity, with CHD2 acting as an enhancer 
binding motif [71,72].  The affinity of F-actin for the CHDs was previously 
shown to be regulated by alternative splicing, post-translational modifications 
and through signalling modules like calmodulin in other SR proteins, 
suggesting that the strength of F-actin binding is variable and tightly regulated 
[73,74,75,76,77].   
 The two CHDs of nesprin-1 and nesprin-2 are separated by a 45-50 
amino acid Proline and Serine rich region, whilst the CHDs in dystrophin are 
separated by a 15 amino acid a-helical linker.  This suggests the nesprin 
CHDs may have a higher degree of flexibility in enhancing the spatial 
versatility of actin binding [78]. 
 
1.2.1.2 Plectin binding domain         
  The N-terminus of nesprin-3 interacts with plectin, a member of the 
plakin family of cytoskeletal linker proteins.  Interestingly, nesprin-3 was 
initially identified as a binding partner of the plectin CHD in a yeast two-hybrid 
screen.  The nesprin-3 gene encodes for two nesprin-3 variants, nesprin-3α 
and nesprin-3β.  Both variants retain the C-terminal KASH domain, however 
only the larger nesprin-3α is able to interact with plectin [68].  Plectin is a 
highly versatile molecule that is able to cross-link the actin cytoskeleton and 
microtubules with intermediate filaments via its N-terminal CHDs and C-
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terminal plakin repeats [79].  The overlapping binding sites for F-actin and 
nesprin-3 within plectin means that plectin can either associate with F-actin or 
nesprin-3.  As a consequence, plectin can only interact with intermediate 
filaments when bound to nesprin-3α [80]. 
 The CHD of plectin has high homology to the CHD of MACF-1 and 
specific neuronal and muscle BPAG1 variants.  Therefore, it has been 
proposed that nesprin-3 may also be able to interact with the CHD of MACF-1 
and BPAG1, allowing nesprin-3 to also associate with microtubules in a 
MACF-1 or BPAG1 mediated manner.  The ability of nesprin-3 to act as a 
cytoskeletal switchboard could allow cells to rapidly change cytoskeletal-
nuclear dynamics in response to both intra-nuclear and/or extra-nuclear 
signals [68,81].  
 
1.2.1.3 Kinesin Binding domains       
 Over recent years, multiple kinesins have been identified to interact 
with the SRs of nesprins-1, -2 and -4.  The heavy chain subunit of kinesin-1, 
kif5b was identified as a binding partner for nesprin-4, an epithelial specific 
nesprin protein [69].  When nesprin-4 was overexpressed in HeLa cells, it 
induced cell polarization and there was a significant increase in the distance 
of the centrosome from the nucleus, indicating a possible role in microtubule-
dependent nuclear positioning. Kif3b, a subunit of kinesin-2, was identified 
as a nesprin-1 binding partner when a portion of the central SR rod region of 
nesprin-1 was used as bait in a yeast-two-hybrid screen.  Overexpression of 
the SRs which associate with kif3b, promoted accumulation of binucleated 
cells, suggesting a role for nesprin-1 in cytokinesis [82].  More recently, 
nesprin-1 and nesprin-2 were found to interact with dynein and kinesin-1 
motor proteins in the developing mouse brain.  Loss of these interactions in 
double nesprin-1/2- KASH knockout mice uncoupled the centrosome from the 
neuronal nucleus resulting in severe nucleokinesis and inter-kinetic nuclear 
migration defects [83].  These findings suggest that other kinesin binding sites 
may exist throughout the nesprin family, allowing different kinesins to be 
recruited to the NE using different nesprins variants.  
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1.2.2 Spectrin repeat rod domain      
SRs are composed of triple α-helical bundles with a left-handed twist 
[84,85,86,87].  These α-helices are characterized by 7 amino acid heptad 
repeats also found in the less ordered coiled-coil motifs of structural and 
signalling proteins [88,89].  Multiple SRs combine to form a flexible rod which 
separates the specialized N- and C-terminal domains of SR proteins.  In 
addition to its functions as a domain spacer, the SR rod scaffolds signalling 
complexes and can directly interact with cytoskeletal proteins [51,90,91,92,93].  
 The SR rod domain of nesprins is made up entirely of SRs, forming an 
almost complete run of unbroken repeats from the N-terminus to the C-
terminal KASH domains.  Nesprin-1 is composed of 72 SRs, neprin-2 contains 
56 and nesprin-3 is made up of 8 SRs, making rod domains which are 
~400nm, 300nm and 40nm long respectively.  All 8 SRs of nesprin-3 appear 
to be highly conserved with those of nesprin-1, whereas the majority of SRs in 
nesprin-2 are highly conserved with those in nesprin-1 [78].  As lower 
organisms only have one nesprin orthrologue, nesprin-2 and nesprin-3 may 
have developed during evolution through gene duplication and mutations in 
nesprin-1.  
1.2.3 KASH domain 
 The KASH domain is the minimal sequence required for targeting 
nesprins to the NE.  The domain is a typical type II transmembrane sequence 
followed by a C-terminal tail that extends into the NE lumen [94,95].  The 
KASH domain tail terminates in a conserved PPPX motif which binds to the 
lumenal Sad1p-UNC84 (SUN) domain of the inner nuclear membrane type II 
transmembrane Sun proteins, and is required for anchoring nesprins to the 
NE [95,96,97].   
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1.3 Nuclear Envelope  
1.3.1 Structure and function  
The nucleus is surrounded by a system of two concentric membranes, 
referred to as the inner nuclear membrane (INM) and outer nuclear 
membrane (ONM).  Together, these two membranes make up the NE and 
separate the cells nuclear contents from the cytosol.  The highly organized 
double membrane structures are separated by a ~50nm lumen, perforated by 
nuclear pore complexes (NPCs) that control protein and RNA trafficking 
across the NE.  Although the ONM and INM are continuous membranes, the 
macromolecular compositions of the two sides vary.  The ONM is continuous 
with the peripheral endoplasmic reticulum (ER), the primary home of 
ribosomes and site of protein synthesis.  The continuity between the two 
structures makes it difficult to distinguish whether proteins are ER-associated 
or NE-associated, however there appears to be a high degree of 
heterogeneity [98].  Although the giant/full-length nesprins are primarily ONM 
associated, they are able to localize within the ER boundary when its 
functional NE spanning complexes are abrogated [99].  However, the INM 
seems to host a wider range of NE transmembrane proteins, which play roles 
in linking ONM nesprins and the INM to the underlying nuclear lamina.  The 
nuclear lamina is composed of polymerized lamins which form type-V 
intermediate filament proteins, or a nucleoskeleton, which provides structural 
support to the nucleus and a scaffold for nuclear signalling complexes 
[100,101,102,103].  Conventional cell biological techniques initially only 
identified ~15 NE transmembrane proteins, including the well characterized 
Emerin, Sun-domain proteins, Lamin Associated Polypeptides (LAPs), LEM 
domain containing protein 3 (MAN1), Lamin B Receptor (LBR) and smaller 
nesprin isoforms, concentrated around the NE [98,104,105] (The individual 
transmembrane proteins are further described throughout this thesis).  
However, proteomics analysis of the NE has identified an additional 67 
potential transmembrane proteins [106].  Although many of these proteins 
have yet to be characterized, when 8 of the detected NE proteins were 
transfected into cultured cells, they all displayed NE localization suggesting 
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that the other proteins identified through this screen will also prove to be NE 
proteins [106].  As well as identifying nesprin-1 and -2, multiple proteins 
contained the conserved LEM-domains, named for its occurrence in the NE 
proteins LAP2, Emerin, and MAN1 [103].  Twelve of the 67 proteins contained 
additional functional domains such as phosphatases, acetyltransferases, and 
glycosyltransferases, suggesting transmembrane proteins with enzymatic 
activity are located within the INM.  Furthermore, extensive proteomic analysis 
of the INM has shown the NE transmembrane proteome to exhibit some 
variations amongst different tissues [107].  Tissue specific NE transmembrane 
proteins suggest the nucleus may scaffold cell-type specific NE-associated 
protein complexes, which may regulate specific intra-nuclear organization and 
signalling cascades, consequently explaining the tissue specificity exhibited 
by many NE-linked disorders.   
 
1.3.2 Nuclear lamina         
 The type-V intermediate filament proteins which make up the nuclear 
lamina are composed of polymerized lamin proteins.   Lamins can be divided 
into two classes, 1) A-type lamins; lamin A, lamin AΔ10, lamin C, and lamin 
C2 are tissue specific lamins generated by alternative splicing of the LMNA 
gene [108,109,110,111].  2) B-type lamins; lamin B1 and lamin B2 are 
encoded by the LMNB1 and LMNB2 genes respectively, and are ubiquitously 
expressed [112].  Other components of the lamina include lamin associated 
polypeptides LAP1 and LAP2, MAN1, Emerin and DNA-binding protein barrier 
to auto-integration factor (BAF) [113,114,115,116].   
 
1.3.2.1 Lamins and development        
 The composition of the nuclear lamina is highly dynamic and 
undergoes extensive re-modelling throughout development in a tissue specific 
manner.  Most cells express at least one B-type lamin at all stages of 
development [117,118,119].  A-type lamins are absent in early embryonic 
development, embryonic stem cells and certain stem cell populations in adults 
and seem to appear at the onset of tissue differentiation [120,121].   
Although A-type lamins are not essential for viability, LMNA knockout 
mice exhibit growth retardation 2-3 weeks post-birth, muscular dystrophy at 3-
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4 weeks, dilated cardiomyopathy at 4-6 weeks and die at approximately 8 
weeks of age [122,123].    
 The lamin A protein undergoes extensive post-translational 
modification to become mature lamin A which resides at the NE.  The 
expression levels of one of the processing enzymes, Zmpste24/Face-1, 
decreases throughout ageing, resulting in the accumulation of a lamin A 
precursor (pre-lamin A) [124,125].  Pre-lamin A within the nuclear lamina 
results in cellular senescence associated with changes in gene expression, 
heterochromatin organization, and failure to effect DNA repair 
[126,127,128,129].  
 
1.3.2.2 Lamin binding proteins      
 Lamin A and INM proteins interact with chromatin-associated proteins, 
including H2A-H2B histone dimers and the non-histone proteins Ha95, Baf 
and the heterochromatin protein-1 (HP1), which can affect chromatin re-
modelling and modulate gene silencing through heterochromatin organization 
[130,131,132,133].  The multi-molecular complexes associated with the 
nuclear lamina represent functional platforms at which factors involved in DNA 
replication, cell survival, and tissue-specific transcription factors can interact 
to modulate gene expression [131,134].       
 Specific transcription factors have been shown to interact with nuclear 
lamina proteins, modulating their activities [135]. Lamin A-LAP2a complexes 
in the nuclear interior bind the tumour suppressor retinoblastoma (Rb) protein, 
impairing the expression of E2F-target genes upon cell cycle exit and 
differentiation. [136,137].  Functional interactions among lamin A/C, 
phosphorylated-Rb (pRb) and cyclin D3 occur in muscle cell differentiation 
[138].  In many cases, the nuclear lamina appears to be able to temporarily 
sequester transcription factors, preventing their binding to target genes [139].  
Lamin A/C has been demonstrated to bind c-Fos, which in serum-starved 
quiescent cells, is retained at the nuclear periphery; upon serum addition c-
Fos is released to the nucleoplasm, thus forming together with c-Jun the 
transcription factor activating protein-1 (AP-1) [140].  Interaction of lamin A 
with the sterol response element binding protein-1 (SREBP1) appears 
particularly intriguing, as the transcription factor is involved in multiple 
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differentiation pathways.  Pre-lamin A is able to bind SREBP1 in vivo and to 
negatively regulate SREBP1 nuclear translocation in adipocytes.  Therefore, it 
is thought that pre-lamin A limits the access of SREBP1 to the nuclear interior 
[141].  The tethering of transcription factors to the NE might aid in fine-tuning 
pathways that are prone to fluctuations, such as growth factor signalling.  In 
particular, the nuclear lamina might bind and inactivate transcription factors to 
ensure that no transcription occurs when activating signals are absent [139]. 
 
1.3.2.3 The nuclear lamina in cellular signalling    
 The ability of the nuclear lamina to interact with various transcription 
factors suggest that lamins can be viewed as signalling modules of the 
nucleus, which are able to receive signals from the extra-nuclear environment 
and transduce them within the nucleus.       
Lamin A/C has been reported to bind TGF-β induced smads 2/3 and 
repress TGF-β/smad dependent gene expression [142].  Furthermore, altered 
signalling via smads occurs in cells bearing mutations in lamin A/C binding 
partner MAN1.  Wild-type MAN1 is able to bind smads and antagonize TGF-β 
signalling by retaining active smads within the cytosol [115].  Mutant MAN1 
leads to enhanced smad signalling, promoting osteoblast differentiation and 
increased bone density [143].         
Rb is an important regulator of cell cycle exit through modulation of the E2F 
transcription factor.  In LMNA knockout mice, the Rb pathway is affected and 
targets of Rb signalling such as MyoD, Desmin and M-cadherin are down 
regulated [144].         
 Zmpste24/Face-1 knockout mice accumulate pre-lamin A within the 
nuclear lamina, making them an ideal model for mimicking an aged phenotype.  
Hyper activation of the p53 pathway occurs in Zmpste24 knockout mice and is 
directly linked to premature ageing, since double knockout of p53 and 
Zmpste24 partially rescues the ageing phenotype [145].  The Zmpste24 
knockout mice and the p53 pathway provide a good example of how nuclear 
signalling pathways change in response to alterations in the nuclear lamina.
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1.3.2.4 Nuclear envelopathies and Laminopathies     
 Nuclear envelopathies or laminopathies are genetic diseases arising 
from mutations or altered post-translational processing of NE/lamina proteins. 
The majority of laminopathies are caused by mutations in the LMNA gene, 
with ~410 different mutations identified to date.  These mutations manifest in 
a diverse range of tissue specific pathologies including cardiomyopathies, 
muscular dystrophy, lipodystrophy, neuropathy, and progeroid syndromes 
(Table 1.2) [146].           
The underlying mechanisms of how mutations in lamina proteins cause 
laminopathies remain elusive.  Defects in the ability of lamins to associate 
with their binding partners or impairments in the lamin associated signalling 
pathways described so far may be accountable for the tissue specific nature 
of laminopathic diseases [146,147,148].  Another plausible explanation 
surrounding laminopathies is based on the ‘structural hypothesis’, which 
involves maintaining the mechanical integrity of the cell through the LINC 
(linker of nucleoskeleton and cytoskeleton) complex; a transmembrane 
complex bridging the nuclear lamina to the cytoskeleton (see below) [97].  A 
‘weakened’ lamina, contributing to the overall loss of the cells ability to 
withstand stress-induced damage would have a significant impact in 
contracting tissues, such as those which make up skeletal and cardiac muscle 
[149,150,151].  Furthermore, both lamin A/C-null and emerin-null mouse 
fibroblasts show impaired mechano-sensitive transduction pathways involving 
NF-κB–regulated transcription in response to mechanical or cytokine 
stimulation [150,152,153]. 
1.4 Nesprins link the nucleoskeleton to the cytoskeleton 
1.4.1 The LINC complex 
Nesprins associated with components of the cytoskeleton are recruited 
to the ONM of the NE via their KASH domains.  At the NE, the PPPX C-
terminal peptide sequence of the KASH domain binds to the lumenal domain 
of the inner nuclear transmembrane Sun proteins to form a double membrane 
spanning complex [94,95,96,97,154,155].  The Sun proteins in turn interact 
with components of the nuclear lamina underlying the nuclear interior to form  
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Table 1.2 Nuclear envelopathies display a range of phenotypes 
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a NE membrane spanning complex which joins the cytoskeleton to the 
nucleoskeleton, referred to as the ‘linkers of nucleoskeleton to cytoskeleton’ 
(LINC) complex [154].  Nesprin-1α and nesprin-2β are small nesprin KASH 
variants that have previously been identified to be embedded within the INM.  
At the INM, their SRs project towards the nuclear lamina where they are able 
to strongly interact with lamin A/C and emerin, suggesting they may be 
integral in proving scaffolds at the INM for transmembrane proteins and the 
nuclear lamina (Figure 1.2) [14,169].  Specific mutations in lamin A/C and 
emerin which result in Emery Dreifuss Muscular Dystrophy (EDMD), disrupt 
interactions with nesprin-1α and nesprin-2β, highlighting the importance of 
this interaction in muscle diseases [170].          
  The LINC complex has mainly been characterized to serve three major 
functions; 1) To anchor the nucleus to the cytoskeleton and govern nuclear 
positioning, 2) facilitate the transfer of mechanotransductive signals to the 
nucleus, 3) regulate the organization of cytoskeletal filaments at the NE.
 LINCs are evolutionarily conserved, with KASH-SUN partnerships 
identified in Schizosaccharomyces pombe (S. pombe), Caenorhabditis 
elegans (C. elegans), Drosophila melanogaster (D. melanogaster), as well as 
vertebrates [154,171,172,173,174,175].   
 
1.4.1.1 Actin LINCs         
 The most characterized nesprin LINCs are those associated with 
F-actin, through nesprin-1 and nesprin-2.  The actin LINCs mediate the 
mechanical properties of the entire cell by propagating mechanotransductive 
signals between the cytoplasm and the nucleus [176].  Uncoupling actin-
LINCs by overexpressing a dominant negative nesprin KASH domain 
(dnKASH) construct or using cells from nesprin-1 KASH domain knockout 
mice, results in nuclear morphology defects, abnormal localization of skeletal 
muscle nuclei and defects in strain transmission between the cell and nucleus.  
Furthermore, uncoupling of the nucleus from the actin cytoskeleton triggers a 
loss of cellular tension. This loss of tension impacts on maturation of focal 
adhesions, important macromolecular cell–matrix adhesions that transmit 
mechanical force and other signals, as well as on cell motility    
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[159,177,178].  This suggests that nuclear tethering to the actin cytoskeleton 
may be crucial for F-actin organization throughout the cell.    
Recently, the N-terminal SRs of nesprin-3 have been shown to interact 
with the N-terminal SRs of nesprin-1 and also directly with F-actin [179].  
Although the significance of these findings still remain unclear, emerging 
evidence suggests that nesprin-3 may be a master organizer of the way 
cytoskeletal networks form around the NE, given its capabilities to interact 
with all three major cytoskeletal filaments [68,80,180,181].   
 
1.4.1.2 Intermediate filament LINCs       
By associating with plectin, nesprin-3 is the only known nesprin which 
links the nucleus to the intermediate filament (IF) network and forms a 
connection between the NE and hemidesmosomes [68,182]. Nesprin-3 
appears to be central to IF LINC complex function as both plectin and keratins 
are drawn to the nuclear periphery of keratinocytes overexpressing nesprin-
3α [68].  It has been proposed that when F-actin is naturally or experimentally 
depolymerised, the nesprin-3-dependent re-localization of endogenous plectin 
to the nuclear periphery may facilitate rapid reorganization of the cytoskeletal 
structures [68]. In endothelial cells, siRNA-mediated nesprin-3 
knockdown resulted in a reduction of plectin and loss of vimentin around the 
nucleus; promoting increased separation between the centrosome and the 
nucleus.  As a result, nesprin-3 depleted endothelial cells adopted an 
elongated phenotype and were inhibited to flow induced polarization in a 
shear stress flow assay [183].  Furthermore, nesprin-3 knockout zebrafish had 
reduced concentrations of IFs around the nuclear periphery, which did not 
hamper embryonic development, viability or fertility of the fish [80].  Studies 
have demonstrated that IF localization around the nucleus is partially 
dependent on nesprin-2, therefore compensatory mechanisms may arise in 
nesprin-3 deficient zebrafish and provide an explanation as to why no 
phenotype is observed [184]. 
 
1.4.1.3 Microtubule LINCs        
 By connecting the nucleus to the microtubule network, nesprins form 
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microtubule motor LINCs with the centrosome that help govern cell polarity 
and cytokinesis.  As described before, kinesin binding domains have been 
identified in nesprins-1 and -4 [69,83].  With nesprin-3 also having the 
potential to interact with microtubules via associating with MACF1 or BPAG1, 
multiple microtubule LINCs could potentially be established [180].       
With the four nesprin genes displaying cell/tissue specificity to a certain 
degree, it is likely that different specialized microtubule LINCs are established 
to meet the cells needs.  For example, nesprin-4 is only expressed in 
specialized secretory epithelial cells where it is thought to be essential for 
establishing centrosome positioning and cell polarity [69].  On the other hand, 
nesprin-3 is more ubiquitously expressed and the LINCs it establishes may be 
dependent on the availability of plectin, MACF1 and BPAG1 [68].  The larger 
nesprin-1 and nesprin-2 proteins are enriched in muscle and could play a role 
in cross-linking CHD bound F-actin to SR bound microtubule motors [185].     
 
1.4.2 Functions of LINC complex      
  
To date, the functional and structural purposes of the LINC complex 
have been studied in depth using dominant negative over expression 
constructs and nesprin, Sun-domain and lamin animal models to uncouple 
cytoskeletal-nuclear lamina interactions.  
 
1.4.2.1 Nuclear anchorage and positioning      
The dynamic nature of cytoskeletal filament associations and 
scaffolding functions which other SR proteins provide with respect to the 
cytoskeleton, suggest that nesprins may play a role in nuclear anchorage.  
The early insights into the cytoskeletal-nuclear coupling came from studying 
the LINC complex in lower organisms such as C. elegans and D. 
melanogaster.  In C. elegans, the nesprin-1/2 orthologue, ANC-1, is critical for 
actin-dependent nuclear positioning in muscle cells during development [186].  
Mutations in the Sun1 orthologue, UNC-84, similarly resulted in defective 
nuclear migration and anchoring [187].  In nesprin-1 KASH domain knockout 
mice, but not nesprin-2 KASH domain knockout mice, nuclear anchorage of 
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synaptic nuclei at the neuromuscular junction in skeletal muscle is severly 
disrupted [177,188].   
Recent studies in mouse and human fibroblasts expressing dominant-
negative LINC complex components or lacking specific nesprin, lamin A/C, 
emerin or SUN proteins have reported defects in centrosome attachment to 
the nucleus.  In scratch-wound assays, the initial cell polarization towards the 
wound fails to occur, and the subsequent migration of cells into the wound is 
impaired [83,189,190,191,192]. Nesprin-1 knockdown, prevents the 
reorientation of endothelial cells in response to cyclic strain and causes a 
decrease in endothelial cell migration in a scratch-wound assay [193]. 
 
1.4.2.2 Mechanical stiffness        
 The nucleus is responsible for the majority of the mechanical stiffness 
of a cell, therefore defects in nuclear anchorage to the cytoskeleton impact 
nuclear strength [194,195].  LMNA-/- mouse embryonic fibroblasts (MEFs) put 
under mechanical stretch and unconfined compression showed a significant 
reduction in mechanical stiffness, with their nuclei spontaneously bursting 
post-compression [150,152].  Furthermore, C2C12 myoblasts expressing 
dnKASH constructs had similar mechanical instability to the LMNA-/- null 
MEFs, and endothelial cells depleted of nesprin-1 were more susceptible to 
nuclear deformations upon cyclic stretching [96,196].  
 
1.4.2.3 Mechanotransduction      
 Mechanotransduction is the ability of cells to respond to mechanical 
stimulation by activating mechano-sensitive genes  through specific signalling 
pathways.  Originally, altered nuclear mechanics and impaired expression of 
the mechano-sensitive genes, Lex-1 and Egr-1 in response to cyclic strain 
[109] were identified in LMNA-/- and STA-/- (gene encoding emerin) MEFs 
[148,152,153].  However, since lamins A/C can also regulate signalling 
pathways by directly interacting with transcription factors, it remains unclear 
whether the observed mechanotransduction defects result from impaired 
nucleo-cytoskeletal coupling, or simply a loss of biochemical interactions 
between transcription factors and the nuclear lamina.  Recent experiments in 
which the LINC complex was disrupted with dnKASH constructs without 
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affecting lamin A/C or emerin levels suggest the latter, as the mechanically 
induced expression of Lex-1 and Egr-1 was not significantly different from 
control cells, in spite of dramatically reduced nuclear deformations in the LINC 
complex-disrupted cells [197].     
Using a C2C12 inducible in vitro model of muscle differentiation, the 
mechanotransductive properties of the LINC complex have been studied in 
muscle cell differentiation.  C2C12 myoblasts normally differentiate into multi-
nucleated myotubes within 5 days of culturing in muscle cell differentiation 
media, a process which can be inhibited by cyclic strain.  However when 
cyclic strain was applied to C2C12 myoblasts expressing dnKASH, myotube 
formation was induced.  Levels of MyoD and myogenin, two major 
transcription factors that drive myogenesis, were substantially elevated in 
dnKASH mechanically stressed cells compared to control stressed cells one 
day after cyclic strain application in muscle cell differentiation media 
[198,199,200].  This data suggests that the LINC complex mediates 
mechanotransduction of myogenic transcription factors during myogenesis 
and plays an important role in muscle physiology.       
 
1.4.2.4 Intracellular force transmission       
 Micro-needle biophysical assays have recently been used to identify 
the LINC complex as the major force-transmitting element between the 
cytoskeleton and nucleus.  Disruption of the LINC complex using a dnKASH 
construct resulted in defective organization of F-actin and IFs around the 
nucleus, promoting impaired intracellular force transmission, measured by the 
length of cytoskeletal and nuclear displacements through passing a micro-
needle along the cell [197].  As a result, cells expressing dnKASH had severe 
functional defects in cell polarization and migration, which may explain why 
nesprins are critical in nuclear positioning. 
 
1.5 Nesprins and disease        
Over recent years the importance of the LINC complex in cytoskeletal 
organization, mechanical stiffness and signalling pathways has become 
apparent.  Importantly it has been implicated in a wide range of disease 
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phenotypes, many resulting from mutations in the nesprin genes.  These 
diseases include cardiac and skeletal muscle defects in Emery Dreifuss 
muscular dystrophy, dilated cardiomyopathy, cerebellar defects in autosomal 
recessive spinocerebellar ataxia 1, tendon contractures in autosomal 
recessive arthrogryposis and bipolar disorder (Table 1.3)  [13,14,159,201,202]. 
 
1.5.1 Emery Dreifuss Muscular Dystrophy     
 Emery Dreifuss muscular dystrophy (EDMD) is a heterogeneous late-
onset disease involving skeletal muscle wasting and heart defects.  Initially, 
mutations in the STA and LMNA genes were identified as the underlying 
cause for EDMD.  Multiple mutations have been identified in STA and LMNA 
that result in EDMD phenotypes, with the severity of the disease varying 
between mutations [160].  More recently, four heterozygous missense 
mutations were identified in nesprin-1 and nesprin-2 when performing DNA 
screens on patients with EDMD or EDMD-like phenotypes (Table 1.4).  
Fibroblasts from these patients exhibited nuclear morphology defects, 
mislocalized emerin and Sun-2, and impaired nesprin/emerin/lamin binding 
interactions, suggesting that defects in the LINC complex in these patients 
may be an underlying cause of EDMD.  siRNA-mediated knockdown of 
nesprin-1 or nesprin-2 in normal fibroblasts reproduced the nuclear 
morphological changes and mislocalization of emerin and Sun-2 observed in 
patient fibroblasts [14].  Later studies demonstrated that one of the nesprin-1 
mutant-derived EDMD primary fibroblast cells were less adhesive, migrated 
slower in a wound healing assay and were more susceptible to senescence 
[203]. 
Nesprin-1 KASH domain or C-terminal SR knockout mice generally 
have reduced survival rates, growth retardation, muscle pathologies and 
cardiac conduction defects, mimicking an EDMD phenotype [159,177].  
Nesprin-2 KASH knockout mice have no obvious phenotype, however 
nesprin-1 and nesprin-2 KASH double knockout mice develop motor neuron 
innervation defects and die shortly after birth due to respiratory failure [188].  
The cause of the respiration failure and lethality associated with the double 
knockout  mice  remains  unclear  but  may  be  due  to  an  unknown  cellular  
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Table 1.3 Nesprin mutations resulting in disease 
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Table 1.4 Nesprin-1 and Nesprin-2 EDMD mutations  	  
  
Nesprin Variant DNA variation Amino Acid Exchange  
Nesprin-1α1 966G>A R257H 
Nesprin-1α1 1910G>T V572L 
Nesprin-1α1 2132G>A E646K 
Nesprin-1α2 466C>T T89M 
Nesprin-1β1 29A>G 5UTR 
Nesprin-2α2 525G>A 5’UTR 
	   44 
function associated with the two nesprin proteins, such as defects during the 
development of the central nervous system.  
 
1.5.2 Cardiomyopathies       
 Mutations in LMNA and nesprin-1 have been identified in severe 
cardiac conduction diseases called cardiomyopathies.  A patient with a 
missense mutation near the KASH domain of nesprin-1 developed severe 
dilated cardiomyopathy (DCM) requiring cardiac transplantation. Fibroblasts 
from this individual had increased expression of nesprin-1α and lamins A and 
C, indicating changes in the nuclear membrane complex [12].  These findings 
mirror what has been described from lamin A/C mutations, suggesting the 
importance of an intact nuclear lamina and LINC complex for a normal 
functioning heart. 
 
1.5.3 Autosomal Recessive Cerebellar Ataxia 1    
 Five nesprin-1 mutations have been identified in patients suffering from 
autosomal recessive cerebellar ataxia (ARCA1), providing the first link 
between nesprins and neurological diseases (Table 1.5) [13].  ARCA1 is 
characterized by neurological abnormalities such as irregular gait and lack of 
limb coordination, without the nuclear morphology defects characteristic of 
laminopathies.  Interestingly, 3 out of the 5 mutations result in premature 
termination codons, suggesting that these patients have impaired nuclear 
anchorage to the actin cytoskeleton.  In supports of this theory, neurological 
defects were observed in nesprin-1 and nesprin-2 double knockout mice 
which developed motor neuron innervation and died shortly after birth,  as 
described above [188].       
 
1.5.4 Autosomal Recessive Arthrogryposis     
 A myogenic form of autosomal recessive arthrogryposis (ARA) has 
been identified in a family spanning two generations.  Clinical symptoms of 
ARA include bilateral clubfoot, multiple joint contractures, delay in motor 
milestones followed by progressive motor decline after the first decade.  A 
genome wide screen in the ARA family line has indicated an A to G mutation 
in a splice acceptor site, resulting in retention of intron 136 of nesprin-1 [201].  
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mutation Exon or Intron 
Protein change in nesprin-1 
giant 
247012 A>T Exon 56 R2906X 
306434 A>G Intron 81 Premature stop at 5244 
310067 A>G Intron 84 Premature stop at 5402 
334338-334342 
Deletion ATTTG  Exon 93 
 
Premature stop at 5880 
426494 C>T Exon 126 Q7640X 
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As with some of the ARCA1 mutations, this mutation produces a premature 
termination codon, resulting in nesprin-1 variants that lack the KASH domain.  
Thus, the production of truncated nesprin-1 KASH variants appear to result in 
two distinct human disease phenotypes, myopathic or neurological, a feature 
similar to that found in laminopathies [204,205].    
 
1.5.5 Bipolar disorder         
 The Psychiatric Genome-Wide Association Study Consortium Bipolar 
Disorder group, performed a genome wide screen from 7481 bipolar 
individuals and 9250 control individuals.  The screen identified a conserved 
single nucleotide polymorphisms within intron 16 of the nesprin-1 gene [202].  
Although this mutation should have no significant effect on the functionality of 
nesprin-1 LINCs due to the position of the mutation within an upstream intron, 
it may effect the production of nesprin-1 isoforms generated through 
alternative transcription (See 1.6).    
 
1.6 Nesprin Isoforms         
 The majority of nesprin research so far has primarily focused on how 
disruption of NE nesprins alter LINC complex functionality.  However, 
immunofluorescence microscopy studies using antibodies targeting the 
different domains of the nesprin-1 and nesprin-2 giants suggest that nesprins 
localize to multiple sub-cellular compartments in a tissue specific manner 
[66,188,206,207,208].  Furthermore, multiple nesprin mRNA transcripts have 
been identified which transcribe a wide collection of tissue specific nesprin 
isoforms (Figure 1.3).  Of these isoforms, many terminate to produce KASH-
less nesprins that localize and have probable functions beyond the NE.    
1.6.1 Nesprin isoforms and muscle      
Immunofluorescence microscopy has localized nesprin-1 and nesprin-2 
isoforms to the cardiac and skeletal muscle sarcomere Z-lines, suggesting 
they may be important in muscle cell function [66,67,206,209].  Interestingly, 
nesprin-1 has been described as both increasing and decreasing at the NE of 
differentiated myotubes  in  vitro,  with  accompanying  re-localizations  to  the  
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nuclear matrix, when compared to undifferentiated mouse C2C12 myoblasts 
[66,209].  In hindsight, nesprin-2 re-localizes from the NE and intranuclear 
speckles to the sarcomere of differentiated myotubes [206].   Despite slight 
variances in staining, which may be due to isoform variation between the cell 
lines examined in each study and the epitopes chosen for antibody production, 
the results support the idea that nesprins are important muscle regulatory 
proteins and that different isoforms may serve different functions during 
muscle development.   
 
1.6.1.1 Nesprins and calcium signalling in striated muscle 
 To date, two muscle-specific nesprin isoforms have been identified; 
nesprin-2α1 and nesprin-1α2 [206] (Unpublished data Professor Shanahan 
laboratory, King’s College London).  SRs within nesprin-1α2 binds to muscle 
A-kinase anchor protein (mAKAP), a striated muscle Ca2+ and cAMP 
signalling regulator.  Overexpression of dominant negative nesprin-1α2 
displaces mAKAP from cardiomyocyte nuclei in vitro, demonstrating that 
nesprin is essential for mAKAP localization to the NE [210].  mAKAP forms a 
cAMP signalling complex with several co-factors, including Ca2+ ion-channel 
ryanodine receptor (RyR), protein kinase A (PKA), and phosphodiesterase 
4D3 (PDE4D3) [91,211,212,213].  Similarly, a region within the nesprin-2α1 
SR rod binds cardiac RyR, indicating that both nesprin-1 and nesprin-2 could 
stabilize the mAKAP complex at the NE (Unpublished data-Professor 
Shanahan laboratory, King’s College London).  
Although no diseases have been directly attributed to mAKAP 
dysfunction, mutations in human cardiac RyR give rise to catecholaminergic 
polymorphic ventricular tachychardia (CPVT) and arrythmogenic right 
ventricular dysplasia type 2 (ARVD2), often responsible for sudden cardiac-
related mortality [214].  Similarly, targeted disruption of mAKAP by mutation or 
siRNA-mediated knockdown promotes cardiac hypertrophy, a stress-inducible 
remodelling of the heart which can lead to severe complications and death 
[211,212].  These results indicate that cardiac-enriched nesprin isoforms, 
such as nesprin-1α2 and nesprin-2α1, may play a key role in the progression 
of these diseases. 
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1.6.1.2 Nesprins and the neuromuscular junction 
Evidence for the importance of nesprins in skeletal muscle function 
comes from its enrichment in the postsynaptic myonuclear envelopes of the 
neuromuscular junction (NMJ), the synapse between motor neurons and 
skeletal muscle fibres [215,216,217].  Endogenous nesprin-1 is displaced 
from the NMJ myonuclei of transgenic mice over-expressing a dominant-
negative nesprin-1 KASH domain, impeding nuclear migration to the NMJ 
[218].  Comparable results were seen in nesprin-1 KASH knockout mice, 
which exhibit abnormal skeletal myonuclear clustering, loss of synaptic 
nuclear aggregation and motor neuron branching defects. As nesprin-2 KASH 
knockout mice did not display these defects and were grossly normal, it 
appears that nesprin-1 and nesprin-2 have distinct functions in muscle and 
other tissues [188].  Nesprin-1α binding partner, skeletal muscle receptor 
tyrosine kinase (MuSK), is necessary for the clustering of acetylcholine 
receptors (AChR) at the NMJ, and therefore plays a key role in synaptic 
function [215,216,217].  Similar to MuSK knockout mice, double nesprin-1 and 
nesprin-2 knockout mice suffocate and die peri-natally due to neuromuscular 
defects that have not yet been characterized, indicating that disruption of the 
MuSK-nesprin-1 interaction as well as nuclear migration could negatively 
affect NMJ formation [188,219].   
1.6.2 Nesprin-1 isoform CPG2 
Given their roles in the regulation of the post-synaptic NMJs, it is not 
surprising that nesprins also play an important part in neuronal functions.  
Novel nesprin-1 isoform, candidate plasticity gene 2 (cpg2), was first identified 
as a gene which contributed to long term plasticity, the ability of neurons to 
stably alter their phenotype in response to various stimuli such as glutamate 
receptor activation and exposure to light [220,221].  ICC and electron 
microscopy using monoclonal anti-cpg2 (nesprin-1 giant amino acids 1315 to 
1334), localized the brain-specific isoform to the cytosol, ER and postsynaptic 
endocytic zone surrounding dendritic spines in vitro, suggesting that cpg2 
could play a role in the clathrin-mediated uptake and recycling of chemokine 
receptors [222].  In agreement with this function, knockdown of cpg2 led to an 
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increase in the number of post-synaptic glutamate receptors with a 
concomitant increase of clathrin coated vesicles within dendritic arms, 
indicating that cpg2 is necessary for receptor internalization and vesicle 
clearance [222].  Interestingly, knockdown of cpg2 decreased spine size, 
suggesting that nesprin-1 also regulates dendritic spine structure and 
morphology. 
1.6.3 Nesprin-1 and Golgi 
1.6.3.1 Novel Golgi-localized region GSRP-56  
A 56 kDa Golgi-localized spectrin-repeat containing protein (GSRP-56) 
nesprin-1 isoform, was originally identified in a yeast-2-hybrid screen as a 
novel binding partner for transient receptor potential cation channel, vanilloid 
family type 2 (TRPV2) [208].  Endogenous GSRP-56 was detected and 
labelled the Golgi apparatus in myoblasts, myotubes, and primary 
cardiomyocytes.  When ectopically expressed in HEK293 cells, GSRP-56 
formed large aggregates that surrounded the Golgi apparatus and induced 
Golgi area expansion, suggesting GSRP-56 may regulate Golgi structure 
[208].  Although GSRP-56 function has been investigated, its association and 
function with TRPV2 still remains elusive.  
 
1.6.3.2 Nesprin-1 contains multiple golgi binding regions  
 In addition to GSRP-56, multiple Golgi localizing domains have been 
identified in nesprin-1.  Nesprin-1 was initially localized to the Golgi by 
Immunofluorescence microscopy using a cross-reacting erythrocyte spectrin 
β1 antibody [223].  Two Golgi-binding regions, one with low affinity (nesprin-1 
giant amino acids 4606 to 4945) and one with high affinity (nesprin-1 giant 
amino acids 5015 to 5410) were later mapped.  Expression of the high-affinity 
region disrupted cytoskeletal links to the Golgi, causing the Golgi to collapse.  
Nesprin-1 Golgi localization was later confirmed by immunofluorescence 
microscopy using three distinct nesprin-1 specific polyclonal antibodies.  
Interestingly, antibody SN357-2 (nesprin-1 giant amino acids 1675 to 1688) 
labelled only the Golgi, while the remaining two antibodies, SN119/120 
(nesprin-1 giant amino acids 5862 to 5875) and anti-nesprin-1 (nesprin-1 giant 
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amino acids 4606 to 4945), additionally labelled the nuclear matrix, indicating 
that other nesprin-1 isoforms exist which include the Golgi localizing SRs 
[223].  An additional Golgi-affecting nesprin-1 fragment, GSSF1 was 
identified upstream of the Golgi-binding sites [224].  Although GSSF1 does 
not localize to the Golgi, ectopic expression caused the Golgi to collapse and 
sequester endogenous nesprin-1 into multiple β-coatomer I (β-COP I) positive 
vesicles, suggesting GSSF1 acts in a dominant negative manner [224].  The 
COP I and COP II protein complexes promote the formation of non-clathrin 
coated vesicles which regulate retrograde and anterograde transport 
respectively within the Golgi, and also between the Golgi and ER [225].  In 
line with these functions, GSSF1 and the high-affinity Golgi binding sequence 
both inhibited retrograde transport of protein disulfide isomerase (PDI) from 
the Golgi to the ER [224].   The retrograde transport defects observed in cells 
expressing dominant negative nesprin-1 fragments suggested that these 
sequences may interact with the microtubule network. A yeast-2-hybrid 
screen for GSSF1 binding partners identified Kif3b, a subunit of the 
heterotrimer kinesin II microtubule motor complex [82].  Kinesin II is a 
ubiquitously expressed motor, involved in anterograde transport of vesicles 
and protein cargo toward the plus-end of microtubules and is also essential 
for mitotic spindle formation and chromosome segregation [226,227].   In 
accordance with these functions, GSSF1 transfected cells both had a 
significantly higher incidence of binucleated cells, a sign of blocked 
cytokinesis.   Overexpressed Kif3b localized to the Golgi but re-distributed to 
GSSF1 induced vesicles in co-transfected cells, further indicating that 
nesprin-1 interacts with the kinesin II complex. Immunofluorescence 
microscopy using Golgi-staining antibody SN120 co-localized endogenous 
nesprin-1 and kinesin II to the mitotic spindle midbody, the accumulation of 
membranes which must be cleaved during telophase to release two daughter-
cells [82].  Cells expressing the dominant-negative tail of Kif3b lost SN120 
staining from the midbody and also had a higher number of binucleated cells.  
Finally, both constructs blocked the accumulation of syntaxin-positive 
membrane vesicles at the midbody, suggesting an essential role for nesprin-1 
in microtubule dynamics, vesicle transport and the progression of mitosis [82]. 
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1.6.4 Nesprins and cancer         
To date, four separate studies have linked nesprins to a collection of 
epithelial cancers [228,229,230,231].  The nesprin-1 promoter is 
hypermethylated and consequently transcriptionally silenced in 95% of 
colorectal cancer cell lines examined [229].  A separate candidate cancer 
gene study also identified nesprin-1 as a gene mutated in colorectal cancer 
cell lines, and nesprin-2 as a gene mutated in breast cancers [230].   Finally, 
hypermethylation of the nesprin-1 promoter occurred in ~50% of lung cancer 
cell lines examined in a third study, leading to significant down-regulation of at 
least four nesprin-1 transcripts [231].  This data suggests that nesprins may 
be a hallmark of cancer and potential targets for cancer therapy. 
 
1.6.4.1 Novel Nesprin-1 isoform Drop1 
A cDNA expression array designed to detect genes which were 
differentially expressed in epithelial ovarian cancer, identified a novel nesprin-
1 isoform, Drop1, as a significantly down-regulated gene, further linking 
nesprins to cancer [232].  Additional analysis determined that Drop1 
expression was substantially reduced in 79% of carcinomas examined, 
including breast, uterus, cervix, vulva, kidney, thyroid, lung and pancreas. The 
cause of this decrease in expression is unknown but may be induced by 
nesprin-1 promoter methylation.  Full-length Drop1 is predicted to be ~350 
kDa and would contain the nesprin-1 CHDs and a stretch of SRs.  However, 
Drop1 would lack the KASH domain and is therefore not expected to 
contribute to NE function.  Although ectopically expressed Drop1 constructs 
localized to the cytosol, the specific sub-cellular localization of full-length 
Drop1 cannot be determined until the entire protein is expressed, or attempts 
are made to detect the endogenous form using immunofluorescence 
microscopy with Drop1 specific antibodies [232]. 
 
1.6.4.2 Nesprin-2 in Meckel-Gruber syndrome     
 Meckel-Gruber syndrome (MKS) is a severe recessively inherited 
developmental disorder that is characterized by dysplasia and developmental 
defects of the central nervous system [233].  MKS is caused by mutations in 
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genes that encode components of the primary cilium and basal body, such as 
MKS1 and Meckelin [234].  The N-terminal SRs of nesprin-2 were identified 
as Meckelin binding partners [191].  Nesprin-2 antibody, K20-478, designed to 
target the CHDs of nesprin-2, co-localized nesprin-2 CHD isoforms with 
mecklein at filopodia prior to the establishment of cell polarity and ciliogenesis.  
Loss of nesprin-2 CHD isoforms impaired centrosome migration, cell 
polarization and ciliogenesis in a IMCD3 ciliated-cell model.  siRNA-mediated 
Meckelin knockdown caused a dramatic remodelling of the actin cytoskeleton 
and mislocalization of nesprin-2 to actin stress-fibres and activation of RhoA 
signalling [191].  These findings further highlight the important roles of the 
nesprins during cellular and developmental processes, particularly in 
centrosome positioning and cell polarity.  Furthermore, it stipulates that the 
actin cytoskeleton and KASH-less nesprin-2 variants that retain the CHDs are 
required for the early stages of ciliogenesis. 
1.6.5 Nesprin-2 scaffolds and regulates ERK 1/2 at nuclear PML bodies 
ERK1/2 were identified as novel nesprin-2 binding partners in a yeast-
2-hybrid screen when using the N-terminus of nesprin-2β as bait [207].  
ERK1/2 signalling is activated in response to extracellular stimuli and has 
essential roles in proliferation, differentiation, and apoptosis [235].  Using co-
immunoprecipitations and various nesprin-2 constructs, a KASH-less nesprin-
2β variant was shown to interact with ERK1/2 at nuclear promyelocytic 
leukaemia (PML) bodies, intra-nuclear foci proposed to anchor and regulate 
many nuclear functions including DNA replication, transcription, or epigenetic 
silencing [207,236].  siRNA-mediated depletion  of nesprin-2 abolished ERK 
1/2  localization from PML bodies and increased ERK1/2 activity, resulting in 
enhanced proliferation of   vascular smooth muscle cells (VSMCs) [207].  This 
data suggests that KASH-less nuclear nesprin-2β variants negatively regulate 
ERK 1/2, which could be a novel disruption during atherosclerosis. 
 
1.6.6 Nesprin isoform expressions are highly adaptable    
The ability of nesprins to generate a wide range of different variants, 
many with over lapping domains suggest that nesprin expression patterns 
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may be highly flexible, with cells being able to change their isoform 
expression patterns in response to different cellular cues or stimuli to adapt to 
their needs.   For example, nesprin-2 CHD knockout mice display an altered 
expression pattern for specific nesprin-2 C-terminal isoforms in certain tissues 
to compensate for the loss of nesprin-2 giant or other nesprin-2 CHD variants 
[237].   
Furthermore, the ability of the nesprin-2 giant to switch expression has 
become evident in S143F lamin A/C progeria dermal fibroblasts.  S143F 
progeria cells have dysmorphic nuclei containing numerous blebs and 
lobulations, which progressively accumulate as cells age in culture.  
Immunofluorescence microscopy showed that the nesprin-2 giant localized in 
the cytoplasm, whereas emerin was unevenly localized along the NE.  
However, a subpopulation of mutant cells expressing the nesprin-2 giant 
isoform failed to show any obvious nuclear morphologies, suggesting that not 
only is nesprin-2 vital for maintaining nuclear architecture, but more 
importantly its expression is adaptable in disease and mechanisms exist to 
signal compensatory expression of certain isoforms [99].    
 
1.6.6.1 Nesprin-1 mediated NE changes during embryonic stem cell 
differentiation        
 The luminal space between the INM and ONM of embryonic stem (ES) 
cells appears to be distinctive and wider than their differentiated counterparts 
under electron microscopy.  ES cells also appear to lack heterochromatin     
around the nuclear periphery, which is present in differentiated cells.  When 
screening a panel of NE proteins, nesprin-1 KASH variants were the only 
significantly increased species upon differentiation.  Although knockdown of 
nesprin-1 KASH variants using siRNA did not effect ES cell differentiation, the 
differentiated cells retained a NE phenotype of that found in undifferentiated 
ES cells [238].  Therefore, it appears that nesprin-1 KASH variants govern NE 
luminal size in ES cells and may participate in regulating chromatin 
organization and gene regulation of differentiated cells. 
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1.6.6.2 Nesprin expression changes during myogenesis  
 The ability of the nesprins to not only switch isoform expression of the 
same gene, but to change nesprin gene expression altogether is particularly 
evident in muscle.  Analysis of nesprins during human muscle development 
revealed an increase in nesprin-1 giant during early myogenesis in vitro. 
During the transition from immature to mature muscle fibres in vivo, nesprin-2 
partially replaced nesprin-1 at the NE, with the short nesprin KASH isoforms 
becoming the primarily dominant variants [185].  Nesprin animals models 
suggest that nuclear positioning nesprins at the ONM appear to be primarily a 
function of nesprin-1 in muscle; consistent with nesprin-1 dominating the 
myonuclear envelope at early stages of myogenesis [159,188].  The 
dominance of nesprin-2 and shorter nesprin KASH isoforms in mature fibres 
remains unclear.  The general acceptance that small KASH isoforms may be 
present at the INM where they interact with emerin and lamin A/C suggests 
they may be required for generating a sturdier LINC complex or be required 
for scaffolding additional sets of nuclear regulatory proteins to the nuclear 
lamina for muscle function [169,206,209].   
1.7 Thesis aims  
 In summary, nesprins play a variety of roles within cells as intra-cellular 
scaffolds and linkers.  The scaffolding roles of giant nesprins in LINC 
complexes have been well studied relative to their KASH-less counterparts.  
To identify new novel nesprin-1 scaffolding roles and/or nesprin regulated 
signalling pathways, I set out to:  
1. Identify new 5’ and 3’UTRs which could generate nesprin-1 variants by 
alternative transcription. 
2. Characterize newly identified nesprin variants using tagged-constructs 
and antibodies to detect and monitor endogenous expression and 
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Chapter 2: Materials and Methods 
 
2.1 Cell work   
2.1.1 Cell culture  
 All cell lines were cultured in a 4% CO2 incubator at 37°C.  
Osteosarcoma cells (U2OS) and Human Dermal Fibroblasts (HDFs) were 
cultured in Dulbecco’s modified eagle’s medium (DMEM) supplemented with 
10% Foetal Bovine Serum (FBS), 1% penicillin/streptomycin and 200 µM L-
Glutamine.  Human vascular smooth muscle cells (VSMC) were cultured in 
M199 media complemented with 20% FBS, 1% penicillin/streptomycin and 
200 µM L-Glutamine, and passaged at 60-80% confluency.    
2.1.2 Cell passaging 
 Once cells had reached 60-80% confluency, the culture media was 
aspirated and the cells were washed thoroughly in tissue culture grade 
phosphate buffered saline (PBS) solution.  Cells were then incubated in a 
small volume of trypsin for 3-5 minutes in the culture incubator at 37°C until 
they detached from surface.  U2OS cells were split 1:10, HDFs 1:3 and 
VSMCs 1:2 in fresh culture media and allowed to adhere in the culture 
incubator.     
2.1.3 Cell treatments 
Cells were counted using a haemocytometer and plated out at medium 
density the day prior to treatment.  The following day, cells were treated with 
sodium arsenite (0.5 mM), nocodazole (10 µg/ml), cycloheximide (10 µg/ml) 
or hydrogen peroxide (2 µM) in fresh culture media for one hour.  Cells were 
then fixed in 4% paraformaldehyde (PFA) for staining.  
 
2.1.4 DNA plasmid transfection  
 Cell were counted and plated out at medium density the day prior to 
transfection.  One well of a 96 well plate, 24 well plate or one well of a 6 well 
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plate was transfected with 0.5 µg, 1 µg or 2 µg of plasmid respectively, using 
a 1:2 ratio of plasmid to Superfect transfection reagent as described by the 
manufacturer (Quiagen).  The transfection mix was mixed thoroughly and 
allowed to stand for 10 minutes at room temperature (RT) while transfection 
complexes assembled.  The transfection mix was then applied to cultured 
cells for rapid uptake of superfect-plasmid complexes.  Two hours post-
transfection, cells were washed twice with PBS and replaced with fresh 
culture media.  Transfected cells were cultured for 16-24 hours before fixation 
or harvesting.    
2.1.5 siRNA transfection 
Cell were counted and plated out at medium dentistry the day prior to 
transfection.  For 6 wells of a 24 well plate or 2 wells of a 6 well plate, 1.5 µl of 
siRNA oligo (20 µM stock) was incubated in 500 µl of serum free Optimem 
with 36 µl of Hiperfect transfection reagent (Quiagen).  The transfection mix 
was mixed thoroughly and allowed to stand for 10 minutes at RT while 
transfection complexes assembled.  During this time cells were washed twice 
with PBS and supplied with fresh media.  The transfection mix was split 
equally between 6 wells of a 24 well plate or 2 wells of a 6 well plate.  The 
cells were incubated with the oligos for 72 hours followed by fixation or 
harvesting.   
2.1.6 MTT assay 
 In vitro toxicity was measured using a (3-[4,5- dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) based assay.  Transfected cells were 
cultured in media supplemented with 10% MTT reagent for 3 hours.  Next, the 
culture was aspirated off and the resulting formazan crystals were dissolved in 
MTT solubilization solution, equal to the original culture medium volume.  The 
96 well plate was then placed on a shaker for 10 minutes to enhance the 
dissolution of the crystals and spectrophotometrically measure were taken at 
570 nm and 690 nm absorbances on a plate reader.  690 nm readings were 
subtracted from 570 nm readings to eliminate background.  Statistical analysis 
for this and other assays were performed using GraphPad Prism software.       
	   58 
2.1.7 Luciferase 
2.1.7.1 CXCR4 miRISC assay 
50,000 U2OS cells were plated into each well of a 24-well plate and 
cultured under standard growth conditions overnight.  The following day, 3 
wells per experimental condition were transfected with Hiperfect siRNA-
plasmid complexes containing 1 µg pRL-TK CXCR4 6x Renilla luciferase 
plasmids, 50 ng pGL3.4 firefly luciferase plasmid as an internal loading control, 
1 µl CXCR4 siRNA oligo (20 µM stock), and 1 µl of siRNA oligo  (20 µM stock) 
targeting proteins to be knocked down.   The transfected cells were incubated 
under standard growth conditions for 48 hours.  Each well was washed with 
PBS and cells lysed in 100 µl 1x passive lysis buffer.  Luciferase readings 
were analysed according to the Promega Dual-Luciferase Reporter assay 
manufacturer’s instructions.  Briefly, Firefly activity was measured on a 
Berthold Mithras LB 940 Luminometer by mixing 20 µl of each lysate with 100 
µl of Luciferase Assay Substrate.  Next Renilla readings were measured in 
the same manner by adding 100 µl of Stop & Glo reagent to each lysate.        
Luciferase activity was normalized by dividing Renilla readings by firefly 
readings.  
  
2.1.7.2 Endogenous Let-7 miRISC assay 
50,000 U2OS cells were plated into each well of a 24-well plate and 
cultured under standard growth conditions overnight.  The following day, 3 
wells per experimental condition were transfected with Hiperfect siRNA-
plasmid complexes containing 1 µg of either FF4LCS (Let-7 WT) or 
FFr4mLCS (Let-7 mutant), 50 ng pRenilla, and 1 µl of siRNA oligo  (20 µM 
stock) targeting proteins to be knocked down.   The transfected cells were 
incubated under standard growth conditions for 48 hours and dual luciferase 
readings were taken as described above.   
2.1.7.3 Tethering assay 
50,000 U2OS cells were plated into each well of a 24-well plate and 
cultured under standard growth conditions overnight.  The following day, 3 
wells per experimental condition were transfected with 1 µg of pRL-TK-globin-
boxB, 1 µg pc1-λN-V5 and 50ng pGL3.4 using Superfect transfection reagent.  
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The transfected cells were incubated under standard growth conditions for 24 
hours and dual luciferase readings were taken as described above.     
 
2.2 Microscopy work  
2.2.1 Immunofluorescence microscopy 
Cells grown on 13 mm glass coverslips in 24-well plates were washed 
twice with PBS and then fixed with either 4% paraformaldehyde (PFA) for 5 
minutes at RT or 1:1 Methanol/Acetone (pre-chilled at -80°C) for 2 minutes at 
RT.  Cells were then washed with PBS and PFA fixed cells were 
permeabilized with 0.5% NP-40 for 2 minutes at RT, followed by two 
subsequent washes with PBS.  PFA and Mehanol/Acetone fixed cells were 
then blocked in 1% bovine serum albumin (BSA) solution for one hour at RT.  
Blocked cells were incubated with primary antibody diluted in 1%BSA  for 1 
hour at RT in humidifying chambers.  Excess primary antibody was washed 
off with PBS and incubated with suitable secondary antibodies diluted in 1% 
BSA for 1 hour at RT.  Cells were next stained with 4’,6’-Diamidino-2-
Pheylindoledihydrochloride (DAPI), followed by multiple washes with PBS 
before being mounted onto slides with Mowiol/Dabco mounting media.   
Light microscopy images were captured using an Olympus IX81 
microscope with a 20x air, 40x air or x 63 oil objective lenses attached to a 
Hamamatsu Orca-R2 cooled CCD camera.  Volocity software (Perkin Elmer, 
USA) was used to control exposure times and store acquired images.  
Confocal images were taken using a filter-free Leica SP5 laser scanning 
confocal microscope.  All confocal images were taken with the 63x oil 
immersion objective lens.  All lasers were used at maximum intensity levels 
with gain and offset being maintained to prevent image saturation.  Z-stacks 
of 0.37µ were taken throughout the height of the cell and restored using Leica 
confocal software. 
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2.2.2 Peptide blocking  
Blocking peptides were designed to the antibody epitope of interest 
and synthesized by Peptide Protein Research Ltd, UK.  10 µg of peptide was 
incubated with every 1 µg of primary antibody diluted in 1% BSA blocking 
buffer.  The mixture was incubated with constant rotation for 1 hour at RT and 
then incubated with fixed cells on coverslips for 1 hour at RT.  The ability of 
the peptide to block staining was was determined by immunofluorescence 
microscopy. 
2.2.3 Time-lapse 
2.2.3.1 P-body tracking 
 U2OS cells were transfected into 35 mm Matech dishes using 
Superfect transfection reagent and imaged on an Olympus IX81 microscope 
with a 40x LCUPlanFLN 0.6NA objective with additional intermediate 
magnification of 1.6x, giving a total magnification of 64x.  Volocity was used to 
control timelapse acquisition and images were acquired every 200 ms for 2 
minutes using a Hamamatsu Orca-R2 cooled CCD camera set to 2x2 binning 
(effective pixel size of 0.21 um/pixel) and with an exposure of 30 ms.  Image 
stacks were deconvolved in Volocity using 'fast' (non-iterative) method.  P-
bodies were detected using a threshold of at least 3 standard deviations from 
the mean of whole image intensity and with a minimum area of 0.5µm2 and 
using a 4um local contrast adjustment.  Resultant objects were dilated by 1 
pixel and subject to a 3x3 pixel Gaussian filter to remove noise.  Touching 
objects were separated by giving a Volocity a size guide of 5µm2.  Dcp1a-YFP 
bodies were tracked using a 'shortest path' algorithm with a maximum 
distance of 1µm between frames.  The area centroid of each tracked object 
was exported as a list of coodrinates and converted to .CEL format in a 
custom-written Mathematica (Wolfram Research, USA) notebook and .cel files 
were imported into the Chemotaxis Analysis notebook V1.6 (Professor 
Graham Dunn laboratory, King's College London) for analysis and statistical 
comparison.  P-body single particle tracking was performed by Daniel Soong, 
(Light microscope officer for Cardiovascular and Randal division, King’s 
College London). 
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2.2.3.2 Phase-contrast filming  
 U2OS cells were transfected in 6 well plates and imaged on an 
Olympus IX81 microscope with a 10x objective.  3 separate points were 
identified for filming per well of the 6 well plate with each point being acquired 
every 2 minutes over a 16 hour time-frame with an exposure of 15 ms.  
Images were compiled by Volocity to form a movie which was analyzed to 
measure cell death.       
 
2.3 Nucleotide techniques  
2.3.1 RNA extraction and Reverse Transcription  
Cells grown in 6 well plates were lysed in 200 µl of Triazole RNA 
STAT- 60.  Total RNA was extracted by incubating lysed cells with chloroform 
for 5 minutes at RT followed by centrifugation at 10350 g for 15 minutes in a 
4°C centrifuge.  The aqueous phase was transferred into a fresh RNAase free 
micro-centrifuge tube and incubated with 100 µl of isopropanol for 5 minutes 
before pelleting total RNA by a subsequent round of centrifugation at 10350 g 
for 15 minutes.  The RNA pellet was washed with 500 µl of 70% ethanol 
solution made up with diethylpyrocarbonate (DEPC) treated water  and 
centrifugated at 5280 g for 5 minutes to re-pellet washed RNA.  The RNA 
pellet was finally re-suspended in 20 µl of DEPC treated water and 2 µg was 
used for reverse transcription using random primers, dNTP mix and Promega 
Avian Myeloblastosis Virus–RT (AMV-RT).  The random primers and RNA 
were denatured by heating at 95°C for 5 minutes before the reverse 
transcription was carried out at 42°C for 1 hour.  Total cDNA was finally 
diluted to the required concentration using nuclease free water.  
2.3.2 Polymerase Chain Reaction (PCR) 
 PCR amplifications were performed using 5 µmol of each primer and 
500 ng of cDNA obtained from RT or a panel of human tissue cDNA (Origene) 
with Taq PCR master mix kit that contains Taq, dNTPs and buffer at 2x 
concentration.  The total content of the PCR reaction was mixed by pipetting 
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in a thin-walled PCR tube and carried out in a thermo-cycler using the 
following conditions:  Initial denaturation 95°C 1 min, denaturation 95°C 30 
seconds*, annealing 55°C 40 seconds*, extension 72°C 1 min per kb*, Final 
extension 72°C 2 min.   (*Repeated for 30 cycles). 
 PCR reactions to be performed with Pfu polymerase contained 1U Pfu, 
3ul 10x Pfu buffer, 1ul dNTP mix (100 mM stock), 1 ug DNA and a final 
volume of water up to 30 ul.  The total content of the PCR reaction was mixed 
by pipetting in a thin-walled PCR tube and carried out in a thermo cycler using 
the following conditions:  Initial denaturation 95°C 1 min, denaturation 95°C 
30 seconds*, annealing 55°C 40 seconds*, extension 72°C 2 min per kb*, 
Final extension 72°C 10 min.   (*Repeated for 30 cycles). 
 PCR reactions were mixed with 6x DNA loading buffer and separated 
by agarose gel electrophoresis.  PCR products were visualized using UV 
detection before being purified, cloned into pGEM-T sequencing vector and 
submitted for sequencing.  DNA Sequencing was carried out by Geneservice 
using primers targeting the T7 and SP6 promoters flanking the multiple 
cloning site of pGEM-T easy.  Returned sequences were blasted against the 
NCBI human genome and human nucleotide database to identify new novel 
sequences or screened for mutations.   
2.3.3 Rapid Amplification of cDNA Ends (RACE) 
Whole brain and HeLa cell Marathon-ready cDNA libraries for RACE 
were purchased from Clontech.  All PCR reactions were carried out using 
Advantage 2 polymerase in a 50 µl reaction using 250 ng of cDNA and 10 µM 
of adapter and gene specific primers.  Initial round of PCR reactions were 
performed using the following conditions: Denaturation 94°C 1 min, 
denaturation 94°C 30 seconds*, anneal/extension 68°C 4 minutes*, Final 
extension 70°C 10 minutes  (*Repeated for 30 cycles).  The primary PCR 
reaction was diluted 1 in 50 and 5ul was taken for secondary PCR reactions 
with nested adapter primer and nested gene specific primers. Nested PCR 
was performed in a thermo cycler using the following conditions: Denaturation 
	   63 
94°C 1 min, denaturation 94°C 30 seconds**, anneal/extension 68°C 4 
minutes*, final extension 70°C for 10 minutes.  (**Repeated for 20 cycles).         
Nested PCR reaction products were separated by agarose gel 
electrophoresis and cloned into pGEM-T for sequencing.  Returned 
sequences were blasted against the NCBI human genome to identify new 
novel cDNA ends. 
2.3.4 Quantitative PCR (qPCR) 
Prior to qPCR, primers sets were examined using Taq based PCR.  
Purified products were diluted to create a 0.5 pmol stock which was serially 
diluted 1 in 10 to create 0.05, 0.005, 0.0005, 0.00005 and 0.000005 pmol 
standards. 
cDNA created from RT was diluted to 100 ng/µl and 900 ng was used 
for each qPCR reaction.  qPCR was performed in a 20 µl reaction containing 
1x Sybr green PCR master mix and 5 µmol of each primer. Cycling 
parameters were 94°C for 15 seconds followed by a single step annealing 
and extension at 60°C for 60 seconds.  Reactions were performed on 
RotorGene-3000 by Corbett.  The cycle threshold (Ct) for each sample was 
automatically determined to be the first cycle at which a significant increase in 
optical signal above an arbitrary base line was detected.  mRNA expression 
was quantified using standard curves for each primer set and fold changes 
were calculated using the delta-delta CT method.   
2.3.5 Agarose Gel Electrophoresis 
PCR products and restriction enzyme digested plasmid DNA were 
resolved on 1% to 3% TAE agarose gels.  Gels were electrophoresed at 150V 
until adequate separation of bands was seen. Sample loading buffer, 1 kb and 
100 bp DNA ladders were obtained from Promega. To facilitate the 
visualization of bands by UV transillumination, 50µg of ethidium bromide was 
supplemented to each gel before electrophoresis.   
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2.3.6 Cloning  
DNA sequences of interest were either directly isolated from plasmids 
by restriction enzyme digest or amplified from plasmid or cDNA templates by 
PCR.  Bands were extracted from agarose gels using the QIAquick Gel 
gxtraction kit (Qiagen) according to manufacturer’s instructions.  Briefly, 
extracted gel pieces were dissolved by heating gel pieces in 800 µl of buffer 
QG for 10 minutes at 50°C.  The dissolved DNA was captured onto QIAquick 
spin columns by centrifugation and washed 2 times with Buffer PE.  Finally 
the DNA was eluted by incubating the spin column with 20 µl of elution buffer 
for 1 minute at RT before collecting DNA through centrifugation.    
For sequencing and cloning purposes, Taq amplified DNA was ligated 
directly into the Promega pGEM-T Easy vector.  For blunt-ended Pfu amplified 
products, an A-tailing procedure was first performed by incubating purified 
cDNA with 2x Taq PCR master mix at 72°C for 30 minutes.     
 
2.3.6.1 Restriction enzyme digest of plasmid DNA 
1 µg of plasmid DNA was digested with 1 unit of each restriction 
enzyme, 2.5 µl of 10x relevant restriction enzyme buffer and 0.25 µl of 100x 
BSA made up to 25 µl with water.  Digests were performed for 3 hours at 
37°C and heat-inactivated by a 20 minute, 65°C incubation when appropriate.  
Digested products were purified by agarose gel electrophoresis.  Extracted 
destination vectors were treated with 1 unit of Antarctic phosphatase for 30 
minutes 37°C and heat-inactivated by a 20 minute, 65°C incubation before T4 
DNA ligation reactions with extracted inserts were carried out. 
 
2.3.6.2 Ligation of digested DNA 
Ligations were carried out in a final 10 µl volume: 1U T4 ligase, 1 µl 
10x ligase buffer, 1-5 µl insert, 1 µl vector and an appropriate volume of water 
up to 10 µl.  Reactions were incubated overnight at 4°C and transformed into 
chemically competent DH5a or BL21 E. coli bacteria.  5 µl of ligation reactions 
were transformed into E.coli bacteria and plated onto LB plates containing 
suitable antibiotics for selection.  
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2.3.6.3 Transformation 
Competent cells were slowly thawed on ice and incubated with up to 5 
µl of plasmid DNA for 20 minutes on ice.  Bacteria were then submerged into 
a 42°C water bath for 40 seconds and then rapidly cooled on ice for 2 minutes.  
700 µl of antibiotic-free LB added to each transformation reaction and left to 
shake in a 37°C incubator for 1 hour for expression of antibiotic resistant 
genes.  200 µl of the transformation was plated out onto appropriate antibiotic 
treated LB agar plates and allowed to culture at 37°C overnight for colony 
formation. 
 
2.3.6.4 LB agar plates 
 LB (Luria Broth) agar plates were created by mixing 35 g of LB-Agar 
powder with 1L of double distilled water.  The mixture was then autoclaved for 
purification.  Upon cooling, the mixture was supplemented with relevant 
antibiotics (2 ml of 10 mg/ml Kanamycin or 3 ml of 50 mg/ml Ampicillin) and 
poured into petri dishes.  LB agar plates were stored for up to one month 
before being discarded.   
 
2.3.6.5 LB media  
 LB media was created by mixing 20 g of LB powder with 1L of double 
distilled water.  The mixture was then autoclaved for purification.  Upon 
cooling, the mixture was supplemented with relevant antibiotics (2 ml of 10 
mg/ml Kanamycin or 3 ml of 50 mg/ml Ampicillin) and stored at 4°C n the dark 
for up to one month.   
 
2.3.6.6 Plasmid isolation  
Single colonies were picked and cultured in 5 ml of antibiotic 
supplemented LB overnight in a 37°C shaking incubator to obtain small yields 
of purified plasmid.  3 ml of the culture was used for plasmid isolation using 
Promega PureYield Plasmid Miniprep System according to the manufacturer’s 
instructions and the resulting 2 ml was used stored as a 15% glycerol stock at 
-80°C for future use.  Briefly, the bacteria were pelted by centrifugation at 
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maximum speed for 2 minutes.  The bacteria were lysed in 100 µl of lysis 
buffer which was then neutralized by the addition of 350 µl of neutralization 
solution.  The mixture was then centrifuged at maximum speed for 5 minutes 
at RT to pellet cell debris and the supernatant was poured in a minicoloumn.  
The plasmid was captured onto a minicoloumn by centrifugation and washed 
with endotoxin removal solution and a coloumn wash solution.  Finally the 
plasmid was eluted by incubating the minicolumn with 30 µl of elution buffer 
for 1 minute at RT before collecting the plasmid in a clean eppendorf tube by 
centrifugation at maximum speed for 1 minute.   
For isolation of larger amounts of plasmid, bacteria was cultured in 200 
ml of LB overnight in a 37°C shaking incubator and isolated using the Qiagen 
Endofree Plasmid Maxiprep kit according to the manufacturer’s instructions.  
Briefly, bacteria were pelted by centrifugation at maximum speed for 10 
minutes.  The bacteria were lysed in 10 ml of lysis buffer, which was then 
neutralized by the addition of 10 ml of neutralization solution.  Plasmid was 
then separated from cell debris passing the mixture through a filtered syringe.  
The plasmid containing liquid was next incubated with 2.5 ml of endotoxin 
removal buffer for 20 minutes on ice before the plasmid was captured and 
washed through a Quiagen-tip coloumn.  The DNA was next eluted in 15 ml of 
elution buffer and precipitated using 10.5 ml of isopropanol followed by 
centrifugation as 4000 g or 1 hour at 4°C.  The DNA pellet was washed in an 
ethanol-based wash buffer and re-pelleted by centrifugation at 4000 g for 1 
hour at 4°C.  Finally the pellet was air dried and re-suspended in 500 µl of TE 
buffer.    
2.3.7 Generation of competent E. coli DH5α and BL21   
E. coli strains DH5α and BL21 were cultured overnight in antibiotic-free 
LB at 37°C in a shaking incubator.  The culture was diluted 1 in 200 the 
following morning and cultured for a further 3 hours at 37°C.  Bacteria were 
next pelleted by centrifugation at 1150 g for 10 minutes and re-suspended into 
20 ml of sterile ice cold 100 mM CaCl2.  The bacteria were then re-pelleted at 
1150 g for 10 minutes and once again suspended into ice cold 100 mM CaCl2.  
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After an additional round of centrifugation, pellted bacteria were stored in 100 
µl aliquots as 15% glycerol stock at -80°C..   
Competency of bacteria was determined by transforming 0.5 ng, 1 ng, 
5 ng and 10 ng of pEGFP-C1 plasmid into 30 µl of competent cells and plating 
out onto kanamycin resistant LB agar plates.  The number of colonies formed 
from each transformant was determined by dividing the number of colonies by 
amount of plasmid in µg.  Anything > 104cfu/µg was deemed competent.     
2.3.8 Site directed mutagenesis   
In vitro site directed mutagenesis was carried out using QuikChange 
Site-Directed Mutagenesis Kit (Stratagene) to create specific mutations in 
DNA plasmid.  The QuikChange site-directed mutagenesis is a PCR based 
method which uses oligonucleotide primers containing the region to be 
mutated, flanked by ~20 nucleotides either side.  The forward and reverse 
primers are created to be complementary to opposite strands of the vector.  
The PCR reaction is carried out using 50 ng of plasmid to be mutated, 
PfuTurbo DNA polymerase, 10x Pfu Turbo buffer and dNTP mix as described 
by the manufacturer.  Cycling parameters were: Initial denaturation 95°C 1 
min, denaturation 95°C 30 seconds*, annealing 55°C 1 minute*, extension 
68°C 1 min per kb*, Final extension 68°C 20 min.   (*Repeated for 18 cycles).  
Incorporation of the oligonucleotide primers generates a mutated plasmid 
containing staggered nicks.  Following PCR, the product is treated with Dpn I 
endonuclease (target sequence: 5 -́Gm6ATC-3 ́) which is specific for 
methylated and hemimethylated DNA and is used to digest the parental DNA 
template and to select for mutation-containing synthesized DNA.  DNA 
isolated from most E. coli strains is dam methylated and therefore susceptible 
to Dpn I digestion. The nicked vector DNA containing the desired mutations is 
then transformed into XL1-Blue super-competent cells.  Colonies containing 
the mutated plasmid is determined by plasmid isolation and DNA sequencing.   
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2.4 Protein techniques 
2.4.1 Cell lysis 
2.4.1.1 Whole Cell lysate      
Plated cells were washed twice with PBS and harvested by scrapping 
cells in RIPA buffer.  Suspended cells were vortexed for 10 seconds and left 
on ice for 10 minutes to lyse.  Cell debris was pelleted by centrifugation at 
13050 g for 12 minutes in a 4°C centrifuge.  The supernatant was transferred 
to a fresh eppendorf tube and its protein concentration was determined by 
DCA protein assay.  Lysates were diluted and boiled at 95ºC in 4x loading 
buffer with β-mercaptoethanol for 5 minutes and centrifuged at 4°C at max 
speed for 30 seconds.  Protein lysates were separated by 10% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
analysed by Western blotting. 
2.4.1.2 Nuclear and cytosolic fractionation 
Plated cells were washed twice with PBS and harvested by scrapping 
cells in in an appropriate volume of nuclear fractionation buffer.  The cells 
were collected and incubated on ice for 10 minutes followed by a 
centrifugation at 845 g for 10 minutes in a 4°C centrifuge to pellet nuclei.  The 
supernatant containing the cytoplasmic fraction was transferred to a fresh 
eppendorf.  The pelleted nuclei were re-suspended in an appropriate volume 
of RIPA buffer, vortexed, incubated on ice for 10 minutes and centrifuged at 
13050 g for 10 minutes in a 4°C centrifuge.  The supernatant was collected as 
the nuclear fraction.  The protein concentration for each fraction was 
determined by DCA protein assay and analysed by Western blotting. 
2.4.2 DCA protein assay 
 Purified BSA at a concentration of 1.48 mg/ml was serially diluted to 
make standards for the DCA protein assay.  2 µl of lysate or standards were 
incubated with 25 µl of Bio-rad DC Protein Assay Reagent A for 5 minutes in 
a 96-well plate.  Next each sample was mixed and incubated with 200 µl of 
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Bio-rad DC Protein Assay Reagent B for 10 minutes in the dark before protein 
concentrations were determined spectrophotometrically at 710 nm by 
comparing to BSA standards.  
2.4.3 Western blotting 
10% resolving gels were created and poured into Biorad gel casting 
kits for maximum resolution.  Once set, 4% stacking gels were poured and 10 
or 15 wells were created using appropriate combs.  Polymerized gels were 
sub merged into running buffer and appropriate volumes of denatured 
proteins were loaded into the wells.   Proteins were resolved at 200V until 
adequate separation was achieved.  Resolved proteins were immobilized on 
PVDF membranes by sandwiching PVDF and SDS-PAGE gel between filter 
papers soaked in transfer buffer.  Transfer was performed via semi-dry 
transfer apparatus as 25V for 90 minutes. Membranes with immobilized 
proteins were blocked for 1 hour at RT in 5% milk solution made up with 0.1% 
Tween in PBS (PBS-T).  Blocked membranes were incubated overnight at 
4°C with primary antibodies diluted in blocking solution.  The following day, 
membranes were subject to 3x 10 minute washes in PBS-T followed by 1 
hour incubation with the appropriate horseradish peroxidase (HRP)-
conjugated secondary antibody diluted in 5% milk solution.  Excess secondary 
antibody was washed off membranes with 3X 20 minute washes in PBS-T.  
Western bands were visualized by ECL chemiluminescent development onto 
X-ray film or a computer attached to a Fuji LAS4010 developing machine. 
2.4.4 Peptide blocking  
Blocking peptides were designed to the antibody epitope of interest 
and synthesized by Peptide Protein Research Ltd, UK.  10 µg of peptide was 
incubated with every 1 µg of primary antibody diluted in 5% milk blocking 
buffer.  The mixture was incubated with constant rotation for 1 hour at RT and 
then incubated with the PVDF membrane overnight and blocking was 
determined by Western blotting. 
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2.4.5 Protein binding techniques  
2.4.5.1 GST pull-downs 
E. coli strain BL21 were transformed with pGEX vectors encoding 
Glutathione-S-Transferase (GST) -fused proteins.  Single colonies were 
cultured in 5 ml of ampicillin LB overnight in a 37°C shaker.  The following 
morning 500 µl of the culture was incubated in 200 ml of fresh ampicillin LB at 
37°C for 2 hours in a 37°C shaking incubator.  Next, GST-fusion proteins 
were induced by the addition of 1 mM Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) to the culture and left to shake at 30°C for 2 hours to induce 
expression of GST-fused proteins.  Bacteria were then pelleted and re-
suspended in 5 ml of sterile 1x PBS and 1% triton, followed by a brief 
sonication.  Bacteria were left on ice for 10 minutes to lyse and debris pelleted 
by spinning bacteria at 13050 g for 15 minutes.  The recombinant protein was 
purified by incubating GST beads with the supernatant for 30 minutes at RT.  
Expression of recombinant proteins was confirmed by SDS-PAGE and 
comassie staining or by Western blotting for anti-GST.   
Human whole cell lysates were prepared by washing cells in PBS and 
scrapping cells in an appropriate volume of ice cold co-immunoprecipitation 
(co-IP) buffer.  Cells were left in the buffer for 30 minutes before cell debris 
was pelleted by centrifugation for 12 minutes at 13050 g in a 4°C centrifuge.  
GST pull-downs were performed by incubating appropriate volume of GST 
beads with   200 µg of protein lysate for 4-16 hours at 4°C.  The beads were 
then pelleted by centrifugation for 2 minutes at 100 g in a 4°C centrifuge and 
washed with 500 µl of IP buffer.  The wash step was repeated an additional 3 
times before proteins were eluted by boiling beads at 95ºC in 4x loading 
buffer with β-mercaptoethanol for 5 minutes.  Pulled-down proteins were 
analysed by SDS-PAGE and Western blotting. 
 
2.4.5.2 Co-immunoprecipitation (co-IPs) 
Endogenous co-IPs were performed on U2OS cells plated out at 
medium density.  Cells were washed with PBS and extracts were prepared by 
scraping cells in ice cold co-IP buffer.  Cells were left in the buffer for 30 
minutes before cell debris was pelleted by centrifugation for 12 minutes at 
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13050 g in a 4°C centrifuge.  The supernatant was pre-cleared with 30 µl of 
Protein-A or Protein-G sepharose beads for 1 hour at 4°C.  Endogenous 
complexes were obtained by incubating 2 µg of relevant antibody with 200 µg 
of cell lysate over night at 4°C with gentle mixing.  Immuno-complexes were 
purified by incubating fresh Protein-A or Protein-G sepharose beads with the 
lysate for 2 hours at 4°C.  The beads were then pelleted by centrifugation for 
2 minutes at 100 g in a 4°C centrifuge and washed with 500 µl of co-IP buffer.  
The wash step was repeated an additional 3 times before proteins were 
eluted by boiling beads at 95ºC in 4x loading buffer with β-mercaptoethanol 
for 5 minutes.  The immune-precipitates were separated by SDS-PAGE and 
analysed by Western blotting or silver staining using Plus One Silver Staining 
Kit according to the manufacturers protocol. 
  
2.4.5.3 Proteomics 
Bands from silver stained gels were excised and cut into small pieces 
of about 2 mm using a sterile scalpel. In-gel digestion was performed with 
trypsin on a robotic digestion system (Investigator ProGest, Genomic 
Solutions). Peptides were separated by a nanoflow LC system on a reverse 
phase column (C18 PepMap100, 3 µm, 100 Å, 25 cm; Dionex) and subjected 
to MS/MS analysis (LTQ-Orbitrap XL, Thermo Fisher Scientific).  The spectra 
were matched against the human database (UniProtKB/Swiss-Prot Release 
14.6, 20,333 protein entries).  Protein hits with identification probability > 
99.0% and at least two unique peptides with identification probability > 95% 
were selected using Scaffold software (version 2.0, Proteome Software Inc., 
Portland, OR) and considered for further work.  Mass spectrometry was 
performed by Dr. Xiaoke Yin  (Professor Mayr lab, King’s College London). 
 
2.4.5.4 Microtubule binding assays 
 In vitro microtubule binding assays were performed using a Microtubule 
Binding Protein Spin-Down Assay Kit from Cytoskeleton.  GST-purified 
proteins were prepared as described above and incubated with polymerized 
microtubules in an eppendorf tube according to the manufacturers instructions.  
Briefly, microtubules were assembled in eppendorfs by incubating Tubulin 
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protein with a cushion buffer for 20 minutes at 35°C.  After assembly, a 
general tubulin buffer containing taxol was added to the microtubules to 
maintain their stability for several hours at RT.  Next 5 µg of GST-purified 
proteins were incubated with microtubules for 30 minutes at RT followed by 
ultracentrifugation at 100 000 g at RT for 40 minutes.  The supernatant 
containing the unbound fraction was carefully placed into an additional 
eppendorf and the pelleted microtubules were re-suspended into protein 
loading buffer with β-mercaptoethanol.  The two fractions were analysed by 
Western blotting using a GST antibody. 
 
2.5 Online bioinformatics tools  
The following bioinformatics programs were used to throughout the 
thesis to analyse the structure and potential functional motifs of nesprin and 
aid with cloning: 
1. NCBI Basic Local Alignment Search Tool (BLAST) 
http://www.ncbi.nlm.nih.gov/BLAST 
2. Protein Families Database of Alignments and HMMs (Pfam) 
http://www.sanger.ac.uk/Software/Pfam  
3. Eukaryotic Linear Motif analysis (ELM) 
http://elm.eu.org/links.html  








8. fr33 DNA translator 
 http://www.fr33.net/translator.php 
9. ExPASy Protein Mw calculator  
 http://www.fr33.net/translator.php 
10. IDT Primer Quest  
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 http://eu.idtdna.com/Scitools/Applications/Primerquest/ 
11. DNA Sequence Reverse and Compliment  
 http://www.cellbiol.com/scripts/complement/reverse_complement_seq
 uence.html 
12. NEB cutter V.20 
 http://tools.neb.com/NEBcutter2/ 
13. siDESIGN centre  
 http://www.dharmacon.com/designcenter/designcenterpage.aspx  
14. UCSC human genome browser 19 
 http://genome.ucsc.edu/goldenPath/credits.html#human_credits 
 
2.6 Primer Sequences 
 All primers were designed between 20-50 nucleotides with a 
Guanine/Cytosine content of approximately 50% depending on purpose of the 
PCR.  Primers were synthesized by IDT DNA and re-constituted into nuclease 
free water to create a 100 µM stocks.  For each PCR reaction, primers were 
diluted 1 in 20 to make a 5 µM working concentration.  Primer sequences 
shown throughout this thesis are orientated in a 5’ to 3’ direction.      
2.6.1 RACE primers  
 For the identification of 5’ ends, nested primers were synthesized 1-10 
nucleotides downstream of the primer used in the first round of amplifications.  
For the identification of 3’ ends, nested primers were synthesized 1-10 
nucleotides upstream of the primer used in the first round of amplifications.  
Primers used for RACE are recorded in table 2.1.       
2.6.2 UTR detection primers  
 For the identification of 5’UTRs, the forward primer was designed 
within the 5’UTR and the reverse primer within the second coding exon to 
control for genomic contamination.  For the identification of 3’UTRs, the 
forward primer was designed within the second to  last  coding  exon  and  the 
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reverse primer within the 3’UTR to control for genomic contamination.  
Primers used for UTR detection are recorded in table 2.2. 
2.6.3 Isoform detection primers 
 The expression of newly identified nesprin-1 isoforms were determined 
by performing PCR amplifications using a forward primer targeting the 5’UTR 
and a reverse primer targeting the 3’UTR.  Primers used for isoform detection 
are recorded in table 2.3.             
  












Table 2.1 Primers used for 5’RACE and 3’RACE 
 Primer Nested Primer 
N1-3’E14 AGGAAACAGCAAACACGATA CAACGGAAACTTGAGCAACATAAG 
N1-3’E44 AAAACAGACATGGAGAG ACCGTGGACAAATGGCTGGAT 
N1-5’E83 TTCAGCTCTTGCTTCACCAACTTTCCA TTAGTCTTCACTTTCTCCTGCATGA 
N1-3’E90 AGGCCAGCCGGCTGCAGCACAC CGCCATCCAGCAGTGTAACATCATG 
Matrin-3 
5’RACE TGTCTGCGGCAGGAATAGGCC TCTTGCTGCTGCTACCCAGTCTTT 
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Table 2.2 Primers used for UTR detection 
 Forward Primer Reverse Primer 
N1-3’E14 ACAATCTTGGGATAGAGTGACCTCC AGTAGGGCTGTTATGCTGCAAGGT 
N1-3’E44 TGCCAGCAGTGTGATTGTAACCAG AGCCTGGGCAACAAGAGTGAAAC 
N1-5’E83 GGGTTCCTTTCACTTCACTTCTGT ACTTCAGCCAACTGAAGGGAGAGT 
N1-3’E90 AGTTGGACGTCTCAGTCTCAAGGA TTTGATGGCTGAGCCCACACAATG 	    











Table 2.3 Primers used for isoform detection 
 Forward Primer Reverse Primer 
p56CHNesp1 GTGCTGCAAAGGCCTGGAATTCAT AGTAGGGCTGTTATGCTGCAAGGT 
p252CHNesp1 GTGCTGCAAAGGCCTGGAATTCAT AGCCTGGGCAACAAGAGTGAAAC 
p31Nesp1 GGGTTCCTTTCACTTCACTTCTGT CACAGCCCTCTAAGTGTTGTGTCA 
p23Nesp1 TACAGCCTTGCCTATAACAGTCCC CACAGCCCTCTAAGTGTTGTGTCA 
p12Nesp1 TCTGATCTCGGGAAACCTGGAGAA CACAGCCCTCTAAGTGTTGTGTCA 
p50Nesp1 GGGTTCCTTTCACTTCACTTCTGT TTTGATGGCTGAGCCCACACAATG 
p41Nesp1 TACAGCCTTGCCTATAACAGTCCC TTTGATGGCTGAGCCCACACAATG 
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2.6.4 Flag cloning primers 
 Primers were designed for DNA transcripts to be cloned into pCMV-
Tag2 vector which places a Flag sequence at the N-terminus of the translated 
protein.  Primers used for Flag-tag cloning are recorded in table 2.4.   
2.6.5 GST cloning primers 
 Primers were designed for DNA transcripts to be cloned into pGEX4T-3 
vector which places a GST tag at the N-terminus of the translated protein.  
Primers used for GST-tag cloning are recorded in table 2.5.     
2.6.6 Primers for qPCR 
 Forward and reverse primers used in qPCR amplifications were 
separated by at least 1 exon-intron boundary to control for genomic 
contamination.  Primers used for qPCR are recorded in table 2.6.        
2.6.7 Matrin-3 Mutagenesis primers 
 Site directed mutagenesis primers were designed to be ~40 
nucleotides with the sequence to be mutated in the central region of the 
primer.  Primers used for matrin-3 site directed mutagenesis are recorded in 
table 2.7.         
2.6.8 Tethering assay cloning primers 
 Primers were designed for DNA transcripts to be cloned into pCI-λN-V5 
vector which places a V5 sequence at the C-terminus of the translated protein.  
Primers used pCI-λN-V5 are recorded in table 2.8.           
 
2.7 siRNA oligos  
 Single siRNA oligos of ~21 nucleotides were designed using siDESIGN 
centre by Dharmacon with a minimum GC content of 30% and a maximum 
GC content of 64%.  siRNA oligos used are recorded in table 2.9.     	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Table 2.4 Primers used for Flag-Tag cloning 
 Forward Primer Reverse Primer 
p56CHNesp1 GATATCATGCAGGAGAAAGTGAAGA



































G3 GATATCATGAATGATACAGAAAAGAA CTCGAGTTACTTGTTGTTAAAGCCCG 	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Table 2.5 Primers used for GST-Tag cloning 









































Matr3 RBD CGCGGATCCAGTCGTCGATG 
CCAGCTTCTTCTTGAAATC 
TCCCCCGGGTTAAAGCATATTA 
GGTTCCTGCTCTGTCTGGTC 	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Table 2.6 Primers used for qPCR 
 Forward Primer Reverse Primer 
N1-3’E87 TCTCCAAGCTCAATCAGGCAGCAT CACAGCCCTCTAAGTGTTGTGTCA 
N1-3’E90 AGTTGGACGTCTCAGTCTCAAGGA TTTGATGGCTGAGCCCACACAATG 
N1-KASH GAGGCAAGTGTAGTCTCTCACAG   AGGGCCATTCGTGTATCTGAGCAT 
Lamin A/C TGAGAACAGGCTGCAGACCATGAA CAAACTCACGCTGCTTCCCATTGT 
Matrin-3 TCGTCGATGCCAGCTTCTTCTTGA CCTTGCAGGTTTCCATTTCCAGCA 
N1-Exon 90 AGTTGGACGTCTCAGTCTCAAGGA AGAGAGGTAAGCTGGCAACCACAT 
GAPDH CGACCACTTTGTCAAGCTC CAAGGGTCTACATGGCAAC 
MACF-1 GE CACGAGGTAGAACTAACATTGAACTT GAAGATGGTTTGGACCTTCG 
MACF-1 Inc GGATGGCCTTGGATGAATTT GGGAGACTGACTGGAAATCG 
MACF-1 Exc ATGATCCCTGCCGAGCAC GAAGATGGTTTGGACCTTCG 
TPM2 GE AGCTGAAGGGGACAGAGGAT GCATCAGTGGCCTTCTTCTC 
TPM2 Inc GGCAAAGTTGGAGAAAACCA TGGTCCAAGGTCTGGTGAAT 
TPM2 Exc GGCAAAGTTGGAGAAAACCA GTCCAGTTCCTCGCTAATGG 
Importin-β TCCAGTCTGGCTGAAGCTGCTTAT AGGTTGTTCTGGTGTCCATCAGGT 
DDx5 TCAACAAGAGCGTGACTGGGTTCT TGGTACTGCGAGCAGTTCTTCCAA 
hnRNP 
A2/B1 ACGGCTACTAAGTTCAGCCAGTCT TGCTCTACACCCTCAGCTTTCGTT 
PCNA ATCCTCAAGAAGGTGTTGGAGGCA ACGAGTCCATGCTCTGCAGGTTTA 	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Table 2.7 Primers used for matrin-3 site directed mutagenesis 
 Forward Primer Reverse Primer 
1-833 CAGAAATTAAAGAAATTT TAGAATAAATTGGCAGAAGAACGC 
GCGTTCTTCTGCCAATTTATTCTA 
AAATTTCTTTAATTTCTG 






1-469 GCCAGTGAGAGTTCATTAATCCC AGAAGTATAAAAGA 
TCTTTTATACTTCTGGGATTAATG 
AACTCTCACTGGC 
1-399 GTGGAAACTAGCAGAGTTTAACA CATCATGGATTTTCAACG 
CGTTGAAAATCCATGATGTGTTAAA
CTCTGCTAGTTTCCAC 




























Table 2.8 Primers used for pCI-λN-V5 cloning 
































Table 2.9 siRNA oligos used for knockdown studies 










Si-hnRNP A2/B1 AACUCUUGACGGCUACUAAGU 
Si-PCNA AAGGGCCGAAGAUAACGCGGA 
Si-Matrin-3 Smart pool Dharmacon L-017382-00-0005 
Si-Rck/p54 Smart pool Dharmacon L-006371-00-000 
Si-GW182 Smart pool Dharmacon L-014107-00-0005 
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2.8 Plasmids 
 Several plasmids used in this thesis were graciously provided by other 
researchers and are listed below.  Plasmids that were spotted onto blotting 
paper were soaked in a small volume of nuclease-free water and vortexed 
vigorously before being transformed into competent bacteria for plasmid 
isolation.  Plasmids kindly provided by other laboratories are recorded in table 
2.10.       
 
2.9 Antibodies 
2.9.1 Generation of nesprin-1 antibodies  
Dr. Qiuping Zhang designed synthetic polypeptides specific to nesprin-1 (table 
2.2).   Immune Systems Ltd, UK (ILT) conjugated each peptide to keyhole 
limpet heamocyanin and injected these complexes into rabbits to generate 
polyclonal antibody sera.  The immune sera were affinity purified against a 
peptide column before use.  Unless otherwise mentioned, all antibodies used 
in this study have been evaluated by epitope-specific peptide block on both 
western blots and immunofluorescence to test for specificity.  Nesprin-1 
antibodies, peptide sequences generated against and position of sequence 
within the nesprin-1 giant are recorded in table 2.11 with peptide sequences 
present amino acids. 
2.9.2 Primary Antibodies 
 Primary antibodies used throughout the thesis were obtained from 
different manufacturers.  The catalogue numbers and the dilutions used for 
Western blotting and immunofluorescence staining and summarized in table 
2.12.  
2.9.3 Secondary antibodies 
2.9.3.1 Western blotting secondary antibodies  
 The HRP-conjugated secondary antibodies used for Western 
blotting and dilutions are summarized in table 2.13.     
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Table 2.10 Plasmids obtained from external laboratories 
Plasmid Provider Reference  
pEYFP-C1-Dcp1a Dr. Kedersha , 
Division of Rheumatology and 






Dr. Wilczynska, Institut André Lwoff, 




pDNA3-HA-e4E-T Dr. Dostie, Dpeartment of 
Biochemistry and McGill Cancer 
Centre, McGill University 
 
[241] 
pDNA3-HA-eIF4E Add gene Plasmid 17343 [242] 
phrGFP-N1-GW182 Dr. Eystathioy Deprtment of 
Medicine and Biochemistry and 




pEYFP-C1-TTP Dr. Kedersha [239] 
pFRT-TO-FLAG-GW182-HA Add gene Plasmid 19883 [244] 
pEGFP-C1-MS2 Dr. Kedersha  [239] 
pEF-7B-MS2bs Dr. Kedersha  [239] 
pRL-TK- CXCR4 6X Add gene Plasmid 11308 [245] 
pcDNA3.1/NT-GFP--Matrin-3 Dr. Zeitz,  Department of Biological 
Sciences, University at Buffalo, 
State University of New York 
 
[246] 
phRL-Gl-5BoxB Dr. Choe, School of Life Sciences 




pCI-λN-V5 Dr. Choe, School of Life Sciences 




pFF4LCS Dr. Steitz, Department of Molecular 
Biophysics and Biochemistry, Yale 
Medical School  
 
[248] 
pFFr4mLCS Dr. Steitz [248] 
 
[239] [240,241]  [242] [243] [244] [245] [246] [247,248] 
 



















Table 2.11 Nesprin-1 antibodies generated and used in thesis 
 Peptide sequence  Nesprin-1 giant amino acids 
CH2 LQDKYQSFKHFRVQC 297-310 
C2 CALSNNFARSFHPMLR 8774-8789 
N4 EQNGQLGKPLAKKIGKL 5488-5504 
N5 QTIRQAENRLSKLNQA 5510-5525 	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Table 2.12 Primary antibodies used in thesis 
Antibody Western Blotting Immunofluorescence 
β-actin (Sigma A2228) 1:10 000 1:1000 
Argounaute-2 (Abcam ab57113) 1:500 - 
Dcp1a (Abcam ab57654) 1:100 - 
DDx5 (Abcam ab21696) 1:1000 - 
eIF3η (Santa Cruz sc-16377) - 1:200 
Focal Adhesion Kinase (Abcam 
ab28152)  
- 1:200 
Fibrillarin (Abcam ab4566) - 1:500 
Flag (Sigma F3165) 1:10 000 1:2000 
Flag (Sigma F7425) 1:10 000 1:2000 
GFP (Abcam ab1218) 1:2000 - 
GST (Abcam ab6613) 1:500 - 
HA (Abcam ab16918) 1:1000 1:200 
Hedls/p70S6Ka (Santa Cruz sc-8418)  - 1:200 
Importin beta  (Abcam ab2811) - 1:1000 
Lamin A/C (Santa Cruz sc-6215) 1:1000 1:100 
Matrin-3C (Abcam ab84422) 1:1000 1:100 
Matrin-3N (Abcam ab51081) 1:2000 1:100 
Nesprin-1 C2  1:1000 - 
Nesprin-1 CH2 1:1000 - 
Nesprin-1 N4 1:1000 1:100 
Nesprin-1 N5 1:1000 1:100 
Nucleophosmin (Abcam ab10530) 1:5000 1:1000 
PABP-1 (Santa Cruz sc-32318) - 1:200 
PCNA (Cell Signalling mAb2586) 1:1000 - 
PSF (Santa Cruz sc-101137) 1:1000 - 
Rck/p54 (Bethyl laboratories A300-
461A) 
1:1000 1:200 
smD1 (Santa Cruz sc-20822) - 1:50 
SRp55 (Santa Cruz sc-34198) - 1:20 
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Tra2b (Abcam ab66901) - 1:250 
α-Tubulin (Sigma T9026) 1:10 000 1:1000 
U1-70K (Millipore 06-1297) - 1:500 
U2 snRNPA (Santa Cruz sc-132132) - 1:50 
V5 (Invitrogen R-960-25) 1:1000 - 
  













Table 2.13 Secondary antibodies used for Western blotting in thesis 
HRP-conjugated secondary antibodies Dilution 
ECL goat IgG, HRP-conjugate (Sigma A9452) 1:5000 
ECL mouse IgG, HRP-conjugate (GE healthcare NA931) 1:5000 
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2.9.3.2 Immunofluorescence secondary antibodies  
 Alexa fluorophore-conjugated secondary antibodies used for 
immunofluorescence staining and dilutions are summarized in table 2.14.   
 
2.10 Laboratory reagents  
2.10.1 Stock Reagents 
100mM dATP – Promega  U1205 
13mm Borosilicate Cover Glass thickness No.1 - VWRTM 631-0149 
1kb DNA ladder – Promega G571A 
1x Trypsin-EDTA solution – Sigma T3924 
dNTPs 100mM stock solution – Promega 
2mm Electroporation cuvettes (long electrode) – Flowgen FBR-202 
30% Acrylamide/Bis solution – BioRad (161-0158) 
4’,6’-Diamidino-2-Pheylindoledihydrochloride (DAPI) –Sigma (D-9542) 
6x DNA loading buffer –Promega G1881 
Acetone ((CH3)2CO) – Fisher Scientific (A/0600/PC17) 
Advantage 2 polymerase -  Clontech 639201 
Ammonium Persulfate – BioRad 161-0700 
Ampicillin sodium salt – Sigma A0166 
Antarctic Phosphatase – New England Biolabs M0289S 
AMV-RT – Promega M5101  
BioSafeTM Coomassie Stain – BioRad 161-0787 
Bovine Serum Albumin (Cohn V fraction) – Sigma A4503 
Bromophenol Blue – Aldrich (11,439-1) 
Calcium Chloride (CaCl2· 2H2O) – Sigma C1016 
Cycloheximide ready made solution – Sigma C4859 
DABCO (1,4-diazabicyclo[2.2.2]octane)–Sigma (D-2522) 
DC Protein Assay – BioRad 500-0113, 500-0114 
Deionized H2O (DI-H2O) –Millipore purification system 
DEPC-treated water – Invitrogen 750023 
D-Glucose – Sigma G7528 
Dried Skimmed Milk- Marvel 









Table 2.14 Secondary antibodies used for immunofluorescence staining 
in thesis 
Alexa Fluor-conjugated secondary antibodies Dilution 
Alexa Fluor 405 goat anti-mouse IgG (Invitrogen A31553) 1:1000 
Alexa Fluor 488 donkey anti-goat IgG (Invitrogen A11055) 1:1000 
Alexa Fluor 488 goat anti-mouse (Invitrogen A11001 ) 1:1000 
Alexa Fluor 488 goat anti-rabbit (Invitrogen A11008) 1:1000 
Alexa Fluor 488 rabbit anti-mouse IgG (Invitrogen A11059) 1:1000 
Alexa Fluor 568 donkey anti-goat IgG (Invitrogen A11057) 1:1000 
Alexa Fluor 568 goat anti-mouse (Invitrogen A11004 ) 1:1000 
Alexa Fluor 568 goat anti-rabbit (Invitrogen A11011) 1:1000 
Alexa Fluor 568 rabbit anti-mouse IgG (Invitrogen A11061) 1:1000 
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Dulbecco’s Modified Eagle’s Medium (DMEM) – Sigma D5671 
Earl’s Balanced Salt solution (EBSS) – Sigma E6267 
Ehtidium Bromide – Sigma (E-1385)  
Ethanol (CH3CH2OH, EtOH) – Sigma E7023 
Ethylenediaminetetra-acetic Acid (EDTA) – Sigma (E-5134) 
First Strand cDNA Human Set 1 – Origene (CH1101) 
First Strand cDNA Human Set 2 - Origene (CH1102) 
Foetal Bovine Serum (FBS) – Sigma (F-7524) 
Glacial Acetic Acid (GAA)- Sigma 537020  
Glycerol –Fisher Scientific BPE229-1 
Glycine – BDH444495D 
Hepes – Sigma H4034 
Hiperfect transfection reagent – QIAGEN 301707 
Hydrochloric Acid-Sigma H1758	  
Hydrogen Peroxide – Sigma H1009  
Immobilon-PTM (PVDF Western Blot Membrane) – Millipore (IPVH00010) 
In Vitro Toxicology Assay Kit, MTT based – Sigma TOX1 
Isopropanol (C3H8O)- Sigma I9516 
Isopropyl-β-D- Thiogalactopyranoside (IPTG) ready made solution  – Sigma 
I1284 
Kanamycin disulfate salt – Sigma K1876 
LB Agar – Sigma L2897 
LB Media – Sigma L3022 
L-Glutamine – Invitrogen 25030-081 
M199 Media - Sigma M4530  
Magnesium Chloride (MgCl2) – Sigma M8266 
Marathon-Ready Brain cDNA libary for RACE – Clontech 639301 
Marathon-Ready HeLa cDNA libary for RACE– Clontech 639339 
Methanol (CH3OH,MeOH) -  Sigma 322415 
Mowiol – Calbiochem 475904 
N,N,N’,N’-Tetra-Methyl=Ethylenediamine (TEMED) –BioRad 161-0800 
Nocodazole – Sigma M1404 
Nonidet P-40 (NP-40) Alternative – Calbiochem 492016 
Optimem – Invitrogen 11058-21 
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Paraformaldehyde powder – Sigma P6148 
PCR master mix –Promega M7502 
Penicillin-Streptomycin-Glutamine solution  liquid – Invitrogen  10378-016 
pGL3-Control vector – Promega E1741 
Phosphate Buffered Saline (PBS) Tablets – Oxoid BR0014G 
PBS tissue culture grade – Sigma D1408 
Polyoxyethylenesorbitan Monolaurate (Tween-20) – VWR 437082Q 
Potassium Chloride (KCl) – Sigma P9333 
Precision Plus ProteinTM Dual Color Standars – BioRad 161-0374 
Protease Inhibitor Cocktail – sigma P8340 
Protein Assay Standard II – BioRad 500-0007 
Protein-A Sepharose beads – Sigma P944 
Protein-G Sepahrose beads – Sigma P3296 
Random Primers – Promega C1181 
RestoreTM Western Blot Stripping Buffer- Thermo Scientific 21059 
siRNA buffer (Dharmacon) 
siRNA oligos - Dharmacon, Invitrogen 
Sodium Arsenite solution- Sigma 35000  
Sodium Chloride (NaCl) – Sigma S7653 
Sodium Deoxycholate – Sigma D6750 
Sodium Hydroxide (NaOH) - Sigma S8045 
Sodium Phosphate, dibasic, anhydrous (Na2HPO4) – Sigma S7907 
STAT-60  -  IsoTex Diagnostics CS-110 
Superfect – QIAGEN 301305 
Sybr green PCR master mix - Eurogentec RT-SY2X-03+NRWOUB 
Triton-X 100 – Sigma X100 
TrizmaTM base – Sigma T6066 
UltraPureTM Agarose – Invitrogen 15510-019 
β-Mercaptoethanol (C2H6OS, βME) – Sigma (M-6250) 
2.10.2 Purchased Kits 
BioRad SDS-PAGE gel pouring kit 
Cell growth determination kit, MTT based – Sigma CGD1 
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Dual Luciferase Reporter Assay- Promega E1910 
ECL Chemiluminescent Kit – Pierce 32106 
Endofree Maxiprep – QIAGEN 12362 
pGEM-T Easy Vector System II – Promega A-1380 
Plus One Silver Staining Kit – GE Healthcare 17-1150-01 
PureYield Plasmid Miniprep System -  Promega A1222 
QIAquick Gel Extraction Kit – QIAGEN 28706 
Microtubule Binding Protein Spin-Down Assay Kit – Cytoskeleton BK029 
QuikChange® Site-Directed Mutagenesis Kit – Stratagene 200518 
 
2.10.3 Laboratory Equipment 
Applied Biosystems 2720 Thermal Cycler 
Berthold Mithras LB 940 Luminometer 
Bio-Rad Trans-Blot® SD semi-dry transfer cell 
Branson Sonifier 150  
Corbett RotorGene-3000 qPCR machien  
Eppendorf Centrifuge 5415R microcentrifuge 
GENios Pro spectrophotometer 
InforsHT Ecotron bacterial shaker 
Leica SP5 Confocal Microscope 
NanoDrop® ND-1000  
Olympus IX81 wide field inverted  microscope 
Thermo Scientific HERA cellISO incubator 
Thermo Scientific HERA Safe biosafety cabinet 
Thermo Scientific Heraeus Multifuge 3SR+ centrifuge 
UVP Bio Spectrum® AC Imaging System 
2.10.4 Enzymes 
Antartic Phosphatase – New England Biolabs M0289L 
Pfu polymerase and buffer- Promega M7741 
T4 DNA ligase and buffer – Promega M1804 
Taq polymerase and buffer- Promega M2031 
ApaI – Promega R6361 
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BamHI – Promega R6025 
EcoRI – Promega R6017 
EcoRV– Promega R6351 
NotI – Proemga R6431 
SalI – Promega R6051 
XhoI – Promega R6165 
SmaI – Promega R6121 
2.10.5 Solutions 
2M KCl (500 ml) 
 74.55 g KCl, 500 ml DI-H2O 
5M EDTA (5 ml) 
 7.3125 g EDTA, 5 ml DI-H2O 
1M Hepes pH 7.4 (50 ml) 
 11.915 g Hepes, 50 ml DI-H2O 
100 mM CaCl2 (500 ml) 
 5.549 g CaCl2, 500 ml DI-H2O 
1M MgCl2 (500 ml) 
 101.5g MgCl2, 500 ml DI-H2O 
10% SDS (w/v) (100 ml) 
 10 g SDS, + DI-H2O to 100 ml total 
PBS-T (500 ml) 
 499 ml 1x PBS, 1 ml Tween-20 
10x Tris-Buffered Saline (TBS) pH 7.6 (500 ml) 
 12.11 g Trizma, 6.5 ml absolute HCl, 40 g NaCl, + DI-H2O to 500 ml 
1x TBS-T (500 ml) 
 499 ml 1x TBS, 1 ml Tween-20  
50x Tris-acetate-EDTA (TAE) Buffer (1000 ml) 
242 g Trizma, 57.1 ml GAA ,18.6 g EDTA, DI-H2O to 1000 ml  
1% Agarose gel (100 m1) 
 1 g molecular grade agarose, 100 ml 1x TAE 
Co-immunoprecipitation (Co-IP) Buffer pH 7.4 (500 mL) 
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5 ml 1M Hepes pH 7.4, 2.5 ml 2M KCl, 500 µ 5M EDTA,  5 ml Triton-X 
100, DI-H2O to 500 ml 
Radio Immunoprecipitation (RIPA) Buffer (100 ml) 
100 µl NP-40, 0.5% Sodiium Deoxycholate, 100 µl 10% SDS, 98.4 ml 
1x PBS. 
Nuclear fractionation buffer (250 ml) 
 0.59g Hepes, 0.076g MgCl2, 0.187g KCl, 0.019g DTT, 12.5 ul NP-40 
4x SDS-PAGE Sample Loading Buffer (10 ml) 
1.25 ml 0.5 M Tris-HCl pH 6.8, 2.5 ml Glycerol, 2.0 ml 10% SDS, 0.20 
ml 0.5% (w/v) bromophenol blue, 500 µl β-Mercaptoethanol 
10x Transfer Buffer (500 ml) 
 72.2g Glycine, 15.15g Trizma,  DI-H2O to 500 mL  
1x Transfer Buffer (1000 ml) 
 100 ml 10x Transfer buffer, 200 ml MeOH, 700 ml DI-H2O. 
10x Running Buffer (500 ml) 
 72.2 g Glycine, 15.15 g Trizma, 10 g SDS, DI-H2O to 500 ml  
10% APS (w/v) (1 mL) 
 10 mg Ammonium Persulfate, 1 ml DI-H2O 
4% Stacking PAGE gel (~10 ml) 
1.7ml 30% acrylamide mix, 2.5 ml 0.5M Tris pH 6.8, 100µl 10% SDS, 6 
ml water, 50 µl 10% ammonium persulfate, 7.5 µl TEMED 
10% Resolving PAGE gel (~15 ml) 
5ml 30% acrylamide, 3.75ml 1.5M Tris pH 8l8, 150 µl 10% SDS, 6 mL 
DI-H2O, 100 µl 10% APS, 7.5 µl TEMED 
Western blocking buffer (100 ml) 
 5 g dried milk, 100 ml 1x PBS-T 
4% Paraformaldehyde (PFA) (50ml) 
 2 g paraformaldehyde, 50 ml 1xPBS 
MeOH/Acetone Fixative (100 ml) 
 50 ml MeOH, 50 ml Acetone, -80ºC 
Mowiol Mounting media  (10ml) 
2.4 g Mowiol 4-88, 6 g Glycerol, 6 ml DI-H2O, 12 ml 0.200M Tris pH 8.5, 
2.5% DABCO,  
1% Bovine Serum Albumin (BSA) (w/v) (100 ml) 
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 1 g BSA, 100 ml 1x PBS 
0.5% NP-40 (100 ml) 
 500µl NP-40, 100 ml 1x PBS 	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Chapter 3: Identification of Novel Nesprin-1 Isoforms   
 
3.1 Introduction 
The versatility of SR proteins is largely due to the expression of 
multiple tissue specific variants generated by alternative mRNA transcripts.  
These alternative transcripts are produced by alternative splicing, alternative 
promoter selection and alternative pre-mRNA 3’end processing [249].  The 
significance of this increased diversity is particularly evident in the dystrophins 
and spectraplakins, which have more than 15 and 13 potential known tissue 
specific isoforms respectively [58,250,251,252].  Studies are now showing the 
existence of alternatively transcribed nesprin variants and their generation 
may be comparable, if not more extensive, than any other SR protein family 
member [66,206,207,208,232,249]. 
 Disruption of the LINC complex via mutations in nesprin-1 and -2 or 
their binding partners, such as emerin and lamin A/C, give rise to Emery 
Dreifuss Muscular Dystrophy (EDMD) [14].  However, emerging evidence 
implicates nesprin-1 in several other unrelated diseases, including epithelial 
cancers and autosomal recessive cerebellar ataxia (ARCA1), which are not 
characterized by NE defects [13,232].  It is likely that these non-canonical 
roles for nesprin are mediated by alternative nesprin variants that lack either 
the CHDs, the KASH domain or both, and localize to a number of sub-cellular 
compartments.  For example, in chapter 1 the roles for KASH-less nesprin 
variants in Golgi structure and function, chromatin organization, clathrin-
mediated uptake and recycling of chemokine receptors, and ERK1/2 
scaffolding were described  [207,208,222,232]  
           In order to further assess the extent of alternate nesprin-1 functionality, 
I set out to identify new novel 5’UTRs and 3’UTRs using rapid amplification of 
cDNA ends (RACE).  By combining these newly identified UTRs with ones 
previously identified by our laboratory, I show that multiple tissue specific 
nesprin-1 variants can be generated.  Furthermore, I show that these variants 
are translated and localize to unique sub-cellular compartments, implying that 
nesprin-1 may have functional and/or structural roles beyond the NE.      
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3.2 Results 
3.2.1 Previously identified nesprin-1 UTRs 
 Originally, our laboratory had screened available online databases to 
identify bone fide novel nesprin-1 5’UTRs and 3’UTRs which may be used to 
generate alternative nesprin-1 transcripts.  The NCBI expressed sequence tag 
database (EST), which consists of one-shot sequences of cloned mRNA, was 
blasted with consecutive 500bp-overlapping 1kb nesprin-1 sequences 
covering the entirety of the giant isoform cDNAs.  Several novel UTRs were 
detected in the EST database screen, typically presenting as retained 
sequences created through alternative promoter usage and alternative 3’end 
processing (Table 3.1).  5’UTRs, generated through the utilization of 
alternative promoters (Figure 3.1), were considered real if they contained an 
identifiable and viable Kozak sequence surrounding the first start codon.  
3’UTRs, generated though alternative pre-mRNA 3’end processing via 
selection of alternative polyadenylation sites, were considered if they already 
included a poly(A) tail or contained at least one poly(A) site downstream of the 
initial ORF termination codon, as determined by scanning with the polyAdq 
program or manually for non-canonical poly(A) signals (Figure 3.1).   
 Nine out of the nineteen nesprin-1 UTRs identified through the 
database screen were verified by Dr. Jason Mellad (Shanahan laboratory, 
King’s College London), using RT-PCR on a multi-tissue cDNA panel and 
DNA sequencing.  Although many UTRs PCR amplified in a range of tissues, 
most were transcribed in a tissue specific manner suggesting they lead to the 
creation of tissue specific nesprin variants (Figure 3.2). The UTRs were 
named based upon their first or last coding exons for 5’UTRs and 3’UTRs 
respectively.  For example, N1-5’E138 is a novel 5’UTR where the first coding 
exon utilized is exon 138, and N1-3’E18 is a novel 3’UTR where the last 
coding exon utilized is exon 18.      
 Figures 3.3 provides an outline of all the identified 5’UTRs and 3’UTRs 
spread across the 146 exons which make up the nesprin-1 gene, with figure 
3.4 highlighting full length isoforms which are known to be expressed, and 
proposed variants that could be created by alternative UTR usage in vivo for  
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nesprin-1 (Figure 3.4A,B). The potential combinations of the different 
seventeen 5’UTRs with the nine 3’UTRs are extensive and would allow 
generation of many variants.  The SRs used in the schematics to represent 
nesprins are based on the predictions of SRs previously described using 
sequence alignments and evolutionary conservation [78].  Although many 
variants could retain the KASH domain, there is a possibility of generating 
isoforms composed solely of SRs and/or CHDs.  Therefore, the identified 
nesprin-1 variants were named according to their predicted molecular weights 
and the domains they contained.  For example, p81CHNesp1 is a nesprin-1 
variant of 81 kDa which has the N-terminal CHDs, p12Nesp1 is a 12 kDa 
nesprin-1 variant which lacks both the CHDs and the KASH domain and is 
composed of SRs, while p53KASHNesp1 is a 53 kDa KASH containing variant 
lacking both CHDs.  
3.2.2 KASH isoforms  
 So far a number of KASH variants including the nesprin-1α and 
nesprin-1β isoforms have been identified.  In principle, any of the 17 different 
5’UTRs could be utilised with the 3’UTR of the nesprin-1 giant to make KASH 
containing NE localized nesprin-1 variants (Figure 3.5, Table 3.2).  The 17 
potential nesprin-1 KASH variants which can be translationally expressed, 
most likely do so in a tissue specific manner due to the specificity of the 
individual 5’UTRs.    
To determine which nesprin-1 KASH variants were translationally 
expressed, whole-cell lysates from human dermal fibroblasts (HDFs) and 
human osteosarcoma (U2OS) cells were analysed by Western blotting using 
the nesprin-1 C2 antibody (Figure 3.6A).  The nesprin-1 C2 antibody was 
created to target the nesprin-1 KASH domain, and therefore recognize all C-
terminal KASH domain nesprin-1 variants.  As predicted, multiple bands were 
detected by nesprin-1 C2, including a doublet at ~100 kDa in HDFs which 
could represent either of the two nesprin-1α and/or p123KASHNesp1 variants.  
Nesprin-1 C2 only produced a single band at ~100kDa from U2OS cell lysate 
suggesting only one of the nesprin-1α variants or p123KASHNesp1 are 
expressed in U2OS cells.  An additional band was seen in U2OS  cell  lysates  
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at ~50kDa, which could correspond to p53KASHNesp1 (Figure 3.6B).  Although 
nesprin-1 C2 should detect other nesprin-1 KASH variants such as the 
nesprin-1 giant and the nesprin-1β isoforms previously described, bands 
corresponding to these large isoforms were not visualized, possibly due to 
lack of expression or size-limited migration into the polyacrylamide gels.   
3.2.3 CHD isoforms 
 The only nesprin-1 CHD containing isoforms identified to date are the 
nesprin-1 giant and Drop1 variants.  As with the potential KASH domain 
isoforms in Figure 3.4, up to 9 CHD isoforms can be generated by combining 
any of the 9 3’UTRs with the nesprin-1 giant 5’UTR (Figure 3.7, Table 3.3).  
To determine what CHD variants were expressed in U2OS cells and HDFs, 
Western blotting on whole cell lysates was performed using the nesprin-1 
CH2 antibody, designed to target the second nesprin-1 CHD (Figure 3.8 A,B).  
Novel nesprin-1 variants p121CHNesp1, p88CHNesp1 and p81CHNesp1 were 
detected in both cell lines with an unknown variant detected at ~50 kDa.  
Furthermore an additional U2OS cell specific nesprin-1 variant was detected 
at ~250 kDa (Figure 3.8 B), suggesting at least two nesprin-1 CHD variants 
exist that have yet to be identified.   
3.2.4 Rapid Amplification of cDNA Ends (RACE) to identify new cDNA 
ends. 
 Online databases did not contain sequences that could encode for 
nesprin-1 CHD variants of ~50 kDa and ~250 kDa in size, as detected by 
Western blotting.  Therefore to identify potential mRNA species encoding 
these variants, Rapid Amplification of cDNA Ends (RACE) was performed to 
identify new 3’UTRs expressed in cells/tissues.  RACE is a technique used to 
obtain the full-length sequence of an mRNA transcript found within a cell. 
RACE can provide the sequence of an mRNA transcript from a small known 
sequence within the transcript all the way to the 5' end (5' RACE) or 3' end (3' 
RACE) of the mRNA.  RACE relies on the ligating a known adaptor sequence 
onto the 5’ and 3’ ends of a cDNA library.  Therefore, by utilizing primers 
targeting the known adaptor sequence with nesprin-1 gene specific primers, it 
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is possible to PCR amplify novel cDNA ends generated by alternative 
transcription.  Previous studies, and the data shown at the beginning of this 
chapter, suggest  that nesprin isoforms are expressed in a tissue specific 
manner.  Therefore, to increase the probability of identifying novel nesprin-1 
cDNA ends, PCRs were performed on RACE-Ready cDNA libraries obtained 
from HeLa cells, the brain and skeletal muscle.  
3.2.5 Characterization of p56CHNesp1 
3.2.5.1 Identification of N1-3’E14 
 To identify the unknown ~50 kDa nesprin-1 CHD variants detected by 
the nesprin-1 CH2 antibody in U2OS and HDF cells, 3’RACE analysis was 
performed using nesprin-1 specific primers in a range of exons that could 
produce a ~50 kDa CHD containing nesprin-1 product.  Forward primers 
targeting multiple nesprin exons were utilized with RACE, many failing to PCR 
amplify any fragments.  However, by using forward nesprin-1 primers 
designed within exon 14, PCR products were amplified from all three RACE-
ready libraries (Figure 3.9A).  DNA sequencing followed by a nucleotide 
BLAST against the human genome aligned the amplicon to exon 14 and 
intronic sequences between exons 14 and 15 of the nesprin-1 gene.  More in 
depth analysis of the ampliicon sequence showed the ORF carried on from 
exon 14 into the retained intron.  The stop codon for this cDNA end was found 
in the retained intron after the unique 37 amino acid coding sequence 
‘KIEAIRKELPPAPTATSTHLRNCICARIHALHFCYYG’.  Downstream of the 
stop codon was an AATAAA polyA signal followed by a polyadenylation site. 
Using the same nomenclature used to describe the nesprin UTRs identified 
previously, this UTR was named N1-3’E14. 
 
3.2.5.2 N1-3’E14 is ubiquitously expressed  
 To determine the tissue specificity of N1-3’E14, RT-PCR was 
performed on a multiple tissue cDNA panel using a primer set to specifically 
detect  N1-3’E14.  The PCR primers were designed so that the reverse primer 
was present within the UTR and the forward primer within exon 13, to control  
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for genomic DNA contamination.  The UTR was undetectable in the small 
intestine but was present in the heart, brain, lung, kidney, prostate, testis, 
ovaries and peripheral blood leukocytes by RT-PCR (Figure 3.9B).   
 
3.2.5.3 p56CHNesp1 is a product of N1-3’E14 termination and differentially 
localizes in U2OS and HDFs  
 By combining the nesprin-1 giant 5’UTR with N1-3’E14 UTR, a 56kDa 
nesprin-1 variant containing both CHDs and a single SR could potentially be 
translated and could account for the ~50kDa band seen in whole cell lysates 
of U2OS cells and HDFs with the nesprin-1 CH2 antibody (Figures 3.8B, 
3.10A).  To determine if the mRNA transcript of p56CHNesp1 could be detected, 
RT-PCR was performed using a forward primer in the 5’UTR of the nesprin-1 
giant and a reverse primer in N1-3’E14.  The transcript for p56CHNesp1 
amplified from all cell lines and tissues examined, suggesting that p56CHNesp1 
is ubiquitously expressed (Figure 3.10B).   
 p56CHNesp1 amplified from brain cDNA was cloned into a vector 
containing an N-terminal Flag-tag and transfected into U2OS cells to monitor 
it’s sub-cellular localization.  Flag staining localized p56CHNesp1 to a sub-
nuclear compartments, which co-localized with nucleolar marker 
nucleophosmin (Figure 3.11).  When Flag-p56CHNesp1 was transfected into 
HDFs, Flag staining surprisingly displayed no nuclear localization.  Instead, 
p56CHNesp1 co-localized with actin stress fibres and focal adhesions, 
suggesting p56CHNesp1 has unique sub-cellular localizations in unique tissues 
(Figure 3.12).    
3.2.6 Characterization of p252CHNesp1 
3.2.6.1 Identification of N1-3’E44 
 As with the N1-3’E14, 3’RACE analysis was performed using nesprin-1 
specific primers in a range of exons that could produce a ~250 kDa CHD 
containing nesprin-1 product seen in U2OS cell lysates.  By using forward 
nesprin-1 primers designed within exon 44, a PCR product was amplified from 
HeLa cell cDNA library (Figure 3.13A).  This amplicon contained sequences to 
exon 44 and intronic sequences between exons 44 and 45 of the nesprin-1  
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gene.  The ORF carried on from exon 44 into the retained intron.  The stop 
codon for this cDNA end was found in the retained intron after the 30 unique 
amino acid coding sequence ‘VSKIITWDSVNYLNIHIPQSNFWTKRYSRM’.  
Downstream of the stop codon was an AATAAA polyA signal followed by a 
polyadenylation site.  
 
3.2.6.2 N1-3’E44 is detected in a subset of tissues  
 Whereas the N1-3E14 UTR was ubiquitously expressed, N1-3’E44 was 
only detected in a subset of tissues including the heart, ovaries and peripheral 
blood leukocytes, suggesting it displays a high degree of tissue specificity 
(Figure 3.13B).      
 
3.2.6.3 p252CHNesp1 is a product of N1-3’E44 termination and localizes to 
cytoplasmic granular structures   
 By combining the nesprin-1 giant 5’UTR with N1-3’E44 UTR, a 252kDa 
nesprin-1 variant containing both CHDs and multiple SR can be translated, 
which could account for the ~250kDa band seen in whole cell lysates of 
U2OS cells with the nesprin-1 CH2 antibody (Figures 3.8B, 3.14A).  To 
determine if the mRNA transcript of p252CHNesp1 could be detected, RT-PCR 
using a forward primer in the 5’UTR of the nesprin-1 giant and a reverse 
primer in N1-3’E44 was performed.  The transcript for p252CHNesp1 amplified 
specifically from U2OS and heart cDNA, suggesting that p252CHNesp1 is 
highly cell/tissue specific (Figure 3.14B).  
 p252CHNesp1 amplified from U2OS cDNA was cloned into a Flag-tag 
vector and transfected into U2OS cells and HDFs to monitor it’s sub-cellular 
localization.  Flag staining localized p252CHNesp1 to granular structures within 
the cytosol in U2OS cells.  However, transfection only appeared in ~1% of 
plated cells suggesting that expression of the protein may be toxic to the cells.  
Indeed, HDFs failed to express Flag-p252CHNesp1 altogether (Figure 3.15).   
3.2.7 Central rod isoforms      
 To date, GSRP-56 and CPG2 are the only nesprin-1 variant identified 
composed entirely of SRs.  GSRP-56 has been shown to be an important  
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protein in maintaining Golgi structure and function, while CPG2 is required for 
clathrin-mediated uptake and recycling of chemokine receptors, suggesting 
that SRs are not only important in mediating protein-protein interactions but 
are also crucial as scaffolds and linkers in maintaining cellular architecture.  
The identification of multiple 5’UTRs and 3’UTRs within the nesprin-1 gene 
through online databases suggests other SR-only nesprin-1 variants could 
possibly be generated with structural roles in additional sub-cellular 
compartments.  
 
3.2.7.1 Nesprin-1 N4 antibody 
 To identify novel endogenous nesprin-1 isoforms composed only of 
SRs of the central rod domain, our laboratory created an antibody called 
nesprin-1 N4.  Nesprin-1 N4 antibody was generated to epitope 
‘EQNGQLGKPLAKKIGKL’ encoded by exon 86 and located at amino acids 
(aa) 5488 to 5504 in SR50 of the nesprin-1 giant (Figure 3.16A).  To 
determine the size of nesprin-1 variants generated by the central rod, Western 
blotting on whole cell lysates of U2OS cells and HDFs was performed.  
Multiple bands were seen in both cell lysates ranging from ~10kDa to 
~150kDa (Figure 3.16B).    
 Peptide blocking experiments were performed to determine whether all 
the bands detected by nesprin-1 N4 were specific for the N4 epitope.  U2OS 
whole cell lysates run out on SDS-PAGE and immobilized on membranes 
were incubated with the nesprin-1 N4 antibody or the nesprin-1 N4 antibody 
which had been pre-incubated with its blocking peptide for 1 hour at room 
temperature.  Following Western development, all bands were blocked with 
the N4 peptide, confirming antibody specificity (Figure 3.17).        
 
3.2.7.2 Potential Nesprin-1 variants  
 The laboratory had previously identified N1-5’E84 and N1-3’E87 as 
novel 5’UTRs and 3’UTRs respectively, that could be utilised to generate 
nesprin-1 variants detected by the nesprin-1 N4 antibody.  By combining the 
N1-3’E87 UTR with N1-5’E84 and the nesprin-1β1 5’UTR it is possible to 
generate    nesprin-1    variants  p23Nesp1   (23 kDa)   and   p12Nesp1   (12 kDa)  




















	   127 
respectively (Figure 3.18A,B).  Bands of approximately 23 kDa and 12 kDa 
were seen in both U2OS cells and HDFs suggesting these variants are 
expressed (Figure 3.16B).      
 
3.2.7.3 Identification of N1-5’E83 and N1-3’E90 
 The nesprin-1β1 5’UTR, N1-5’E84 and N1-3’E87 alone could not 
account for the multiple bands seen by the nesprin-1 N4 antibody, therefore 
both 5’ RACE and 3’ RACE were performed downstream of exon 84 and 
upstream of exon 87 respectively, to identify additional UTRs which could 
account for nesprin-1 isoform diversity. 
 5’RACE using reverse primers designed in exon 83 amplified a PCR 
product in brain, skeletal muscle and HeLa cDNA libraries.  The amplicon 
contained a novel 5’UTR with a start codon encoded by exon 83, presumably 
transcribed by an alternative promoter upstream on exon 83.  N1-5’E83 RT-
PCR amplified from multiple tissue cDNAs, suggesting it is ubiquitously 
expressed (Figure 3.19A,B).   
 3’RACE using forward primers designed in exon 90, amplified a PCR 
product containing sequences to exon 90 and intronic sequences between 
exons 90 and 91 of the nesprin-1 gene.  The ORF carried on from exon 90 
into the retained intron.  The stop codon for this cDNA end was found in the 
retained intron after the unique coding sequence ‘AGAGYPHQ’.  Downstream 
of the stop codon was an AATAAA polyA signal followed by a polyadenylation 
site.  As with N1-5’E83, N1-3’E90 also RT-PCR amplified from a wide range 
of tissue cDNA samples (Figure 3.19A,B).   
 
3.2.7.4 Multiple nesprin-1 variants can be generated though alternative UTR 
combinations  
 By combining the newly identified N1-5’E83 and N1-3’E90 with each 
other and the pre-existing nesprin-1β1 5’UTR, N1-5’E84 and N1-3’E87 UTRs, 
it is possible to create six alternative nesprin-1 variants which may represent 
some of the bands detected by the nesprin-1 N4 antibody (Table 3.4, Figures 
3.20 A,B 3.16B).  
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3.2.7.5 p50Nesp1 is a microtubule nesprin-1 variant  
 p50Nesp1 is created through the utilization of the N1-5’E83 and N1-
3’E90 UTRs.  The 50 kDa variant composed of 4 SRs was detected in 
multiple tissues by RT-PCR (Figure 3.19).  Flag-p50Nesp1 localized to fibrous 
structures that co-localized with α-Tubulin in U2OS cells suggesting that 
p50Nesp1 localizes to microtubules.  Transfected cells also displayed α-Tubulin 
staining which appeared more structured and polymerized, resembling 
bundled microtubules [253] (Figure 3.21). 
 
3.2.7.6 p41Nesp1 is a diffusive nesprin-1 variant  
 p41Nesp1  terminates with the same N1-3’E90 3’UTR as p50Nesp1 but 
initiates at N1-5’E84, making it approximately half a SR shorter at the N-
terminus than p50Nesp1.  p41Nesp1  transcript appears to be a peripheral blood 
leukocytes specific nesprin-1 variant suggesting the protein may have a 
function in the immune response (Figure 3.20).        Flag-p41Nesp1  localized 
diffusively within the cytosol when transfected into U2OS cells (Figure 3.21A).   
Therefore the localization of the protein was also examined in HDFs where it 
also displayed a similar diffusive localization pattern (Figure 3.22B). 
 
3.2.7.7 p31Nesp1, p23Nesp1 and p12Nesp1 are nucleolar nesprin-1 variants   
 p31Nesp1  initiates from N1-5’E83 and terminates with N1-3’E87 to 
create a 31 kDa variant composed of 2 and a half SRs.  p31 Nesp1 transcript 
expression is limited to kidneys and peripheral blood leukocytes by RT-PCR 
(Figure 3.19).  Flag-p31Nesp1 localized diffusively within the cytosol when 
expressed in U2OS cells and localized to the nucleolus in HDFs (Figure 3.23, 
3.24A). 
 p23Nesp1 is composed of 2 half SRs either side of a full SR as a result of 
utilizing N1-5’E84 and N1-3’E87.  Expression of this 23 kDa variant was 
limited to the brain (Figure 3.20). Flag-p23Nesp1 localized diffusively within 
the cytosol when expressed in U2OS cells (Figure 3.23).  However in HDFs 
the nesprin-1 variant localized to and disrupted nucleolar morphology, causing 
fibrillarin to redistribute into peri-nucleolar caps (Figure 3.24B). 
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p12Nesp1 is the smallest nesprin-1 central rod isoform and is composed of 1 
SR composed of 2 half SRs from adjacent repeats.  p12Nesp1 initiates from the 
nesprin-1β1 5’UTR and terminates with the N1-3’E87 3’UTR, containing a 
coding region which spans over two coding exons.  p12Nesp1 was detected in 
the kidney and peripheral blood leukocytes (Figure 3.20).  Flag-p12Nesp1 
localized diffusively within the cytosol when expressed in U2OS cells (Figure 
3.23).  However as with Flag-p31Nesp1, in HDFs, Flag-p12Nesp1 localized to and 
disrupted nucleolar morphology, causing fibrillarin to redistribute into peri-
nucleolar caps (Figure 3.24C).  This data suggests that nesprin-1 isoforms 
that terminate with N1-3’E87 may have nucleolar functions.  
 
3.2.7.8 p30 Nesp1 failed to amplify from cDNA panel. 
 p30Nesp1 composed of 2 and a half SRs as a result of initiating from the 
nesprin-1b1 5’UTR and terminating with the N1-3’E90 3’UTR.  The 30 kDa 
nesprin-1 variants could however not be amplified from any of the multiple 
tissue cDNA panel suggesting it is not expressed (Figure 3.20).      
3.2.8. Nesprin-1 N4 bands represent newly identified nesprin-1 variants   
 To determine if any of the newly identified nesprin-1 variants were 
accountable for the many bands seen with the nesprin-1 N4 antibody, RT-
PCR on cDNA isolated from U2OS cells and HDFs was performed to 
determine which N4 epitope containing variants were expressed in respective 
cell lines (Figure 3.25).  The largest nesprin-1 variant with an accountable 
mRNA transcript was p50Nesp1 and was detected both by RT-PCR and 
Western blotting in large amounts from both U2OS cells and HDFs.  Similarly 
p41Nesp1 and p31Nesp1 could be detected at both the mRNA level and protein 
level.  The smaller nesprin-1 variants p12Nesp1 and p23Nesp1 were translated 
less abundantly relative to the bigger variants and displayed more of a cell 
specific expression.  The transcription and translation products of p23Nesp1 
were only present in HDFs whilst p12Nesp1 was specific to U2OS cells (Figure 
3.25).  Whereas many of the nesprin-1 N4 variants now appear accounted for, 
bands at ~130kDa, ~75kDa, ~37kDa and ~10kDa which remain unknown and 
will require  further  investigation.    Furthermore,  multiple  nesprin-1  variants  
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were knocked down in U2OS cells using siRNAs designed to target specific 
coding exons surrounding the nesprin-1 N4 epitope.  Together with the 
peptide blocking experiments, this highlights the specificity of the multiple 
bands presented by the polyclonal antibody (Figure 3.17 and Chapter 4, figure 
4.28).    
 
3.2.9 Nesprin isoform expression is highly adaptable   
 To further confirm the validity of the novel variants, and because 
previous evidence indicates that nesprins have the ability to self-compensate, 
the effects of how knocking down a sub-set of transcripts would effect 
expression levels of variants encoded for by nearby transcripts was measured 
[191].  By designing an siRNA targeting exon 90 of nesprin-1 (si-90), it was 
possible to monitor by qRT-PCR the levels of transcripts terminating with N1-
3’E87 and N1-3’E90 UTRs (Figure 3.26). In theory, si-90 should target all 
transcripts terminating with N1-3’E90, but have no effect on N1-3’E87 where 
the final coding exon is  exon 87.  As expected, si-90 significantly reduced 
levels of N1-3’E90 expression in U2OS cells, but more interestingly also  
significantly knocked down levels of the transcripts terminating with N1-3’E87. 
Furthermore, si-136 (targeting exon 136 of nesprin-1), an siRNA designed 
towards the KASH domain of nesprin-1 increased expression of N1-3’E87 
transcripts, showing that perturbations in the expression of one transcript can 
influence expression of other downstream transcripts. Conversely, no change 
in N1-3’E90 was detected with si-136, however both si-90 and si-136 knocked 
down levels of nesprin-1 KASH expressing transcripts (Figure 3.26). 
 
3.3 Discussion  
3.3.1 Nesprins as adaptable, tissue specific, intracellular scaffolds  
 The potential combinations of nesprin-1 5’UTRs and 3’UTRs are 
multitudinous and would allow a vast array of nesprin-1 variants to be 
generated.  Using alternative 5’ and 3’UTRs, it is possible to generate at least 
17 nesprin-1 KASH domain containing variants that may localize to the INM 
and/or the ONM (Figure 3.5).  Likewise, 9 nesprin-1 CHD containing variants  
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that range vastly in molecular weight have the potential to be generated by 
alternative UTRs (Figure 3.7).  Although these variants were only briefly 
characterized, it is likely that they are expressed in a cell/tissue specific 
manner and are able to scaffold different sub-cellular compartments or protein 
complexes to the NE and actin cytoskeleton.  Alternatively, these variants 
may be dynamically regulated, which would allow cells to fine-tune their 
nesprin isoform repertoire as needed to maintain and restore homeostasis 
following stress or to regulate tissue-specific signalling pathways [99,185].  As 
a proof of principle, adaptability in nesprin-1 transcription with a feedback loop 
was shown in figure 3.26.  By using si-136 to knockdown a region of nesprin-1 
near the KASH domain, an up regulation of N1-3’E87 UTR transcripts were 
observed. These observations are consistent with studies that have shown 
nesprin-2 CHD knockout mice display an altered expression pattern for 
specific nesprin-2 C-terminal isoforms in certain tissues to compensate for the 
loss of nesprin-2 giant or nesprin-2 actin binding domain isoforms [191]. 
These observations suggest that nesprin alternative transcript generation is 
highly flexible and more complex than a simplified tissue-specific expression 
model. 
3.3.2 Generation, regulation and function of novel tissue specific 
nesprin variants via alternative initiation and alternative 3’end 
processing.    
 Multiple novel nesprin-1 variants were identified by RT-PCR using 
UTRs identified by 5’ and 3’ RACE, along with sequences identified previously 
by out laboratory (Table 3.1, Figures 3.9, 3,13, 3.19).  RT-PCR was used to 
establish the existence of mRNA transcripts for full-length short isoforms 
(Figures 3.10, 3.14, 3.25). The multiple UTRs allow nesprin-1 to express a 
large number of sequence variants via alternate initiation and pre-mRNA 
3’end processing and many of these were generated in a tissue specific 
manner (Figure 3.27 for updated nesprin-1 genomic map with new UTRs). 
Therefore, in addition to the novel UTR’s verified in this study, it is likely that 
by performing RACE on a greater collection of cells/tissues it may be possible 
to identify further nesprin-1 UTRs.  To date, the mechanisms of tissue specific  
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generation of nesprin variants has not been studied. Analysis of the human 
transcriptome shows a direct correlation between alternative promoter use 
and alternative splicing [254]. Alternative promoters can produce mRNAs with 
different 5’UTRs that encode the same protein, distinct N-termini, and even 
different proteins from the same locus [255,256,257].  The identification of 
multiple novel 5’UTRs in nesprin-1 indicates the presence of several internal 
alternative promoters. The existence and regulation of alternative nesprin-1 
promoters has not yet been explored but this study suggests that these 
promoters are utilised in a tissue specific manner. Furthermore, because 
many individual variants have unique pairs of 5’ and 3’UTRs, additional 
control and regulation of variant expression can be maintained.  The 5’UTR is 
an important regulator of mRNA translation and can contain regulatory 
motifs/sequences which affect the rate of translation as well as containing a 
kozak sequence upstream of the start codon which plays a major role in 
determining the translational strength of the transcript [258,259]. The 3’UTR of 
mRNA transcripts can play a role in mRNA localization, stability, and 
translation [260,261,262,263].  For example, binding of miRNAs to partially 
complementary sequences in the 3’UTR can result in de-adenylation and 
translational inhibition or destruction of the target mRNA [264].  Future work 
should focus on scanning the entire length of all the 5’ and 3’ UTRs for 
regulatory motifs, such as miRNA binding sites. 
 Importantly, many of the variants generated through alternative 3’end 
processing, generate unique peptide sequences that range in size from 8 
amino acids in N1-3’E90 to 37 amino acids in N1-3’E14.  It is highly likely that 
these sequences expose new functional domains that give the variants 
additional localization signals or motifs that play an important role in their 
function or localizations. For example, p31Nesp1, p23Nesp1 and p12Nesp1 which 
terminate with N1-3’E87 have a unique C-terminal peptide sequence which 
may contribute to the nucleolar localization of these variants in HDFs.  
Furthermore, ELM analysis predicts a novel myristoylation site in the N-
terminus of p931KASHNesp1, a post-translational modification which facilitates 
membrane anchoring, suggesting this variant of nesprin-1 may link 
membranous organelles to the NE [265,266].  ELM analysis also predicts 
multiple PKA, MAPK and CDK phosphorylation sites in the unique 37 amino 
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acids of p56CHNesp1, which may play a role in contributing to its different sub- 
cellular localizations observed in U2OS cells and HDFs.  To further explore 
this hypothesis, yeast-2-hybrid analyses or co-immunoprecipitation assays 
should be performed to identify binding partners for specific nesprin-1 variants. 
Post-translational modifications such as phosphorylation, sumoylation, 
and enzymatic cleavage may be partially responsible for the range of Western 
bands often visualized using the current crop of available nesprin antibodies 
[14,66,191]. Designing isoform-specific antibodies will help to distinguish 
between modifications and splicing. 
3.3.3 Nesprin-1 variants display different sub-cellular localizations  
 In this chapter, I demonstrated that KASH-less nesprin-1 variants 
displayed sub-cellular localizations which varied depending on the cell lines 
they were expressed in (Figures 3.11, 3.12, 3.22, 3.23, 3.24, 4.17).  In U2OS 
cells, p56CHNesp1 localized to the nucleolus while the same protein localized 
along actin stress fibres and focal adhesions in HDFs (Figures 3.11, 3.12).  
The reasons behind the differential sub-cellular localizations currently remain 
a mystery, but could be partially regulated by the actin cytoskeleton.  The 
nesprin-1 CHDs contain two nuclear localization signals which may be utilized 
in cells with low F-actin levels such as U2OS cells, but not in structural cells 
like HDFs where there is increased levels of cytoplasmic actin available for 
binding.  Alternatively, potential p56CHNesp1 phosphorylation events predicted 
by ELM analysis may occur in a tissue specific manner, which may contribute 
to the differences seen in localizations between the two cell types as 
described above.  Similarly, differential sub-cellular localizations were seen 
when central rod isoforms p12Nesp1, p23Nesp1 and p31Nesp1, were transfected 
into U2OS and HDFs (Figures 3.23, 3.24). In U2OS cells, all isoforms 
displayed diffuse cytoplasmic localization, while in HDFs nucleolar localization 
was observed. Differences in post-translational modifications could vary 
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Chapter 4: Nesprin-1 Links P-bodies to Microtubules 
and is Required for miRISC 
 
4.1 Introduction 
 In chapter 3, I identified novel nesprin-1 variants composed of SRs 
encoded by the central rod domain and demonstrated they have sub-cellular 
localizations beyond the NE.  RT-PCR and Western blotting with the nesprin-1 
N4 antibody, was used to demonstrate that these species are transcribed and 
translated into protein.  In this chapter, nesprin-1 N4 variants are further 
characterized by monitoring their endogenous sub-cellular localizations, which 
show they match the sub-cellular localizations of ectopically expressed 
constructs.        
 This chapter of the thesis primarily focuses on the role of nesprin-1 in 
cytoplasmic RNA processing bodies (P-bodies), a localization confirmed for 
the nesprin-1 N4 antibody (see below).  P-bodies are membrane-less 
cytoplasmic foci conserved in vertebrates and invertebrates as well as yeast, 
plants and trypanosomes.  At the cellular level, P-bodies are dynamic 
aggregates of mRNA-protein complexes (mRNPs) that predominantly serve to 
store translationally silenced mRNAs and recruit mRNAs which are targeted 
for deadenylation and degradation by the decapping/Xrn1 pathways [267].  I 
show that nesprin-1 variant, p50Nesp1, localizes to P-bodies and scaffolds them 
to microtubules.  p50Nesp1 was chosen to primarily be characterised because 
no SR proteins have previously been implicated in P-body biology, and this 
work significantly contributes to how microtubule based P-body attachment 
regulates cellular mRNA dynamics.     
4.1.1 P-bodies as sites for mRNA decay 
 P-bodies play host to a range of proteins implicated in mRNA decay.  
Degradation of most mRNAs in eukaryotic cells is initiated by shortening and 
removal of the poly(A) tail which is mediated by deadenylating enzymes such 
as the Ccr4–Caf1 and Pan2– Pan3 complexes which localize to P-bodies 
[268].  Following deadenylation, mRNA can be degraded in either the 5’-3’ 
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direction through the decapping pathway or 3’-5’ direction via the exosome 
pathway [269].   
 P-bodies also contain the exoribonuclease Xrn1 together with the 
associated Lsm1–7 protein complex, which is believed to bind to mRNAs with 
short poly(A) tails [270,271].  P-bodies further contain the decapping enzyme 
Dcp2 together with many of its enhancers: Dcp1a, Dcp1b Edc3, Hedls, Pat1 
and Rck/p54 [272,273,274,275].  The presence of all the proteins required for 
degrading mRNAs via the deadenylation–decapping–5′–3′ decay pathway in 
P-bodies suggest that these micro-environments are able to deal with mRNA 
degradation to a high efficiency.  Exosome components, which mediate 3’-5’ 
degradation localize to cytoplasmic granules distinct from P-bodies 
suggesting that the two major mRNA degradation pathways are spatially 
segregated within the cytoplasm [276,277].  Although the sequestration of 
mRNA degradation enzymes in P-bodies does not necessarily imply that 
mRNA degradation occurs within these microenvironments, four lines of 
evidence support the notion that P-bodies are mRNA degradation centers.  1) 
P-bodies disappear after inhibition of deadenylation by deletion of Ccr4 in S. 
cerevisiae or in cells depleted of Caf1, indicating that deadenylation is a 
requirement for P-body formation [273,278].  2) Poly(A)-binding protein 
(PABP) is absent from P-bodies, suggesting that most of the mRNAs within P-
bodies lack long poly(A) tails. Since deadenylation is the initial step of most 
mRNA decay pathways, this suggests that mRNAs located within P-bodies 
are already engaged in the degradation process [239].  3) P-bodies increase 
in number and size when mRNA decay is inhibited in an Xrn1-deleted S. 
cerevisiae strain. The mRNA itself accumulates in P-bodies under these 
conditions, and the same was observed after knockdown of Xrn1 in human 
cells [269,273].  4) mRNA decay intermediates could be trapped in S. 
cerevisiae P-bodies [273].  Taken together, these findings support a model 
where deadenylation is linked to the initial step by which mRNAs enter P-
bodies. This model would further suggest that decapping and 5′–3′ decay of 
the mRNA subsequently occur within P-bodies, since mRNAs remain trapped 
and accumulate in P-bodies if these steps are inhibited [273].  However, it is 
important to note that not all mRNAs are degraded within P-bodies, as 
mRNAs can also exit P-bodies and re-initiate translation [279]. 
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4.1.1.1 Non-sense Mediated decay (NMD) 
 mRNA transcripts which have premature termination codons (PTC) 
have a tendency to be rapidly degraded by the NMD pathway before they 
translate a truncated faulty protein.  Many protein factors required for NMD 
appear to have transient localization to P-bodies in yeast, the essential NMD 
factors Upf (up-frameshift) 1, Upf2 and Upf3 have a diffuse cytoplasmic 
distribution, but accumulate in P-bodies when mRNA decay is inhibited as 
observed in Xrn1-, Dcp1- or Dcp2-deletion strains [280].  Similarly, human 
Upf1, Upf3 and Upf3X visibly accumulate in P-bodies only when NMD is 
inhibited by a chemical compound, that causes the hyperphosphorylation of 
Upf1 [281]. Additional factors required for NMD such as Smg (suppressor with 
a morphogenetic effect on genitalia) 5, Smg6 and Smg7 also localize to P-
bodies [281,282]. More importantly, the PTC-containing mRNA itself is 
specifically recruited to P-bodies both in yeast and in human cell lines when 
Upf1 is locked in P-bodies by an NMD inhibitor [281].  Rather than being 
permanently associated with P-bodies, it appears that most NMD factors cycle 
through P-bodies as NMD substrates are delivered for degradation [282].  
 
4.1.1.2 ARE (AU-rich-element) mediated decay (AMD) 
 AREs are found in the 3’UTR of many cytokine and proto-oncogene 
mRNAs, and by mediating rapid mRNA degradation they potently inhibit gene 
expression at the post-transcriptional level [283].  Bioinformatic approaches 
have estimated that 5–8% of all mRNAs may contain AREs, indicating that 
AMD is a widespread mode of regulating gene expression [284].  The three 
main mammalian inducers of AMD are TTP (tristetraprolin), BRF (butyrate 
response factor) 1 and BRF2 proteins.  These proteins function as adaptors 
that connect ARE-containing mRNAs to the exosome as well as to the 
decapping 5′–3′ decay complex, thereby delivering the bound mRNAs to the 
general decay machinery [285,286].  TTP, BRF1 and BRF2 all localize to P-
bodies with ARE-containing reporter mRNAs.  The presence of ARE-
containing mRNAs in P-bodies depends on the TTP/BRF proteins, suggesting 
that these proteins deliver bound mRNAs to P-bodies, or nucleate P-bodies 
once they bind to target mRNAs. Both ARE-containing mRNAs and TTP/BRF 
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proteins strongly accumulate in P-bodies when the general decay pathway is 
inhibited by the knockdown of Xrn1 or Dcp2 and therefore AMD factors 
appear to also associate transiently with P-bodies [287]. 
 
4.1.1.3 miRNA induced mRNA silencing  
 miRNAs silence gene expression by either repressing translation or by 
inducing decay of the mRNAs to which they are bound.  miRNAs exert their 
function by recruiting RISC (RNA-induced silencing complex) to the mRNA. 
Many proteins that are associated with RISC and important for miRNA-
mediated suppression localize to P- bodies.  This includes all four human 
Argonaute (Ago) proteins, GW182 (TNRC6A) together with its two human 
paralogues TNRC6B and TNRC6C, as well as the RNA helicase Rck/p54 
[243,288,289,290].  Both Rck/p54 and GW182 are essential for P-body 
formation [290,291].  An important function of GW182 protein is to target Ago 
proteins to P-bodies [292].  Using transfected reporters, it has been 
demonstrated that miRNAs and their target mRNAs specifically localize to P-
bodies [288].  For example, endogenous CAT-1 (cationic amino acid 
transporter-1) mRNA together with miR-122 localizes to P-bodies in liver cells.  
CAT-1 mRNA associates with P-bodies under conditions where translation is 
suppressed by miR-122, yet the same mRNA is released from P-bodies when 
its translation is activated by amino acid starvation [293]. Importantly, studies 
in both D. melanogaster and mammalian cells conclude that P-body formation 
is the consequence rather than the cause of miRNA-mediated mRNA 
silencing. Indeed, when general mRNA silencing is prevented by knocking 
down components of the miRNA biogenesis pathway, this leads to the loss of 
P-bodies. Interestingly, re-introduction of siRNAs caused P-bodies to re-
emerge, emphasizing that the pool of silenced mRNAs is a key determinant of 
P-body formation [294]. Similar to the studies with NMD and AMD targets, 
these results point towards a very dynamic model of P-body formation.  In this 
flux-based model, P-bodies are formed and resolved according to the amount 
of mRNA that is subject to silencing, be it translational arrest or targeting for 
decay. 
 
	   149 
4.1.2 Stress Granules (SGs) 
 SGs are large aggregates of mRNAs, translation initiation factors and 
40S ribosomal subunits that accumulate in the cytosol of cells undergoing 
translational arrest.  SGs are formed in cells that have been exposed to 
different forms of stress such as heat shock, oxidative stress or energy 
deprivation [295].  Although P-bodies and SGs are distinct structures, there is 
strong evidence that the two compartments are functionally linked.  SGs 
emerge next to P-bodies in S. cerevisiae, and in these cells the formation of 
SGs is dependent on the presence of P-bodies [296].  In mammalian cells 
however, P-bodies and SGs are formed independently, since abrogation of P-
bodies does not hamper SG assembly and vice versa [239].  Transient 
contacts between P-bodies and SGs are frequently observed in mammalian 
cells suggesting that mRNPs may be exchanged between the two bodies. 
This would imply that cells may utilize dynamic compartments to regulate the 




4.2.1 Nesprin-1 N4 localizes endogenous nesprin-1 variants to the 
nucleolus and cytoplasmic foci 
 To identify the sub-cellular localization of endogenous nesprin-1 
variants described in chapter 3, immunofluorescence microscopy using the 
nesprin-1 N4 antibody  was performed on cultured U2OS cells and HDFs 
(Figure 4.1 A,B,C).  In both cell lines, nesprin-1 N4 stained multiple 
cytoplasmic foci that varied in size and number between individual U2OS cells 
and HDFs.     
 Additionally, the antibody stained sub-nuclear compartments that co-
localized with nucleolar marker fibrillarin (Figure 4.2).  The nucleolar 
localizations of endogenous nesprin-1 appear to match the localizations of the 
novel transfected nesprin-1 variants identified in chapter 3.  Both cell lines 
expressed nucleolar nesprin-1 variant p31Nesp1, whilst p12Nesp1 appears to be 
U2OS specific and p23Nesp1 HDF specific (Figures 3.24, 3.26).   
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To determine whether the cytoplasmic foci and nucleolar staining were 
specific for the nesprin-1 N4 antibody, and not due to cross-reaction with 
other epitopes present in fixed cells, peptide blocking experiments were 
performed.  All staining was diminished when the nesprin-1 N4 antibody was 
pre-blocked with its excess peptide and then used to stain U2OS cells, 
confirming the antibody stains genuine nesprin-1 proteins with the N4 epitope 
(Figure 4.3).  To further confirm antibody specificity, siRNA knockdown 
experiments performed in the latter sections of this thesis eliminated certain 
nesprin-1 staining (Figure 4.28).      
4.2.2 Nesprin-1 localizes to P-bodies        
 To identify the sub-cytoplasmic foci structures detected by the nesprin-
1 N4 antibody, the online literature was scanned for potential proteins which 
localize as foci’s within the cytosol.  One group of proteins resembled those 
which belong to a family of RNA binding proteins which aggregate with RNA 
within the cytosol.  These proteins localize in membrane-less compartments 
known as mRNA processing bodies (P-bodies) or stress-induced granules 
called stress granules (SGs) [291,297,298].   
 To ascertain if the nesprin-1 cytoplasmic foci could be P-bodies, 
nesprin-1 N4 was co-stained with a P-body marker, human enhancer of 
decapping large subunit (Hedls), in U2OS cells [299].  All the nesprin-1 foci 
co-localized with Hedls P-bodies confirming the presence of nesprin-1 in P-
bodies (Figure 4.4).  
Next, a series of experiments were carried out to compare the physical 
properties of nesprin-1 P-bodies. Oxidative stress is commonly used to not 
only induce P-body formation but also to promote assembly of (SGs) 
[239,299].  The number of Hedls-positive nesprin-1 foci substantially 
increased in U2OS cells exposed to sodium arsenite (0.5 mM) for one hour 
(Figure 4.5).  Furthermore, a population of stressed cells displayed a loss of 
nucleolar nesprin-1 staining, indicating the nucleolar variants may be stress 
responsive.  Immunostaining for eIF3-η which labels SGs in arsenite stressed 
U2OS cells failed to co-localize with the nesprin-1 foci suggesting that 
nesprin-1 is only present in P-bodies [239].   However the nesprin-1   foci   did 
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often  juxtapose  to the eIF3-η SGs, a typical phenomenon seen between the 
two types of RNA granules in stressed cells (Figure 4.6). 
4.2.3 Nesprin-1 foci display P-body features  
Previous work has demonstrated that P-bodies display three 
characteristics which facilitate their formation and disassembly.  P-bodies not 
only significantly increase in number during stress, but also increase in 
number in response to nocodozole-mediated microtubule depolymerization 
[300].  The nesprin-1 and Hedls P-bodies greatly increased in number, but 
appeared smaller in size, when U2OS cells were treated with nocodozole for 
1 hour (10 µg/ml), indicating that microtubules may adhere P-body mRNP 
complexes (Figure 4.7).  Staining for α-tubulin, which became diffusely 
cytoplasmic in nocodazole treated cells, served as a positive control for 
microtubule de-polymerization (Figure 4.8).  
Finally, the effect of P-body disruption on nesprin-1 foci was examined.  
Cycloheximide is a translational inhibitor that stabilizes the association of 
mRNA with polysomes, thereby depleting the availability of stalled mRNAs 
which are necessary for P-body formation [279].  As expected, Hedls and 
nesprin-1 foci’s were eliminated in U2OS cells treated with cycloheximide (10 
µg/ml) (Figure 4.7). 
4.2.4 Nesprin-1 P-bodies co-localize with decapping factors and 
translational repressors 
 As described above, P-bodies are multi-functional microenvironments 
comprised of proteins and enzymes implicated in a host of cytoplasmic mRNA 
processing events such as mRNA decay and translational repression.  To 
identify the groups of mRNP subsets nesprin-1 associate with, a panel of 
previously identified P-body components were transfected into U2OS cells 
and confocal microscopy was used to determine components nesprin-1 co-
localized with in P-bodies. 
 Endogenous nesprin-1 P-bodies co-localized with the ectopic foci 
formed by the mRNA decapping  co-factor  Dcp1a-YFP  and  the  translational  
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regulator RFP-Rck/p54 [269,290] (Figures 4.9 A,B).  Similarly, transfected 
mRNA cap-binding translation factor, HA-eIF4E, and its inhibitor, HA-4E-T, 
both co-localized with endogenous nesprin-1 within cytoplasmic foci [301] 
(Figure 4.9 C,D).  On the contrary, exogenous adenine/uridine rich element 
(ARE)-mediated decay factor, TTP-YFP, and pan-RISC regulator, GW182-
GFP, formed multiple nesprin-1-negative P-bodies [302,303] (Figures 4.10 
A,B).   
4.2.5 Nesprin-1 variant p50Nesp1 exists in a complex with Rck/p54 and 
Dcp1a 
 These results indicate that P-body localized nesprin-1 may 
preferentially interact with cytoplasmic mRNA decapping factors such as 
Rck/p54 and Dcp1a.  To further examine this possibility, endogenous nesprin-
1 was immunoprecipitated from U2OS whole cell lysates and probed for 
mRNA decapping factors.  Nesprin-1 pulled down complexes containing 
Dcp1a and its binding partner Rck/p54.  Similarly, a rabbit polyclonal Rck/p54 
antibody, used as a positive control, immunoprecipitated endogenous 
Rck/p54 and Dcp1a to the same degree as the nesprin-1 antibody, 
demonstrating the strength of nesprin-1 association with the two P-body 
proteins (Figure 4.11A).   
 To determine what nesprin-1 variant was involved in this complex and 
localized to P-bodies, a reverse co-immunoprecipitation (co-IP) experiment 
with a murine monoclonal Rck/p54 antibody was performed.  This precipitated 
a 50kDa nesprin-1 variant corresponding to p50Nesp1, a 4SR containing 
nesprin 1 variant (Figure 4.11B). To show this variant was indeed p50Nesp1, 5 
µg of lysate from U2OS cells transfected with untagged-p50Nesp1 was run on 
the same gel, which migrated the same distance as the endogenous product 
detected by the nesprin-1 N4 antibody.    
 To prove p50Nesp1 interacted with Dcp1a and Rck/p54, full-length 
p50Nesp1 along with the first 2 SRs (p50NT), final 2 SRs (p50CT) and 
individual SRs of p50Nesp1 were GST-tagged and incubated with whole cell 
lysates from U2OS cells.  Endogenous Rck/p54 and Dcp1a pulled-down with 
full-length GST-p50Nesp1 and GST-p50NT.  Interestingly, the first SR was able  
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to pull-down Rck/p54 but not Dcp1a (p50SR1), whilst the second SR pulled-
down Dcp1a but not Rck/p54 (p50SR2) (Figure 4.12).  Flag- GW182 failed to 
interact with GST- p50Nesp1 or any of its deletion constructs, consistent with 
the failure of GW182-GFP to co-localize with endogenous nesprin-1 N4 
(Figure 4.10A, 4.12). 
When a flag-construct of the N-terminal SRs of p50Nesp1 (Flag-p50NT) 
was transfected into U2OS cells, the construct displayed a diffusive 
localization pattern.  However, the construct was drawn into ectopically 
formed foci in approximately 10% of transfected cells co-expressing YFP-
Dcp1a or RFP-Rck/p54 (Figures 4.13, 4.14, 4.15).  To prove that this was a 
specific localization and not an artifact of overexpression, YFP-Dcp1a and 
RFP-Rck/p54 were co-transfected with Flag-G3, a pair of negative control 
SRs downstream of the p50Nesp1 SRs located in the giant isoform.  No co-
localization of the G3 SRs with the ectopically formed bodies in any of the co-
transfected cells were observed, suggesting association of p50NT SRs with 
ectopic P-body proteins is a specific organization (Figures 4.13, 4.14, 4.15).      
4.2.6 p50Nesp1 localizes to microtubules and P-bodies  
 In chapter 3 the nesprin isoforms were shown to have different sub-
cellular localizations in primary and transformed cell lines.  To determine the 
localization of p50Nesp1, a Flag-variant of full-length p50Nesp1 was transfected 
into primary Vascular Smooth Muscle Cells (VSMCs), HDFs and U2OS cells.  
In VSMCs, p50Nesp1 induced P-body formation, however in U2OS cells and 
HDFs the isoform formed fibrous structures that co-localized with α-tubulin, 
suggesting it additionally localizes to microtubules (Figure 4.16).  Furthermore, 
these tubules displayed an enhanced polymerized structure, resembling 
microtubule bundling [253].  
4.2.7 p50Nesp1 interacts with microtubules in vitro 
 The microtubule coating of ectopically expressed p50Nesp1 in U2OS 
cells suggests that this nesprin-1 variant may have attributes which make it a 
Microtubule Associated Protein (MAP).  Therefore, in vitro microtubule binding 
assays were performed by incubating recombinant GST-tagged  p50Nesp1  and  
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its deletion constructs with purified polymerized microtubules.  To determine 
whether   p50Nesp1   was    capable   of   binding    to    microtubules    directly, 
microtubules were pelleted by ultracentrifugation and the pellet and 
supernatant fractions were analysed by Western blotting.     Full-length 
p50Nesp1 and p50CT pelleted after ultracentrifugation in the presence of 
microtubules, but not in their absence, suggesting a direct interaction exists 
between the final 2 SRs of p50Nesp1 and microtubules (Figure 4.17).  However, 
SR3 and SR4 which make up p50CT, failed to pellet with microtubules 
indicating that the microtubule binding region of p50Nesp1 is shared between 
the two SRs.  The P-body binding p50NT SRs remained in the supernatant 
upon ultracentrifugation in the presence and absence of microtubules, ruling 
out microtubule interaction with these SRs (Figure 4.17).     
4.2.8 p50Nesp1 localizes microtubules in cells  
 To confirm that the C-terminal pair of SRs in p50Nesp1 could associate 
with microtubules in cells, a Flag construct of p50CT was expressed into 
U2OS cells. These SRs also promoted microtubule bundling in a similar 
manner to full length p50Nesp1, confirming its activity  as a MAP (Figure 4.18). 
4.2.9 p50Nesp1 is a P-body-microtubule scaffold  
 The ability of p50Nesp1 to associate with P-body mRNP complexes 
through it first two SRs and microtubules through it final two SRs suggest this 
nesprin-1 variants may be a functional scaffold which links P-body mRNP 
complexes to the microtubule cytoskeleton.  The p50Nesp1 binding domains are 
summarized in figure 4.19.  The next set of experiments focus on thoroughly 
investigating whether p50Nesp1 is indeed a microtubule linker protein, and the 
implications associated with P-body and mRNA dynamics when this scaffold 
is disrupted.      
4.2.10 p50CT knocks endogenous Rck/p54 off microtubules.  
 Next, P-body phenotype was examined in U2OS cells overexpressing 
Flag-p50Nesp1, therefore p50Nesp1 binding partner Rck/p54 was stained for as 
an   endogenous   P-body  marker.    Rather  than   forming  cytoplasmic  foci,  
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endogenous Rck/p54 co-localized to and coated the p50Nesp1 bundled 
microtubules  (Figure  4.20A).   However,  when  endogenous   Rck/p54   was 
stained in U2OS cells overexpressing Flag-p50CT, which lacks the Rck/p54 
binding site, Rck/p54 coating along the microtubules was no longer observed 
and instead Rck/p54 positive P-bodies localized adjacent to the microtubules 
(Figure 4.20A).  Furthermore, cells expressing Flag-p50Nesp1 had enhanced 
expression of Rck/p54 and Dcp1a, whereas cells expressing Flag-p50CT had 
reduced expressions when compared to Flag-control transfected cells (Figure 
4.20B).  This data suggests that p50Nesp1 may be a key regulator of P-body 
formation, by controlling the expression of P-body proteins and assembly of 
mRNP complexes in response to microtubule attachment.  Alternatively, 
p50Nesp1 may stabilize and/or protect P-body mRNP complexes by extending 
protein half-lives or protecting them from the cells degradation machinery.    
 I hypothesised that Flag-p50CT acts in a dominant negative manner, 
where it is able to displace endogenous p50Nesp1 and mRNP complexes 
associated with it from microtubules (Figure 4.21).  This dominant negative 
construct now provides an invaluable tool to allow p50Nesp1 microtubule-
associated P-body dynamics to be studied.      
4.2.11 p50CT expression results in reduced P-body coverage  
 Previously, P-body dynamics have been shown to be regulated by the 
cytoskeleton, of which P-body movement is microtubule dependent [297].  As 
p50CT overexpression in U2OS cells was able to knock Rck/p54 bodies off 
microtubules, P-body mobility was initially examined.  In collaboration with Dr. 
Daniel Soong (Divisional Microscopy Officer, King’s College London), real-
time tracking of DCP1a-YFP P-bodies in U2OS cells co-transfected with a 
control empty Flag-vector, Flag-p50Nesp1 or Flag-p50CT was performed.  
Using a method originally described by Aizer et al., 2008, Dr. Soong tracked 
individual bodies using single particle tracking in each sample over a time-
frame of 2 minutes and then determined the area covered by each body [297].  
The area centroid of each tracked object was exported as a list of coodrinates  
and converted to .CEL format in a custom-written Mathematica (Wolfram 
Research, USA)  notebook and .cel files were imported  into  the  Chemotaxis  
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Analysis notebook V1.6 (Graham Dunn, King's College London) for analysis 
and   statistical   comparison.   The  videos  generated  from  this  experiment 
support the findings described by Aizer et al., 2008 and the concept that P-
bodies localize to spatially confined regions within the cytosol [297].    The 
empty Flag-vector control cells (n=84) and Flag-p50Nesp1 (n=262) expressing 
cells covered areas of 0.0798µ and 0.0799µ while the cells expressing Flag-
p50CT (n=116) covered a significantly reduced area averaging 0.0514µ, 
comparable to control Flag-vector cells treated with nocodozole (n=429) at 
0.0501µ.  However, no significant P-body area coverage was observed 
between the control Flag-vector cells treated with nocodozole and Flag-
p50CT expressing cells, suggesting that overexpression of Flag-p50CT has a 
similar effect as nocodozole treatment (Figure 4.22).    
 To determine that U2OS cells co-expressing YFP-Dcp1a and the 
respective Flag-protein were being filmed, the culture dishes were fixed after 
filming and stained for anti-Flag.  Every cell expressing Dcp1a-YFP was also 
expressing Flag-p50Nesp1 or Flag-p50CT, allowing easy selection for co-
transfected cells.  Interestingly, Flag-p50Nesp1 no longer localized to 
microtubules but instead co-localized with Dcp1a foci in P-bodies in co-
transfected cells.  Flag-p50CT however localized to microtubules with Dcp1a-
YFP bodies located adjacent to the microtubules, providing further evidence 
for strong association between these P-body proteins and the N-terminal SRs 
of p50Nesp1 (Figure 4.23).   
4.2.12 p50CT expressing cells have reduced P-body-stress granule 
connections and fail to disassemble stress granules post-stress  
 SGs are thought to be compartments where mRNAs are sorted before 
they juxtapose to P-bodies to allow mRNA transcript transferral for 
degradation or storage.  Previous studies using nocodazole treatment have 
demonstrated that P-bodies and SGs associate in a microtubule dependent 
manner during stress and a single class of mRNA can be transferred between 
the two classes of granules [239,297].  Therefore, the dynamics of P-body-SG 
associations by displacing P-bodies from microtubules using exogenous 
p50CT was examined.  Flag-Control or Flag-p50CT were transfected into 
U2OS cells  with  a  β-globin  mRNA  containing  the  MS2-binding  site  in  its  
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3’UTR (pEF-7B- MS2bs) together with a GFP-MS2 coat protein allowing the 
β-globin mRNA to  be  tracked  with  a  GFP  signal   (Figure 4.24) [239].   
Cells were then stressed with 2 µM hydrogen peroxide (H2O2) for 1 hour and 
stained for Rck/p54 P-bodies and PABP-1 labelling SGs.   In co-transfected 
cells the β-globin reporter containing the MS2-binding site, bound to the GFP-
MS2 protein with cytoplasmic GFP signal found in SGs and P-bodies.  In 
control cells, frequent P-body-SG contacts were seen with the majority of the 
β-globin transcript detected in P-bodies (Figure 4.25 A,B,C).  However in the 
Flag-p50CT expressing cells, association between P-bodies and SGs were 
almost non-existent and the GFP-signal for the tethered RNA accumulated 
solely in SGs, suggesting mRNA species stored in SGs were failing to be 
transferred into P-body compartments (Figure 4.25 A,B,C).  
4.2.13 p50CT expressing cells fail to disassemble SGs during recovery  
 When U2OS cells were allowed to recover for 3 hours in H2O2 free 
growth media, the SGs in control cells disassembled and the β-globin mRNA 
localized to P-bodies.  However in the Flag-p50CT expressing cells, the SGs 
failed to dissolve and accumulated the β-globin mRNA suggesting the cells 
were in a translationally repressed state (Figure 4.26).   
4.2.14 Oxidative stress triggers cell death in Flag-p50CT expressing 
cells  
 The ability of Flag-p50CT U2OS cells to disassemble SGs during 
recovery suggests that these cells are locked in a translationally repressed 
state.  To determine the phenotypic effect Flag-p50CT had on transfected 
cells post-stress, time-lapse microscopy was performed.  U2OS cells were 
filmed from the start of recovery over a period of 16 hours.  After 
approximately 8 hours into recovery, Flag-p50CT cells underwent extensive 
cell death suggesting that p50CT was harmful to cells once exposed to a 
stress agent (Figure 4.27A).  Using MTT assays, Flag-p50CT expressing cells 
experienced mild cellular toxicity between 4-5 hours into recovery and severe 
toxicity after 7 hours, confirming the lethal effects of this construct post-stress 
exposure (Figure 4.27B). 
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4.2.15 p50Nesp1 knockdown eliminates P-bodies  
 By overexpressing p50Nesp1 and dominant negative p50CT, I have 
demonstarted the importance of nesprin-1 in P-body and mRNA dynamics.  
To further determine the role of p50Nesp1 in P-bodies, a knockdown approach 
was utilized to determine the effects of disrupting complete functionality of 
p50Nesp1.  A panel of siRNA oligos, si-83, si-86, si-90 and si-136, were 
designed to target exons 83, 86, 90 and 136 respectively, to knockdown the 
central SR rod of nesprin-1.  si-86 was created in the same coding exon as 
the nesprin-1 N4 epitope but consistently induced cell death in a large 
proportion of transfected cells, therefore was excluded from further work.  si-
83 and si-90 were created towards the N- and C-terminal SRs of p50Nesp1 
respectively, while si-136 was created towards the C-terminus of the nesprin-
1 giant and designed as a negative control siRNA (Figure 4.28A). 
 qRT-PCR performed in chapter 3 demonstrated si-90 was capable of 
knocking down p50Nesp1 terminating N1-3’E90 UTR in U2OS cells (Figure 
3.25).  Western blotting confirmed that only si-83 and si-90 knocked-down 
p50Nesp1 , p41Nesp1 and the unknown ~75 kDa nesprin-1 variant, while si-136 
had no effect on N4 variants in U2OS cells (Figure 4.28B).  Nesprin-1 N4 and 
Hedls staining were used to assess P-body phenotype in U2OS cells 72 hours 
post-transfection (Figures 4.28C).  Cells transfected with si-136 showed no 
differences in P-body phenotype when compared to control siRNA, indicating 
that KASH-domain nesprin-1 isoforms neither localize to nor directly regulate 
P-body formation.  In contrast, si-83 and si-90 both eliminated nesprin-1 N4 
and Hedls-positive P-bodies in up to 80% of transfected cells.  Similarly, 
knockdown of Rck/p54 resulted in a similar % loss of P-bodies and served as 
a positive control (Figure 4.28D) [290].  
4.2.16 p50Nesp1 knock-down attenuates miRISC function  
 The loss of macroscopic P-bodies does not necessarily imply loss of 
function of the mRNA processing pathways associated with these structures 
[290].  p50Nesp1 binding partner Rck/p54 is a component which regulates 
general miRNA-induced silencing complex (miRISC) mediated translational 
repression, therefore a CXCR4 miRISC luciferase reporter assay  was used to  
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determine the effects of p50Nesp1 knock down on miRISC activity [245,290].  
The pRL-TK6x vector encoding luciferase has 6 CXCR4 miRNA partially-
complementary binding sites within its 3’UTR and becomes silenced when co- 
expressed with the CXCR4 miRNA (Figure 4.29A).  However, concomitant 
knockdown of proteins involved in the miRISC pathway should reduce 
luciferase silencing and enhance relative luciferase and luminescent levels.  
Knockdown of positive control Rck/p54 and p50Nesp1 using si-83 and si-90, but 
not si-136, significantly decreased miRISC activity in U2OS cells compared to 
scrambled control suggesting, p50Nesp1 is required for efficient miRNA function 
(Figures 4.29B). 
 Next a Let-7 miRNA reporter construct which contains 4x Let-7 
complementary sites (FF4LCS) for endogenous Let-7 was utilized as an 
additional tool to confirm p50Nesp1 as an essential miRNA silencing component 
[248].  As with the CXCR4 reporter, si-Rck/p54 and both si-83 and si-90, but 
not si-136, were sufficiently able to attenuate miRNA function of endogenous 
Let-7 in U2OS cells (Figure 4.30A).  However, when this assay was 
performed in U2OS cells transfected with a miRNA reporter construct carrying 
a mutation in the target seed region of Let-7 (FFr4mLCS), rather than the WT 
FF4LCS construct, none of the p50Nesp1 targeting siRNAs or si-Rck/p54 were 
able to attenuate its silencing function relative to si-Control (Figure 4.30B).  
Instead, ~3 fold increase in luciferase activity was observed in si-Control cells 
transfected with FFr4mLCS compared to those transfected with FF4LCS.        
4.2.17 SR1 and SR2 of p50Nesp1 are required for miRISC  
 To show miRISC attenuation was due to p50Nesp1 knock down and not 
depletion of other endogenous nesprin-1 variants eliminated by si-83 and si-
90, a series of rescue experiments were performed using p50Nesp1 and 
p50Nesp1 constructs described throughout this chapter.  The si-83 targeting 
nucleotides in full length p50Nesp1, p50NT and p50SR1 were mutated so they 
could not be targeted for knockdown, however the codons still encoded for 
WT amino acids to not mutate the translated proteins.       
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First, the CXCR4 miRISC reporter was used in the rescue experiments.  
Not only did over expression of p50Nesp1 result in reduced luminescence, 
indicative of miRISC rescue, but a similar score was also achieved when 
p50NT was over expressed into si-83 transfected U2OS cells.  Expression of 
p50Nesp1 or p50NT in si-Rck/p54 transfected cells failed to rescue miRISC 
activity suggesting that both p50Nesp1 and Rck/p54 are required for miRISC 
function.  miRISC activity could not be rescued by overexpressing the 
microtubule binding p50CT or the individual SRs which make up p50Nesp1 in s-
83 transfected cells, suggesting that the two N-terminal SRs together make up 
the scaffold which complexes translationally-repressed mRNPs (Figures 4.31).      
 Next, the same rescue experiments were performed in U2OS cells 
transfected with FF4LCS or FFr4mLCS to measure Let-7 function.  Once 
again, only expression of p50Nesp1 or p50NT were able to significantly rescue 
the silencing function of endogenous Let-7 in U2OS cells transfected with si-
83 and FF4LCS (Figure 4.32A).  When mutant FFr4mLCS is transfected into 
U2OS cells, it failed to be suppressed by endogenous Let-7 under any of the 
knockdown and/or rescue conditions (Figure 4.32B).  As expected, the Let-7 
luciferase activity in FF4LCS transfected U2OS cells was repressed ~3 fold 
compared to FFr4mLCS in si-Control U2OS cells.    
 
4.3 Discussion  
  In this chapter of the thesis, the nesprin-1 N4 antibody was used to 
determine the sub-cellular localization of endogenous nesprin-1 variants 
containing the N4 epitope described in chapter 3 (Figures 3.21, 3.22, 3.23, 
3.24).  Nesprin-1 variant p50Nesp1 was shown to localize to P-bodies where it 
interacts with decapping proteins and translational repressors, Dcp1a and 
Rck/p54 (Figures 4.12, 4.13).  More importantly, p50Nesp1 provides a 
cytoskeletal-scaffold to P-bodies by acting as a microtubule-linker (Figure 
4.33).  Using recombinant p50Nesp1 constructs, the N-terminal domains, SR1 
and SR2, were shown to associate with P-body proteins Dcp1a and Rck/p54 
in GST pull-down assays (Figure 4.13).  Recombinant SR3 and SR4 in 
tandem  could  interact  directly  with  microtubules  in vitro,  and  furthermore  
 






























	   194 
promoted microtubule bundling in U2OS cells, strongly favouring p50Nesp1 as a 
MAP (Figure 4.18, 4.19).  To confirm p50Nesp1 as a microtubule-P-body linker, 
full-length Flag-p50Nesp1 recruited Rck/p54 to microtubules bundles when 
expressed in U2OS cells.  However when Flag-p50CT, which fails to bind to 
Rck/p54, was transfected into U2OS cells, no localization or association of 
Rck/p54 with the microtubules was observed (Figure 4.20).  Moreover, the 
latter cells had defects in two microtubule-regulated processes; abrogated P-
body movement and the failure of P-bodies to attach to SGs in stress-induced 
cells [297] (Figures 4.22, 4.25).  The latter resulted in the failure of transferring 
GFP-labelled β-globin mRNA transcripts from SGs to P-bodies (Figure 4.26).  
Moreover, SGs were unable to resolve in the recovery phase and promoted 
cell death at around ~7 hours, suggesting the cells were locked in a 
translationally repressed state (Figure 4.27).   
Furthermore, p50Nesp1 knockdown resulted in P-body loss, similar 
attributes to Rck/p54 [290], while p50Nesp1 promoted P-body formation when 
overexpressed in VSMCs and enhanced Rck/p54 and Dcp1a production in 
U2OS cells (Figures 4.17, 4.20).  On the contrary, Rck/p54 and Dcp1a 
production was reduced in Flag-p50CT over expressing U2OS cells (Figure 
4.20).  This data suggests that expression of proteins associated with p50Nesp1 
mRNP complexes may be dependent on them being attached to microtubules 
via nesprin-1, or expression of these proteins is governed by the availability of 
p50Nesp1 binding sites, which could help stabilize the proteins by providing a 
microtubule-scaffold, or protect them from the cells degradation machinery.  
Additionally, p50Nesp1 knockdown attenuated miRISC function of two 
independent reporter constructs, which could be recovered by overexpressing 
p50NT (Figures 4.29, 4.30, 4.31, 4.32).  This data suggests that not only is 
p50Nesp1 required for stabilizing other P-body proteins by providing a 
microtubule-scaffold, but it maybe an essential component in silencing and 
transferring miRISC complexes around the cell.            
 
4.3.1 p50Nesp1 scaffolds mRNP Dcp1a, Rck/p54 and miRISC complexes to 
microtubules 
 Transcribed and processed mRNAs are packaged into mRNP 
complexes and transferred from the nucleus into the cytosol, where the 
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destiny of the mRNA is decided.  Once in the cytosol, mRNAs can be loaded 
onto ribsosomes for protein translation or they can be stored in a 
translationally repressed state for protein synthesis at a later point of the cells 
cycle.  When the mRNA is no longer required for cellular function, signals can 
be sent to the cells mRNA degradation machinery for decay or alternatively 
for mRNA storage.  When degradation occurs from the 5’cap end, the mRNA 
decapping machinery is required for cap removal, which initiates the events 
for mRNA degradation.  The eukaryotic decapping machinery localizes to P-
bodies and is comprised of the decapping enzyme Dcp2 and its two co-factors 
Dcp1a and Dcp1b [272].  Furthermore, proteins required for RNA-mediated 
silencing, translational repression and non-sense mediated decay such as 
GW182, Argounautes, Rck/p54, eIF4E and UPF proteins amongst many 
others also localize to P-bodies, suggesting P-bodies play a regulatory role in 
mRNA storage and degradation [267,304,305,306]. 
 In this chapter, the first 2 SRs of p50Nesp1 were able to interact with 
Dcp1a and Rck/p54, and were required for miRISC function, suggesting that 
p50Nesp1 may act as a scaffold for these regulatory proteins (Figures 4.13, 4.30, 
4.31).  The final 2 SRs of p50Nesp1 were shown to localize and interact directly 
with microtubules (Figures 4.18, 4.19).  Because p50CT was unable to 
interact with Rck/p54 and Dcp1a, it was  proposed as a potential dominant 
negative construct to disrupt P-body dynamics.  Indeed when overexpressed, 
p50CT was able to knock endogenous Rck/p54 and Dcp1a-YFP off 
microtubules in U2OS cells, however the P-bodies remained in close 
proximity to the microtubules, presumably trying to re-attach (Figures 4.20, 
4.23).  Furthermore, these cells had abrogated P-body movement in their 
spatially confined regions, mimicking P-body detachment from microtubules 
as previously described [297].  The same study suggested that the erratic 
confined movement of P-bodies was due to the dynamic swaying nature of 
individual microtubule tracks, agreeing with the data provided in this chapter 
showing that this erratic movement is reduced when P-bodies are removed 
from microtubules (Figure 4.22).  Microtubule attachment allows P-bodies to 
probe a greater cytosolic area and therefore increases the likelihood of 
colliding with RNAs that need to be degraded or translationally repressed in a 
miRNA-dependent or –independent manner for storage.    Furthermore, 
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previous studies indicate that cytoplasmic mRNAs can be associated with and 
move rapidly along microtubules [307].  Therefore, P-bodies are more likely to 
encounter these mRNAs along their travel and sequester them through their 
membrane-less compartments for degradation and/or storage, signifying that 
P-body anchorage to microtubules is required for regulating cytosolic mRNA 
turnover events and translation. 
4.3.2 p50Nesp1 promotes microtubule bundling. 
Microtubules are required for a host of cellular processes, including 
spindle assembly for chromosome segregation, organelle positioning, 
polarized growth, cell migration, assembly of cilia and flagella, and 
intracellular transport [308].  In all these functions, it is crucial that the 
microtubule polymers are precisely organized.  The variety of microtubule 
structures observed across different cell types require a diverse group of 
proteins to assemble, stabilize, and dynamically control microtubule tracks.  
MAPs, which include both molecular motors and non-motor proteins, regulate 
the global properties of microtubule structures by moving and cross-linking 
filaments.  Previously, Protein Regulator of Cytokinesis 1 (PRC1, also know 
as MAP65) was the first protein shown to interact directly with microtubules 
via its SR domains [309].  Like p50Nesp1, PRC1 promotes microtubule bundling, 
however bundles anti-parallel running tracks, by forming homodimers 
produced from opposing centrioles before chromosome segregation.  
Whether p50Nesp1 forms bundles with anti-parallel tracks, or those running in 
the same direction have yet to be determined.  Furthermore, the mechanism 
of p50Nesp1-mediated microtubule bundling has yet to be characterised, 
whether through N-terminal homodimerization events or through the 
recruitment of additional protein complexes.  Interestingly, PRC1 works with 
various kinesins to organize microtubule bundles.  For example, in 
mammalian cells, PRC1 is transported to the midzone of tracks by kif4, a 
kinesin-4 motor protein, before it detaches and promotes microtubule bundling.  
Previously, components of kinesin-1 and -2 have been identified to interact 
with SRs of nesprin-1 and nesprin-4 [69,82].  With SRs being structurally 
conserved, it is not unreasonable to assume multiple kinesin binding sites are 
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located throughout the nesprins, including domains within p50Nesp1 [78].  
Whether localization of p50Nesp1 to specific points along tubule tracks is 
mediated via a similar mechanism to that of PRC1 would make an interesting 
hypothesis.  
4.3.3 P-body-SG association is dependent on P-bodies being linked to 
microtubules  
 mRNA translation is the most energy consuming process that cells 
undergo, and during certain stress responses such as oxidative stress, UV 
exposure, hyperthermia and hypoxia, cells rapidly reprogram their 
translational machinery to produce proteins such as heat shock proteins and 
DNA repair enzymes necessary to deal with the stress for cell survival and to 
stop synthesis of housekeeping proteins [295,310,311,312,313,314].  During 
such times, SGs form and potentially aid in sorting non-essential transcripts 
into P-bodies, whilst loading essential transcripts for cell survival onto 
ribsosomes for translation.  Previously, P-body-SG association has been 
shown to be microtubule dependent, where fluorescently labelled P-body and 
SG components lost connections in nocodozole treated cells [297].  This 
chapter shows that by knocking P-bodies off microtubules, using p50CT, its 
connections with SGs are abolished; suggesting P-body-SG connections are 
dependent on P-bodies being linked to microtubules (Figure 4.25).  Both SGs 
and P-bodies are attached to the microtubule cytoskeleton, however P-body 
detachment could substantially reduce the number of collisions with SGs.  
Furthermore, the data in this chapter shows that there was an inability to 
transfer mRNA transcripts from SGs to P-bodies using a β-globin mRNA 
reporter, confirming that transfer of species between the two bodies is 
dependent on P-bodies being attached to microtubules (Figure 4.25).  U2OS 
cells expressing p50CT were unable to disassemble SGs in the recovery 
phase signifying that SG disassembly is somehow dependent on P-bodies 
being attached to microtubules (Figure 4.26).  Currently the mechanism for 
SG disassembly remains unclear, but one plausible explanation is that P-
bodies are unable to transfer specific protein and/or RNA components during 
stress that may act as disassembly stimuli for SGs entering a recovery period.  
Previous studies have also highlighted impairment of SGs in nocodozole 
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treated cells, suggesting microtubules play an important role in SG dissolution 
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Chapter 5: Identification of Matrin-3 as a novel miRISC 
and P-body Protein 
 
5.1 Introduction 
 So far a candidate approach has been used to identify Rck/p54 and 
Dcp1a as p50Nesp1 binding partners, based on their ability to co-localize with 
endogenous nesprin-1 foci using confocal microscopy.  Although Rck/p54 is a 
novel miRISC component, nesprin-1 foci failed to co-localize and interact with 
ectopically expressed GW182, a silencing protein considered to be core for 
miRISC function [290,302].  These data suggest that p50Nesp1 may be part of 
a GW182 independent sub-silencing complex that has yet to be identified.   
Therefore to further characterize proteins associated with p50Nesp1 miRISC 
function and also proteins that could be associated with microtubule-based P-
body dynamics, in this chapter an attempt is made to identify novel nesprin-1 
binding partners.  By using stringent conditions, co-immunoprecipitation 
experiments were performed which identified a host of RNA binding proteins 
associated with nesprin-1.  Of these binding partners, Matrin-3 was identifed 
as a new novel miRISC component that localizes to P-bodies and the nuclear 
matrix.   
5.1.1 Matrin-3 is an integral component of nuclear matrix       
Matrin-3 is a 95kDa protein which is predicted by SMART program to 
consists of two RNA binding domains (RBDs) which are flanked by two zinc 
finger (ZnF) motifs.  The purpose of these domains in matrin-3 remains 
unknown and the functional biology of matrin-3 is limited to the DNA damage 
response, RNA editing and cell survival [316,317,318,319].  Matrin-3 is an 
RNA binding protein that abundantly localizes to the nuclear matrix and is 
required for cell survival [317,318,320].  Although matrin-3 was identified and 
cloned two decades ago, its potential roles in the nucleus have only recently 
begun to emerge through the identification of novel binding partners.  Yeast-2-
hybrid data suggest that matrin-3 may play a role in a number of key nuclear 
processes including chromatin remodelling, RNA processing, transcription, 
translation, DNA replication and repair, translation, and apoptosis [246,316].  
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Matrin-3 is an RNA binding protein which has been shown to stabilize a group 
of mRNA transcripts as well as associate with hyperedited RNA, implying its 
RNA binding domains are likely to have functional roles in novel RNA 
processing events [319,321].  More interestingly, matrin-3 has been identified 
as a novel splicing factor and depletion of matrin-3 in HeLa cells results in the 
de-regulation of cassette exon splicing in a wide range of mRNA transcripts 
(Professor Chris Smith, Biochemistry Department, University of Cambridge, 
unpublished data).     
5.1.2 Matrin-3 associated diseases 
5.1.2.1 Autosomal-Dominant Distal Myopathy 
Matrin-3 has been implicated in multiple diseases, however the 
underlying defective signalling pathways involving matrin-3 remain to be 
characterized.  A genomic screen identified a S85C matrin-3 point mutation in 
patients suffering from a form of autosomal-dominant distal myopathy with 
vocal cord and pharyngeal weakness (VCPDM) [322].  Distal myopathies are 
a group of genetic muscle disorders, and the S85C point mutations resulted in 
weakened distal muscles of the upper and the lower limbs, with some patients 
suffering from mild cardiac hypertrophy.  Furthermore, these patients 
displayed myofibre degeneration and a substantial amount of muscle was 
replaced by fat and connective tissue.  At the cellular level these patients had 
degenerative nuclei, a typical characteristic displayed by multiple myopathies.     
 
5.1.2.2 Down’s syndrome 
Down’s syndrome (DS) is the most frequent genetic (trisomy 21) cause 
of mental retardation caused by meiotic defects resulting in an extra 
chromosome 21.  Although known for more than a hundred years, the 
underlying pathomechanisms for the phenotype and abnormal brain functions 
remain elusive.  Protein expression studies found that matrin-3 expression 
levels were significantly reduced in fetal DS brain relative to control [323].  
The trisomic effect of chromosome 21 is not thought to directly have any 
effects on matrin-3 expression, which is encoded by a gene on chromosome 5.  
However, dysfunctions in regulatory elements such as miRNAs or proteins 
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which stabilize matrin-3 may be impaired and as a consequence result in 
abrogated matrin-3 function.   
 
5.1.2.3 DGAP105 
A 5-year old male with multiple congenital anomalies, including posteriorly 
rotated ears, webbed neck, congenital heart defects, mental retardation and 
mild hypertelorism was described (Developmental Genome Anatomy Project 
(DGAP), Harvard University, Unpublished data).  A chromosomal 
translocation of the matrin-3 3’UTR on chromosome 5 to chromosome 1 (t1;5) 
is believed to be the underlying cause of these symptoms.  Matrin-3 is 
strongly expressed throughout the developing heart, and also in the nuclei of 
adult and embryonic skeletal muscle, smooth muscle, vascular endothelial 
cells, and in the developing lung, brain and kidney, suggesting a requirement 
for matrin-3 function in development and muscle function.  The 3’UTR of 
mRNA transcripts can play a role in mRNA localization, stability, and 
translation [262]. For example, binding of miRNAs to partially complementary 
sequences in the 3’UTR can result in de-adenylation and translational 
inhibition or destruction of the target mRNA [264].  With matrin-3 containing 
potential miRNA binding sites in its 3’UTR, defects in matrin-3 expression 
could be a cause of the phenotype observed in DGAP105 [324].    
 
5.2 Results 
5.2.1 Identification of p50Nesp1 specific binding partners  
 To further characterize protein complexes associated with p50Nesp1 
functions in miRISC and P-body dynamics, U2OS cells were transfected with 
Flag-p50Nesp1 or an empty control Flag vector and stringent co-
immunoprecipitations (co-IPs) were performed with anti-Flag to purify p50Nesp1 
associated protein complexes.  Precipitated protein complexes were 
denatured by boiling in β-mercaptoethanol loading buffer and separated by 
SDS-PAGE.  Silver staining of the gel identified multiple bands in the Flag-
p50Nesp1 co-IP, however these bands were also present in the negative control 
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co-IP suggesting no p50Nesp1 specific protein complexes were purified (Figure 
5.1).     
5.2.2 Generation of nesprin-1 N5 antibody. 
The failure to identify p50Nesp1 specific binding partners using anti-Flag 
co-IPs suggested another approach would be required for characterizing 
p50Nesp1 associated proteins.  Performing a yeast-2-hybrid screen using 
p50Nesp1 as bait would have been the ideal option, as it would have identified 
both strong and weak p50Nesp1 interacting partners.  Instead, an approach to 
identify endogenous binding partners was used by performing co-IPs with 
nesprin-1 N4.  However to identify nesprin-1 specific binding partners, 
nesprin-1 N5 was created against nesprin-1 amino acids 
QTIRQAENRLSKLNQA (amino acids 5510-5525 of nesprin-1 giant).  These 
amino acids are located downstream of the nesprin-1 N4 epitope, however 
are still encoded for by exon 86 and present in SR50 of nesprin-1. 
5.2.3 Nesprin-1 N5 stains p50Nesp1 P-bodies and the nuclear matrix but 
recognizes non-specific species by Western blotting.   
 In theory, nesprin-1 N5 should localize the nesprin-1 variants to the 
nucleolus and P-bodies, and detect the same bands on a Western blot as 
nesprin-1 N4.  Indeed, nesprin-1 N5 did stain P-bodies in U2OS cells as well 
as strongly staining the nuclear matrix, which the nesprin-1 N4 antibody stains 
weakly (Figure 5.2A).  However, the antibody did not localize any nesprin-1 
variants to the nucleolus.  
To determine if nesprin-1 N5 recognized p50Nesp1 P-body complexes, 
co-IPs with nesprin-1 N5 were performed on U2OS cell lysates.  The lysates 
were then probed for endogenous p50Nesp1 binding partners Rck/p54 and 
Dcp1a, which precipitated strongly with nesprin-1 N5 (Figure 5.2B).  Nesprin-1 
N4 and Rck/p54 co-IPs were performed alongside nesprin-1 N5 as positive 
controls, which also pulled down Rck/p54 and Dcp1a.   
Next, co-IPs were performed with nesprin-1 C2 and nesprin-1 CH2, 
which served as additional negative controls.  Nesprin-1 C2 and nesprin-1 
CH2 antibodies are described  in  chapter 3  and  target  the  nesprin-1  KASH  
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domain and nesprin-1 CHDs respectively, domains absent in p50Nesp1 
(Figures 3.6, 3.8).  Although both antibodies precipitated with Rck/p54 and 
Dcp1a, the amount detected was substantially reduced relative to the nesprin-
1 N4 and nesprin-1 N5 antibodies. (Figure 5.2C)  
 To confirm specificity of the nesprin-1 N5 antibody, peptide blocking 
experiments were performed, which diminished nuclear matrix staining and P-
body staining when the N5 antibody was pre-blocked by the N5 peptide via 
immunofluorescence microscopy (Figure 5.3). 
 When nesprin-1 N5 was used for Western blotting, the antibody 
detected different molecular weight bands in different experiments that were 
not reproducible from U2OS whole cell lysates.  Furthermore, the bands failed 
to be attenuated in peptide blocking experiments, suggesting the antibody 
was unsuitable for Western blotting (Figure 5.4). 
5.2.4 Identification of novel nesprin-1 N4/N5 binding partners  
 Although the nesprin-1 N5 antibody is not suitable for Western blotting, 
it does appear to recognize nesprin-1 P-body complexes suggesting it may be 
suitable for co-IPs when used with adequate controls.  Therefore, co-IPs on 
untransfected U2OS cells were performed with both nesprin-1 N4 and N5 
antibodies in tandem to identify endogenous nesprin-1 binding partners.  The 
advantage of this approach over a yeast-2-hybrid is that it would obtain 
binding partners for other nesprin-1 variants as well as p50Nesp1, allowing the 
function of other nesprin-1 variants to be identified.        
 Purified nesprin-1 N4 and N5 complexes from U2OS cells were 
separated by SDS-PAGE and silver staining identified several bands present 
in the nesprin-1 N4 and N5 purification but absent in the negative control IgG 
(Figure 5.5).  Mass spectrometry performed by Dr. Xiaoke Yin (Professor 
Mayr laboratory, King’s College London) was used to identify all the bands 
stained from both the nesprin-1 and negative control co-IPs.  Any proteins 
identified from the nesprin-1 co-IPs and the control IgG co-IPs were 
subtracted and only proteins that co-IP with both nesprin-1 antibodies were 
considered for further investigation.  Interestingly the majority of proteins 
identified were nuclear  components  involved  in  RNA  processing  (Matrin-3,  
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PSF, DDx5, hnRNP A2/B1) although some cytoplasmic proteins were also 
identified (HSP90, 40S ribosomal protein SA, Creatine kinase).  Remarkably, 
NE protein importin-β and cytoskeletal protein actin were also purified, 
suggesting larger nesprin-1 N4/N5 variants may also be associated with the 
LINC complex (Table 5.1).       
5.2.5 Validation of nesprin-1 binding partners 
 The nuclear nature of many of these binding proteins suggests that 
they may preferentially interact with nesprin-1 variants other than P-body 
p50Nesp1.  Therefore, to narrow down the binding regions of these proteins to 
nesprin-1, GST constructs covering a wider range of SRs in the vicinity of the 
nesprin-1 N4/N5 epitopes were created (Figure 5.6A).  
GST pull-downs were performed on U2OS lysates using four different 
GST clones.  The pull-down products were then probed for some of the 
binding partners obtained from mass spectrometry such as matrin-3, DDx5, 
PCNA and importin-β.  Matrin-3 interacted specifically with GST-G4, whilst 
PCNA had a strong association with SRs in GST-G3.  Although DDx5 and 
importin- β appeared to have strong attraction for GST in general, DDx5 had 
an enhanced attraction for the SRs attached to GST-G3 (Figure 5.6B).  Of the 
four GST constructs, only GST-G4 contains SRs which overlap with p50Nesp1 
while the rest of the constructs contain SRs downstream of SR48.  The ability 
of matrin-3 to interact with SRs in GST-G4 suggest it is the most likely binding 
partner to associate with p50Nesp1 complexes.   
5.2.6 Identifying new miRISC components  
In Chapter 4, p50Nesp1 was identified as a protein required for miRISC 
function using the CXCR4 and Let-7 miRISC reporter constructs (Figures 4.29, 
4.30, 4.31, 4.32).  Interestingly, p50Nesp1 failed to interact with core silencing 
protein GW182 suggesting that p50Nesp1 may scaffold silencing complexes 
independent of GW182.  Therefore to further characterize the p50Nesp1 
silencing complex, the CXCR4 and Let-7 luciferase assays were performed 
on cells depleted of either Importin-β, DDx5, hnRNPA2/B1, PCNA or  matrin-3.    
Cells  depleted  of  Importin-β,  DDx5,  hnRNPA2/B1  or  PCNA  
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(knockdowns determined by qRT-PCR, Figure 5.7A) failed to show any 
significant changes in the CXCR4 luciferase reading compared to control cells, 
signifying these proteins are not required for RNA silencing.  Cells lacking 
matrin-3 had increased luciferase activity suggesting they had attenuated 
miRISC to similar levels observed in p50Nesp1, GW182 and Rck/p54 depleted 
U2OS cells (Figure 5.7B).  Similar observations were achieved when U2OS 
cells were transfected with the FF4LCS construct to measure endogenous 
Let-7 function (Figure 5.8A).  However, endogenous Let-7 was unable to 
attenuate the silencing of FFr4mLCS mutant construct in any of the 
knockdown conditions (Figure 5.8B).       
5.2.7 Matrin-3 localizes to P-bodies 
The requirement for matrin-3 in miRISC function and the lack of 
understanding in general matrin-3 biology through the literature suggested 
matrin-3 warranted further investigation.  To determine the sub-cellular 
localization of matrin-3, antibodies targeting the N-terminal and C-terminal 
ends (matrin-3N and matrin-3C, respectively obtained from Abcam) of the 
protein were used to stain U2OS cells for endogenous matrin-3 (Figure 
5.9A,B,C).  Both the antibodies stained the nuclear matrix, while matrin-3N 
additionally stained cytoplasmic foci that co-localized with Hedls protein, 
suggesting an N-terminal matrin-3 isoform or cleavage product may localize to 
P-bodies (Figure 5.9B,C).  
5.2.8 Matrin-3 foci display typical P-body characteristics 
In chapter 4, I demonstrated that nesprin-1 P-bodies were induced in 
response to oxidative stress and microtubule depolymerisation, and they 
disassembled in cells that had no free pool of cytoplasmic mRNAs (Figures 
4.6, 4.8) .  To determine whether matrin-3 P-bodies behaved in a similar 
manner, they were examined in response to arsenite, nocodozole and 
cycloheximide.  The number of matrin-3- foci increased following arsenite-
induced oxidative stress and nocodozole mediated microtubule 
depolymerisation, whilst being eliminated in cells treated with the translational 
inhibitor cycloheximide (Figure 5.10). 
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5.2.9 Matrin-3 co-localizes and interacts with a host of P-body 
components  
To determine the post-transcriptional mRNA pathways matrin-3 was 
involved in, U2OS cells were transfected with tagged -GW182, -Rck/p54, -
Dcp1a, and -eIF4E, and co-localizations with matrin-3N were examined by 
confocal microscopy.  Unlike p50Nesp1, matrin-3 co-localized with all the P-
body markers including GW182-GFP (Figure 5.11).  This data along with the 
functional domains present in matrin-3, suggest it might be involved in a more 
extensive range of post-translational mRNA processing events relative to 
p50Nesp1.       
Next, to determine what protein complexes matrin-3 was physically 
associated with, co-IPs were performed with U2OS cells ectopically 
expressing Flag-GW182 and HA-eIF4E in the absence and presence of 
RNAase A.  Matrin-3 immunoprecipitated both proteins, in a RNA independent  
manner, suggesting these interactions were protein-protein dependent.  
Furthermore, matrin-3 co-purified with endogenous Argounaute-2 (Ago2), 
Rck/p54 and Dcp1a of which the matrin-3 – Argounaute-2 association 
occurred in an RNA dependent manner.  P-body proteins did not precipitate 
with the C-terminal nuclear matrix staining matrin-3 antibody, suggesting 
interactions with GW182, eIF4E, Dcp1a, Rck/p54 and Argounaute-2 were 
specific to P-body matrin-3.  Western blotting with PTB-associated splicing 
factor (PSF) served as a positive control for matrin-3 purified complexes 
(Figure 5.12) [319]. 
5.2.10 A 50 kDa matrin-3 variant localizes to P-bodies 
Next, studies were undertaken to examine whether nuclear and 
cytosolic matrin-3 shared a common pool of the protein.  Western blotting on 
U2OS cytosolic and nuclear fractions isolated using a hypotonic buffer 
showed differences in matrin-3 molecular weights between the two 
compartments.  The previously identified novel 95kDa matrin-3 appeared in 
the nuclear pool only, while a smaller 50kDa band was present in the cytosolic 
fraction (Figure 5.13A).  Furthermore, endogenous Ago2, Rck/p54 and 
Dcpa1a  co-immunoprecipitated  only  with  the  small  50 kDa  matrin-3  while  
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PSF,  a known binding partner of matrin-3 used as a positive control, only co-
immunopreicpitated with the 95kDa nuclear matrin-3 (Figure 5.13B).  A 
protein BLAST of the matrin-3N peptide sequence revealed no overlap with 
any other protein sequences on the database suggesting the antibody is 
specifically targeting matrin-3.      
To identify whether the 50kDa band was a novel isoform/splice variant, 
cleavage product or a non-specific protein recognized by the N-terminal 
antibody, siRNAs were created against the N-terminal and C-terminal (si-N 
and si-C, respectively) ORF of matrin-3.  Si-M3N knocked down both the 
95kDa and 50kDa bands on a Western blot while also eliminating nuclear 
matrix and P-body matrin-3 staining in U2OS cells, while si-M3C eliminated 
nuclear matrin-3 but failed to have any effect on P-body matrin-3 staining, 
suggesting a unique novel N-terminal matrin-3 splice variant exists in P-
bodies (Figure 5.14A,B).   
5.2.11 Multiple potential matrin-3 splice variants exist 
 The data obtained so far suggests that P-body matrin-3 possibly has 
the same coding sequence and therefore same 5’ mRNA end as nuclear 
matrin-3, with the two transcripts only differing in the 3’ end.  Therefore, to try 
and identify a new novel matrin-3 splice variant, 3’RACE was performed to 
obtain a new cDNA end that could correspond to P-body matrin-3 using HeLa, 
Brain and Skeletal muscle cDNA libraries. Primers sets were designed to 
target the first coding exon of matrin-3, which is recognized by the N-terminal 
antibody.  Although 3’RACE worked successfully with identifying new nesprin-
1 cDNA ends, no PCR amplicons were produced for matrin-3, including 
nuclear matrin-3.   
 Due to limitations with RACE, such as its inability to detect transcripts 
which may have long UTRs and therefore long cDNA ends, the EST and 
ensemble databases were screened to see if novel sequences were available 
which could represent the ~50 kDa matrin-3 protein.  The EST database was 
initially scanned for cassette exons which could generate matrin-3 variants 
through alternative splicing, followed by searching for sequences that could 
provide new 3’ termination sites.  Searches through the  EST  database  failed  
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to provide any novel findings in either case.  The Ensemble database 
contained a matrin-3 clone MATR3-011 which encoded a 47 kDa protein that 
contained the N-terminal matrin-3 antibody epitope.  This transcript had the 
same 5’UTR as nuclear matrin-3 but contained no terminating 3’ end, 
suggesting the MATR3-011 may be an incomplete sequence and difficult to 
validate.  Other matrin-3 sequences in the Ensemble database produced 
protein products which lacked the matrin-3 N-terminal antibody epitope or as 
with MATR-011, had no identifiable 3’end.     
5.2.12 Matrin 3 ZnF1 and RBD1 form nuclear and cytoplasmic foci 
 The inability to identify any novel nucleotide sequences which could 
correspond to P-body matrin-3, implied a cloning approach to identify P-body 
localizing and interacting domains would be required as an alternative.  The 
staining of P-body foci with the N-terminal antibody and siRNA knockdown of 
the 50 kDa band with si-M3N suggests P-body matrin-3 is likely to retain its N-  
terminal domains assuming no unusual alternative splicing events occur.  
Therefore, matrin-3 N-terminal truncation constructs were created by 
introducing stop codons after every major domain of GFP-matrin-3 using site 
directed mutagenesis (Figure 5.15).  
GFP-833 encodes matrin-3 amino acids 1-833, GFP-798 encodes 
matrin-3 amino acids 1-798, GFP-567 encodes matrin-3 amino acids 1-567, 
GFP-469 encodes matrin-3 amino acids 1-469, GFP-399 encodes matrin-3 
amino acids 1-399, GFP-322 encodes matrin-3 amino acids 1-332 and GFP-
288 encodes matrin-3 amino acids 1-288 (Figure 5.15A).  GFP-matrin-3, 
GFP-833, GFP-798 and GFP-567 all showed nuclear matrix localization in 
U2OS cells, while removal of the second RBD in GFP-469 induced 
cytoplasmic and nuclear foci formation.  Subsequent truncation constructs 
eliminated cytoplasmic foci localization, however still localized to nuclear foci 
as seen in GFP-399 and GFP-322.  The N-terminal uncharacterized motif of 
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5.2.13 Matrin 3 ZnF1 and RBD1 localize to P-bodies 
 To characterise the cytoplasmic foci structures formed by the 52 kDa 
GFP-469 matrin-3 construct, confocal microscopy was used to determine 
whether these structures co-localized with P-body markers Hedls, Rck/p54, 
eIF4E, GW182 and p50Nesp1 (Figure 5.16).  GFP-469 cytoplasmic foci strongly 
co-localized with endogenous Hedls and Rck/p54 and ectopically expressed 
HA-eIF4E and Flag-GW182 in U2OS cells, suggesting GFP-469 cytoplasmic 
foci resemble P-bodies (Figure 5.16A,B,C,D).  Although GFP-469 did co-
localize with some endogenous nesprin-1 N4 foci, the majority showed no co-
localization with a minority of bodies showing juxtaposed localization (Figure 
5.16E).  The nuclear foci formed by GFP-469 failed to co-localize with any P-
body markers, suggesting they represent different sub-cellular structures.      
 
5.2.14 Matrin 3 ZnF1 and RBD1 interact with P-body components  
 To determine whether matrin-3-469 (matr3-469) also contained binding 
sites for P-body proteins, the construct was cloned into a GST vector and pull-
down experiments were performed.  GST-matr3-469 pulled down endogenous 
Rck/p54, Ago2 and Dcp1a from U2OS whole cell lysates suggesting that 
matr-469 has all the relevant domains for P-body localization and interactions.  
Furthermore, this construct was able to interact with exogenous GW182 and 
eIF4E obtained from U2OS cells transfected with Flag-GW182 and HA-eIF4E 
(Figure 5.17). 
5.2.15 Matrin-3 mutation S85C attenuates tethering function and 
interactions with eIF4E, Dcp1a and Rck/p54 
Recently a S85C missense mutation in matrin-3 was reported to be a 
cause of an adult-onset progressive autosomal-dominant distal myopathy with 
vocal cord and pharyngeal weakness (VCPDM) [325] (See section 5.1.1.1.1).  
Currently the effects of this point mutation on cells are unknown due to a lack 
of knowledge behind matrin-3 function.  Although muscle diseases are often 
associated with structural proteins, I wanted to investigate whether this 
mutation had any effect on mRNA processing associated with P-body matrin-
3. 
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To examine whether protein-protein interactions were effected as a 
result of this mutation, the S85C mutation and a control S85A mutation were 
introduced into GST-tagged matr3-469 and protein-protein interactions were 
examined with GW182, Ago2, eIF4E, Dcp1a and Rck/p54.  Interactions with 
GW182 and Ago2 were unaltered while a weakened interaction was observed 
with eIF4E, Dcp1a and Rck/p54.  The control S85A mutation showed the 
same degree of interaction as the WT, suggesting that the missense mutation 
to cysteine negates the interaction rather than the serine being absolutely 
required (Figure 5.18A,B).  
Next the ability of the WT, S85C and S85A mutants to silence a β-
globin reporter construct in a tethering assay was examined.  To do this WT, 
S85C and S85A matr3-469 were cloned into pc1-λN-V5 and tethered to a 
luciferase tagged β-globin reporter construct (pRLTK-globin-boxB) in U2OS 
cells [326].  The λN-peptide has a high affinity for the boxB sites within the 
luciferase-tagged β-globin transcript, allowing β-globin suppression to be 
measured by luminescence in response to the recruitment of matr3-469.   All 
three matr3-469 constructs significantly reduced luciferase expression by 
direct tethering, however the S85C mutant showed impaired reduction relative  
to the WT and the S85A control, suggesting VCDPM patients may have 
mRNA silencing defects in muscle.  Rck/p54 tethering served as a positive 
control and expression levels of all constructs were determined by Western 
blotting for the V5-tag  (Figure 5.18C,D). 
 
5.3 Discussion  
5.3.1 Nesprin-1 variants may be involved in a wide range of RNA 
processing events 
The initial aim of this chapter was to further characterise the role of 
p50Nesp1 in miRISC silencing and P-body dynamics. As the purification of  
p50Nesp1 using Flag-based co-IPs in U2OS cell transfected with Flag-p50Nesp1 
was unsuccessful, an alternative approach was used to identify binding 
partners.  The generation of nesprin-1 N5 not only further proves the 
existence  of  nesprin-1  within  P-bodies,   but  provides  a  valuable  tool   for  
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characterizing other nesprin-1 variants (Figure 5.3).  Like many other 
antibodies available on the market, it remains unsuitable for Western blotting 
and therefore fails to identify the molecular weights of P-body and nuclear 
matrix nesprin-1 variants.  Nesprin-1 N5 failed to stain nucleolar structures 
recognized by nesprin-1 N4 and Flag-constructs, however this could be due to 
a number of reasons including epitope masking.  Instead of performing a 
yeast-2-hybrid screen to identify p50Nesp1 binding partners, purified protein 
complexes associated with all nesprin-1 N4/N5 variants using co-IPs were 
performed.  Interestingly, this method yielded a range of binding partners 
primarily involved in RNA processing. 
Many of the potential binding partners have previously been shown to 
be involved in transcription (DDx5, PSF) [327,328,329,330,331], alternative 
splicing (PSF, DDx5, hnRNP A2/B1) [332,333,334,335], DNA 
replication/damage repair (PCNA, Matrin-3) [336,337], transport (Importin, 
hnRNP A2/B1) [338,339,340,341,342] and protein chaperoning (HSP90) [343], 
further highlighting the capabilities of nesprin-1 as a multi-functional protein 
through generation of diverse isoforms.  Although this chapter focused on 
identifying new miRISC associated binding partners, functional assays in 
transcription, splicing and transport involving the function of newly identified 
binding partners can be used to gain further insight into nesprin-1 function.  
Furthermore, future work should try and attempt to match binding partners to 
each of the individual nesprin-1 isoforms so the function of each individual 
isoform can be determined.     
5.3.2 Matrin-3 as a novel P-body and miRISC component  
 Using co-localization studies along with co-IPs, a ~50 kDa cytosolic 
matrin-3 splice variant was shown to associate with P-body proteins (Figure 
5.13).  However, matrin-3 P-body localization was only observed with an 
antibody created against an N-terminal peptide of the protein, but not with an 
antibody targeting the C-terminal end (Figure 5.9).  The ability to abolish P-
bodies and a 50kDa matrin-3 Western band using a siRNA targeting the N-
terminal region of the protein but not the C-terminal region, implies that at 
least two splice variants of the protein exist, one which localizes to the nuclear 
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matrix and another which localizes to P-bodies (Figure 5.14).  Using RACE 
and online databases, attempts were made to identify novel mRNA 
sequences which could code for P-body matrin-3.  However due to the 
multiple limitations with RACE and lack of novel online sequences, the 
transcribed product encoding P-body matrin-3 could not be identified.  The 
constant addition of new sequences to online databases will hopefully reveal 
possible clues to help identify the true coding sequence of this matrin-3 
species in the future.   
 As an alternative approach, matrin-3 N-terminal truncation constructs 
were created in order to identify the major domains required for matrin-3 P-
body localization (Figure 5.15).  Matr3-469 which terminates after the first 
RBD, encodes a 52 kDa construct and co-localize with Hedls, Rck/p54, 
GW182 and eiF4E (Figure 5.16).  Interestingly, rather than co-localizing with 
endogenous p50Nesp1, the majority of matr3-469 foci showed a juxtaposed 
localization, indicatinf that overexpression of this construct may act in a 
dominant negative manner to remove nesprin-1 from P-bodies.  Although this 
phenomena requires further investigation it would be interesting to determine 
whether matr3-469 promotes nesprin-1 localization to SGs which display a 
similar juxtaposition to P-bodies in stressed cells (Figures 5.16, 4.7).  
Additionally, it would be interesting to see what effect this construct has on P-
body dynamics such an P-body movement and their ability to associate with 
SGs, particularly if matr3-469 is able to remove endogenous nesprin-1 from 
P-bodies.       
The degree of alignment which exists between matr3-469 and the 
actual ~50kDa matrin-3 isoform has yet to be determined, but P-body 
localization through truncation constructs suggests that RBD1 is necessary for 
localization, as its removal resulted in disappearance of P-bodes (Figure 5.15).  
Although matrin-3 has been studied for a number of years now, the biological 
function of this apparent multi-functional protein has yet to be determined, let 
alone the role of the various RNA binding and zinc finger domains that exist 
within the protein.  
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5.3.3 Matrin-3 silencing and Autosomal-dominant distal myopathy  
 Not only did matr3-469 localize to P-bodies, but it was also able to 
interact with P-body proteins and silence a luciferase reporter construct 
through direct tethering (Figures 5.16, 5.17, 5.18).  Furthermore, when a 
S85C mutation causing autosomal dominant distal myopathy was introduced 
into matr3-469, interactions with certain P-body proteins and silencing 
function of matrin-3 was significantly hindered (Figure 5.18).  Although 
myopathies are normally associated with structural defects, this data suggests 
that the silencing ability of matrin-3 could also be a contributing factor [146].  
As well as abrogating interactions with Rck/p54, Dcp1a and eIF4E, the next 
set of experiments should take a closer look at whether interactions with 
cytoskeletal proteins are also effected, which could effect how P-bodies 
migrate and how silenced mRNAs are transported to distant cellular sites in 
muscle cells.  Ideally work performed on skin fibroblasts and/or muscle 
biopsies obtained from patients will allow the effects of mRNA silencing to be 
properly studied, as they will allow mRNA silencing to be studied on 
endogenous P-body matrin-3 mutant rather than an artificial constructs.    
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Chapter 6: Summary and Future Directions 
 
6.1 Thesis Summary 
Nesprins were originally identified as giant SR proteins which scaffold 
the NE to components of the cytoskeleton [67,68,69].  Nesprins are 
characterized by N-terminal cytoskeletal-binding motifs followed by a flexible 
SR rod that terminates with a C-terminal KASH domain, promoting NE 
localization.  Initial studies concentrated on the interactions between nesprins 
and nuclear lamina associated proteins, such as lamin A/C and emerin, which 
are mutated in a class of devastating diseases known as nuclear 
envelopathies.  Although nesprin mutations have been identified in nuclear 
envelopathies, more recent studies have implicated nesprins in diseases not 
directly linked to the NE, such as bipolar disorder and cancers [202,232].  
Previous work conducted by our laboratory, and the work presented in this 
thesis, confirmed that alternative transcript generation produces multiple 
tissue- and organelle-specific nesprin-1 variants with roles beyond the NE.   
In chapter 3, the true extent of nesprin-1 isoform diversity was 
determined.  Initially, Western blots on whole cell lysates of U2OS cells and 
HDFs using antibodies targeting the nesprin-1 CHD, KASH domain and a SR 
present in the central rod domain was preformed (Figures 3.6, 3.8, 3.16).  
Unsurprisingly, all the antibodies detected multiple bands of various molecular 
weights suggesting various nesprin-1 isoforms exist that contain specific 
domains.  Although some of these bands could be assigned to specific 
nesprin-1 variants based on the identification of novel 5’ and 3’ UTRs 
previously discovered by our laboratory, many were unidentifiable (Figures 
3.5, 3.7, 3.18).  Therefore, 5’ and 3’ RACE analysis was performed using 
nesprin-1 specific primers to detect new UTRs that could help identify new 
novel isoforms.  By alternatively combining the newly identified UTRs with 
pre-existing ends, it became possible to identify almost every band detected 
by nesprin-1 antibodies on a Western blot (Figures 3.10, 3.14, 3.20).  Many 
small nesprin-1 variants were verified by RT-PCR on cDNA isolated from 
multiple tissues and cell lines, which demonstrated nesprin-1 expression 
specificity.  When the small nesprin-1 variants were flag-tagged and examined 
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in vitro, they localized to multiple sub-cellular compartments such as actin-
stress fibres, focal adhesions, cytoplasmic granules, microtubules, P-bodies, 
nucleolus and the cytosol (Figures 3.11, 3.12, 3.15, 3.21, 3.22, 3.23, 3.24, 
4.17).  Interestingly, the localization of the ectopically expressed nesprin-1 
variants appeared to be cell-type specific, suggesting individual isoforms may 
have distinctive functions in different cell types.     
In chapter 4, variants generated within the central rod region of 
nesprin-1 were further examined.  To determine their endogenous 
localizations, immunofluorescence microscopy was performed with the 
nesprin-1 N4 antibody on cultured U2OS cells and HDFs (Figure 4.1).  
Nesprin-1 N4 labelled the nucleolus and multiple cytoplasmic foci that co-
localized with mRNA decapping factors and translational repressors in P-
bodies (Figures 4.2, 4.10).  Not only did p50Nesp1 co-IP with Rck/p54 P-body 
protein, but it also localized to P-bodies when ectopically expressed in 
VSMCs, strongly linking p50Nesp1 to P-bodies (Figures 4.10, 4.12).  
Interestingly, p50Nesp1 localized to and recruited Rck/p54 to microtubules 
when ectopically expressed in U2OS cells suggesting it may scaffold/link P-
bodies to microtubules (Figure 4.20).  Indeed, when the final two SRs of 
p50Nesp1 (p50CT), which were demonstrated to have microtubule binding 
capabilities (Figure 4.18), were transfected into U2OS cells they were able to 
act in a dominant negative manner and displace P-bodies from microtubules 
(Figure 4.20).  The displacement of P-bodies from microtubules resulted in 
reduced P-body movement as demonstrated by live-cell imaging using single 
particle tracking (Figure 4.22).  Furthermore, it stopped P-bodies from 
associating with SGs and blocked β-globin mRNA transfer from SGs to P-
bodies during the stress response, resulting in the accumulation of β-globin 
mRNA within SGs (Figure 4.25).  Additionally, SGs were unable to dissemble 
during recovery which resulted in cellular toxicity and cell death (Figures 4.26, 
4.27).  Finally, P-body phenotype in response to siRNA-mediated p50Nesp1 
knockdown was examined.  Elimination of p50Nesp1 resulted in P-body loss 
and attenuated miRISC function, which could be rescued by overexpression 
of the first two SRs of p50Nesp1, measured by a luciferase reporter assays 
(Figures 4.28, 4.29, 4.30, 4.31, 4.32).  Interestingly p50Nesp1 failed to interact 
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with GW182, a core miRISC protein, suggesting that p50Nesp1 may scaffold 
GW182 independent miRSIC complexes.   
To gain further insight into the p50Nesp1 sub-silencing complex, nesprin-
1 binding partners were identified and validated in chapter 5 using co-IP and 
GST pull-down experiments (Figures 5.5, 5.6, Table 5.1).  Interestingly, the 
majority of binding partners identified were RNA binding proteins associated 
with nuclear events, including matrin-3.  In this chapter, an additional matrin-3 
isoform was found to localize to P-bodies and be a component required for 
efficient miRISC function (Figures 5.7, 5.8, 5.9, 5.11).  Although the identity of 
the matrin-3 P-body isoform remains elusive, P-body localizing domains were 
identified (Figures 5.15, 5.16).  When a P-body matrin-3 constructs was 
tethered to a luciferase reporter construct, it was able to induce luciferase 
repression, which was significantly hampered when a single point mutation 
(S85C), previously described in a form of autosomal dominant distal 
myopathy, was introduced (Figure 5.18).  Furthermore, the S85C mutated 
construct had weakened interactions with core P-body proteins Rck/p54, 
Dcp1a and eIF4E, indicating myopathy patients may have hampered mRNA 
processing functions (Figure 5.18).   
 
6.2 Discussion and future directions    
6.2.1 Nesprins are cellular scaffolds and linkers 
Originally nesprins were identified as members of the LINC complex 
that connect the NE to components of the cytoskeleton.  The importance of 
nuclear-cytoskeletal scaffolding has been widely studied using nesprin animal 
models, dnKASH constructs and siRNA-mediated knockdown experiments 
described in Chapter 1.   
In addition to functions of nesprins as nuclear-cytoskeletal couplers, 
scaffolding roles have been identified for nesprins beyond the NE through the 
generation of KASH-less nesprin variants.  GSRP-56, CPG2 and Drop1 are 
three KASH-less nesprin-1 variants with identifiable transcripts, whereas 
KASH-less nesprin-2 has been shown as an important mediator of ERK1/2 
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signalling [207,208,222,232].  In this thesis I have identified additional 
nesprin-1 variants, which not only act as potential cytoskeletal scaffolds, but 
may also have cell/tissue specific nuclear scaffolding functions.  
6.2.2 Nespin-1 in nuclear scaffolding  
In chapter 3 I identified 3 nucleolar nesprin-1 variants terminating with 
the N1-3’E87 UTR (Figure 3.20).  The largest isoform, p31Nesp1 composed of 2 
and a half SRs, localized to the nucleolus without hampering nucleolar 
morphology in HDFs.  However, when the two shorter nucleolar variants 
p23Nesp1 and p12Nesp1 composed of 2 SRs and 1 SR respectively, were 
transfected into HDFs, they caused fibrillarin to re-distribute into nucleolar cap 
structures (Figures 3.24).  Segregation of nucleolar components into cap 
structures occurs under some physiological conditions of transcriptional arrest, 
which can be mimicked by transcriptional arrest using actinomycin D or 
cellular stress [378,379].  The ability of the two smaller nesprin-1 variants to 
induce cap formation without the application of stress or translational 
inhibitors implies that they may be crucial nucleolar organizer, or stress-
induced nucleolar signalling proteins.  As the primary function of SRs is to 
mediate protein-protein interactions, it is difficult to speculate what nucleolar 
proteins these nesprin-1 variants scaffold without identifying binding partners.  
Future work regarding these nucleolar variants should involve identifying 
binding partners for each of the 3 nucleolar variants terminating with the N1-
3’E87 UTR.  Undoubtedly p31Nesp1 is expected to scaffold a greater number of 
proteins than p23Nesp1 and p12Nesp1.  Therefore identifying binding partners for 
p31Nesp1, via a yeast-2-hybrid screen, and then mapping their binding sites to 
the individual SRs of p31Nesp1, p23Nesp1 and p12Nesp1 would be the most 
efficient strategy in identifying binding partners for all three variants, assuming 
the structural properties of the C-terminal ends remain unchanged as the 
protein truncates.  The nucleolus is classically known to be a site of rRNA 
assembly, however mass spectrometry on purified nucleoli has revealed over 
700 proteins related to cell cycle regulation, DNA damage repair, mRNA 
processing and miRNA biogenesis in the nucleolus, suggesting it has 
additional roles [380,381].  The unique tissue specific expression patterns of 
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the three nesprin-1 variants suggest they may influence nucleolar 
organization and function in a tissue specific manner (Figure 3.20).      
  Previously a group of nuclear matrix proteins, mostly RNA binding 
proteins, have been shown to re-localize from the nuclear matrix to nucleolar 
cap during transcriptional inhibition [379].  Matrin-3 binding protein PSF 
(which may also interact with nesprin-1 nuclear variants, (Table 5.1) was one 
of the proteins shown to re-localize to nucleolar caps under these conditions.  
Although the matrin-3 binding site in nesprin-1 needs to be narrowed down 
further, potentially all three nucleolar nesprin-1 variants have the ability to 
associate with matrin-3.  Future work should therefore focus on determining 
whether these nucleolar nesprin-1 variants are capable of interacting with 
nuclear matrin-3.  If they fail to interact, then further extensive RACE will need 
to be performed to identify additional nesprin-1 variants associated with 
matrin-3 nuclear function. 
Finally p56CHNesp1, which is composed of both nesprin-1 CHDs and a 
single SR, was shown to localize to the nucleolus in U2OS cells suggesting 
multiple nesprin-1 variants generated across the nesprin-1 gene may posses 
signals to promote nucleolar localization (Figure 3.11).  Interestingly, the 
ability of a CHD variant to localize to the nucleolus suggests it may play a role 
in linking the nucleolus to nuclear F-actin in U2OS cells.  Although the 
function of nuclear F-actin in transcription and chromatin re-modelling has 
been well established, the literature shows no link between it and the 
nucleolus, therefore making an interesting path to pursue [382].  
6.2.3 Nesprin-1 in cytoskeletal scaffolding  
In addition to nuclear scaffolds, p56CHNesp1 and p50Nesp1 were 
identified as ubiquitously expressed components associated with the 
cytoskeleton in a cell specific manner suggesting, nesprin-1 variants have 
functions as cytoskeletal scaffolds.   
 
6.2.3.1 p56CHNesp1 in cell adhesion and migration 
Although p56CHNesp1 was shown to localize to the nucleolus in U2OS 
cells, it strongly associated with actin stress fibres in HDFs (figures 3.11, 3.12).  
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The ability of p56CHNesp1 to also strongly associate with focal adhesions in 
HDFs suggest it may play a role in cell migration and adhesion (Figure 3.12).  
Often knockdown studies with time-lapse microscopy are performed to study 
the function of proteins in cell motility.  However designing siRNAs against the 
CHDs of nesprin-1 would target global knockdown of all CHD containing 
nesprin-1 variants with probable drastic F-actin organization throughout the 
cell.  The alternative 3’ end processing of the p56CHNesp1 transcript provides it 
with a unique 37 amino acid peptide sequence absent in the nesprin-1 giant 
and other nesprin-1 variants, which could be utilised for targeting with siRNAs 
to specifically knockdown p56CHNesp1.  Furthermore, the large peptide 
sequence makes an ideal target for synthesizing p56CHNesp1 specific 
antibodies, which will allow the endogenous localization of the variant to be 
distinguished in multiple cell lines.  SRs generally mediate protein-protein 
interactions, and with p56CHNesp1 containing a single SR and a long unique 
peptide sequence it would be interesting to determine what protein(s) 
associate with the C-terminal end of p56CHNesp1.  Therefore, future studies 
should focus on the identification of p56CHNesp1 binding partners followed by 
knockdown experiments to see if disruption of p56CHNesp1 complexes effects 
F-actin organization and cell migration.   
 
6.2.3.2 Nesprin-1 variants as a microtubule scaffold 
In chapter 4, the final two SRs of p50Nesp1 were shown to directly 
interact with microtubules and therefore any nesprin-1 variants which 
terminates with the N1-3’E90 UTR would retain these the C-terminal SRs and 
microtubule binding capabilities.  Figure 6.1 highlights all potential nesprin-1 
variants which could terminate with N1-3’E90 UTR and scaffold various 
protein complexes to the microtubule cytoskeleton.  The variants terminating 
with this UTR are both large and small, with the largest variant pCH661Nesp1 
also retaining the N-terminal CHDs suggesting it could act as a microtubule – 
actin cross linker.  The other large variants include pCH620Nesp1, pCH579Nesp1  
and pCH292Nesp1 which posses numerous SRs.  Nesprin isoforms tend to be 
expressed in a tissue/cell specific manner and therefore these microtubule 
associated protein (MAP) variants  could  link  multiple  tissue-specific  protein  
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complexes to microtubules, regulating transport of intra-cellular complexes 
within the cell.  Validation of the large variants by RT-PCR would be difficult 
and therefore other methods such as Northern blotting should be utilized in 
future experiments to confirm their expression.  Components of kinesin-1 and 
2 have been identified to interact with SRs of nesprin-1 and nesprin-4 [69,82].  
With SRs being conserved, it is not unreasonable to assume multiple kinesin 
binding sites are located throughout the nesprins [78].   
 Previously, 5 unique mutations were identified in the nesprin-1 gene 
which resulted in a form of autosomal recessive cerebellar ataxia (ARCA1) 
[13].  Two of these mutations 306434A-G and 310067A-G, located in splice 
acceptor sites of introns 81 and 84 of the nesprin-1 gene respectively, 
abrogated correct splicing of the gene, resulting in premature termination of 
the protein.  Both mutations would result in pre-mature termination of the 
larger variants and de-regulate signalling pathways of protein complexes 
associated with nesprin- MAP variants.  Identification of binding partners for 
SRs downstream of the nesprin-1 MAP domain will further aid in the 
understanding the protein complexes and signalling pathways associated with 
these nesprin-1 variants.   
 
6.2.3.3 p50Nesp1 as a P-body microtubule scaffold 
 p50Nesp1 is the first SR-containing protein to date identified as a novel 
P-body component.  Importantly, p50Nesp1 fulfils nesprins role as an intra-
cellular scaffold by linking P-bodies to microtubules.  Although SR3 and SR4 
of p50Nesp1 are accountable for microtubule linkage, it appears that SR1 and 
SR2 of the protein provide functionality by interacting with enzymes and co-
factors required for mRNA decapping, translational repression and miRISC 
(Figure 4.33).   
 In chapter 5, attempts were made to identify p50Nesp1 binding partners.  
Although matrin-3 was identified as a binding partner and miRISC regulator, 
the screen did not provide any other useful clues in further dissecting p50Nesp1 
associated protein complexes.  Rather than providing a list of cytoplasmic 
RNA binding proteins, the co-IP screen revealed nuclear RNA binding 
proteins as preferential binding partners.  This suggests that either nuclear 
	   241 
nesprin-RNA complexes are more abundant than cytosolic nesprin-RNA 
complexes within U2OS cells, or the nesprin-1 N4 and N5 antibodies have a 
stronger affinity for associating with nuclear nesprin-1.  Nonetheless, this data 
along with the ability of p50Nesp1 to associate with Rck/p54 and Dcp1a suggest 
that SRs present around the nesprin-1 N4/N5 epitope may have a high affinity 
for RNA binding proteins.  To overcome this issue, SR1 and SR2 of p50Nesp1 
should be incorporated into a yeast-2-hybrid screen which will pick up both 
strong and weak interacting RNA binding partners and help further 
characterize the p50Nesp1 complex.   
As described above, the 310067A-G  (in splice acceptor site of intron 
84) ARCA1 mutant would result in pre-mature termination of p50Nesp1 and may 
be a possible contributor to the ataxia phenotype observed by the patient.    
Previously, mutations in P-body proteins have been described in 
neurodegenerative diseases.  For example, the Huntington protein (Htt), 
mutated in Huntington’s disease, was identified as an Argounate-2 binding 
protein, which localizes to, and is necessary for, the formation and function of 
P-bodies, as determined by siRNA knock-down of Htt and expression of 
dominant-negative disease-causing mutants [383].  Furthermore, ataxin-2, 
mutated in a related neurodegenerative disorder spinocerebellar ataxia type 2 
(SCA2), interacts with the p50Nesp1 binding partner Rck/p54 and localizes to 
both P-bodies and SGs [306,384].  Whether any of the ARCA1 patients, in 
particular 310067A-G, have defects in P-body dynamics such as assembly, 
motility, hindered SG connections and mRNA transfer, would provide a 
plausible explanation behind the disease.            
6.3 Concluding remarks 
 In this thesis I have identified a vast range of diverse tissue specific 
nesprin-1 isoforms, with the majority still needing to be experimentally 
characterized.  Although this thesis has contributed significantly to the nesprin 
field, there still remains a large uncertainty into the plethora of functions for 
nesprins as both cellular scaffolds and signalling proteins.  For example, the 
other nesprin genes, in particular nesprins-2, are sure to have similar levels of 
isoform complexity and diversity to nesprin-1, suggesting much more needs to 
be done in understanding nesprin biology.      
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Abstract
Background: Nesprins (Nuclear envelope spectrin-repeat proteins) are a novel family of giant spectrin-repeat containing
proteins. The nesprin-1 and nesprin-2 genes consist of 146 and 116 exons which encode proteins of ,1mDa and ,800 kDa
is size respectively when all the exons are utilised in translation. However emerging data suggests that the nesprins have
multiple alternative start and termination sites throughout their genes allowing the generation of smaller isoforms.
Results: In this study we set out to identify novel alternatively transcribed nesprin variants by screening the EST database
and by using RACE analysis to identify cDNA ends. These two methods provided potential hits for alternative start and
termination sites that were validated by PCR and DNA sequencing. We show that these alternative sites are not only
expressed in a tissue specific manner but by combining different sites together it is possible to create a wide array of
nesprin variants. By cloning and expressing small novel nesprin variants into human fibroblasts and U2OS cells we show
localization to actin stress-fibres, focal adhesions, microtubules, the nucleolus, nuclear matrix and the nuclear envelope (NE).
Furthermore we show that the sub-cellular localization of individual nesprin variants can vary depending on the cell type,
suggesting any single nesprin variant may have different functions in different cell types.
Conclusions: These studies suggest nesprins act as highly versatile tissue specific intracellular protein scaffolds and identify
potential novel functions for nesprins beyond cytoplasmic-nuclear coupling. These alternate functions may also account for
the diverse range of disease phenotypes observed when these genes are mutated.
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Introduction
Nuclear envelope (NE) spectrin-repeat proteins, or nesprins, are
a novel family of nuclear and cytoskeletal proteins with rapidly
expanding roles as intracellular scaffolds and linkers [1,2,3,4].
Nesprins are characterized by a central extended spectrin-repeat
(SR) rod domain and a C-terminal Klarsicht/ANC-1/Syne
homology (KASH) transmembrane domain, which acts as a NE
targeting motif. At the NE, via interactions with the Sun-domain
family of proteins and the nuclear lamina, nesprins on both the
inner and outer nuclear membrane form the linker of the
nucleoskeleton and cytoskeleton (LINC) complex [5,6]. This
complex requires the giant nesprin-1 (,1 MDa) and nesprin-2
(,800 kDa) isoforms, which possess a pair of N-terminal calponin
homology domains, which bind directly to F-actin [7,8]. Nesprin-3
(,110 kDa) and nesprin-4 (,43 kDa) are smaller family members
with more divergent spectrin-repeats. These lack the N-terminal
CH domains of nesprin-1 and -2 and via SRs interact with
intermediate filaments and microtubules respectively [3,4,9].
Disruption of the LINC complex via mutations in nesprin-1 and
-2 or their binding partners, such as emerin and lamin A/C, give
rise to Emery Dreifuss Muscular Dystrophy (EDMD)
[6,10,11,12,13,14,15,16,17]. However, emerging evidence impli-
cates nesprin-1 and -2 in several other unrelated diseases,
including schizophrenia, epithelial cancers and autosomal reces-
sive cerebellar ataxia (ARCA1), which are not characterized by
NE defects [18,19,20]. It is likely that these non-canonical roles for
nesprin are mediated by alternative transcription that has been
shown to generate multiple tissue-specific nesprin variants that
lack either the CH domain, the KASH domain or both and
localize to a number of subcellular compartments [2,21]. For
example, nesprin-1 has been shown to localize to the Golgi
apparatus and over-expression of dominant-negative nesprin-1
fragments composed of SRs within the central rod domain disrupt
Golgi organization and function [22,23,24]. Nesprin-1 isoform
Drop1, which consists of the N-terminal CH domain and SRs but
lacks the KASH domain, is significantly down regulated in
epithelial cancer and may play a role in chromatin organization
[16,25,26]. Furthermore, the brain-specific nesprin-1 isoform,
candidate plasticity gene 2 (cpg2), consists solely of SRs and
localizes to the neuronal postsynaptic endocytic zone surrounding
dendritic spines where it regulates clathrin-mediated uptake and
recycling of chemokine receptors [27,28].
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In order to assess further the extent of alternate nesprin
functionality, in this study we set out to identify novel nesprin
variants by identifying 59UTRs and 39UTRs transcribed from the
nesprin-1 and nesprin-2 genes. We provide evidence that both
nesprin-1 and -2 undergo alternative splicing and express multiple
tissue specific variants generated by alternate initiation and
termination and that the sub-cellular localization of these variants
is cell type dependent. We also provide a unifying nomenclature
system for nesprin variants and their UTRs.
Results
Identification of Novel Nesprin-1 and Nesprin-2 UTRs
We adopted two approaches to identify bone fide novel 59 and
39UTRs. We first performed 59 and 39 RACE from HeLa, Skeletal
Muscle and Brain cDNA libraries using multiple gene specific
nesprin primers and nested primers designed towards the end of a
range of exons throughout the nesprin gene. Many PCRs
produced non-specific or no amplicons (data not shown) however,
products for multiple UTRs as retained introns were detected
(Figure 1A). For nesprin-1 we identified N1-59E83, a novel 59UTR
where the first coding exon utilised is exon 83. Multiple nesprin-1
39UTRs were detected in a tissue/cell specific manner where the
last coding exons were either exons 14, 44, 82, 90 or 106 (N1-
39E14, N1-39E44, N1-39E82, N1-39E90 and N1-39E106 respec-
tively). Similarly N2-39E50 and N2-39E90 are two novel nesprin-2
39UTRs also identified by RACE. The stop codons for isoforms
terminating with these novel 39 ends were found in retained
intronic sequences between the last coding exon and the exon
thereafter. In nesprin variants using these 39 ends the ‘retained
intron’ resulted in the addition of unique amino acids followed by
a stop codon that were absent from the giant isoforms.
Downstream of the stop codon will be a polyA signal followed
by a polyadenylation site. For example, variants terminating with
the N1-39E90 UTR contain eight codons before the stop codon in
the retained intron between exon 90 and exon 91. Thus variants
terminating with this 39UTR possess a novel 8 amino acid peptide
sequence, ‘AGAGYPHQ*’, which is absent in the giant isoform
(Figure 1B).
Due to limitations with RACE analysis we next screened
available databases for novel nesprin cDNA transcripts. The
NCBI expressed sequence tag database (EST), which consists of
one-shot sequences of cloned mRNA, was blasted with consecu-
tive, 500 bp-overlapping 1 kb nesprin-1 and nesprin-2 sequences
covering the entirety of the giant isoform cDNAs. Several novel
UTRs were detected in the EST database screen, typically
presenting as retained introns between two exons (Table 1).
59UTRs were considered real if they contained an identifiable and
viable Kozak sequence surrounding the first start codon. Only
those 39UTR sequences which already included a poly(A) tail or
contained at least one poly(A) site downstream of the initial ORF
termination codon, as determined by scanning with the polyAdq
program or manually for non-canonical poly(A) signals, were
considered for further study.
The majority of UTRs identified by RACE or through the EST
screen were verified by PCR and DNA sequencing using a multi-
tissue cDNA panel (Figures 1C,D. Table 1 contains a column
showing the UTRs which have been verified by PCR). PCR
primers were designed so that one primer was present within the
UTR and the second within a constitutively present exon with at
least one intervening intron sequence to control for genomic DNA
contamination. Although many UTRs PCR amplified in a range
of tissues, most were transcribed in a tissue specific manner
suggesting they lead to the creation of tissue specific nesprin
variants. The potential combinations of 59 UTRs with 39UTRs are
extensive and would allow generation of many variants. Figures 2A
and 3A provide an outline of the nesprin-1 and nesprin-2 UTRs
across their respective genes with figures 2B and 3B highlighting
proposed variants that could be created by a ‘mix-and-match’
approach in vivo for nesprin-1 and nesprin-2 respectively (Table S1
and Table S2 shows the UTRs that when combined generate these
nesprin-1 and -2 variants respectively). The spectrin repeats (SRs)
used in our schematics to represent nesprins are based on the
predictions of SRs as previously described [29]. Many of the
predicted nesprin variants are too large to be detected by
conventional PCR and are therefore hypothetical. The smaller
nesprin variants were however validated by PCR and are
described below.
Although many variants could retain the KASH domain, there
is a possibility of generating isoforms composed solely of SRs.
Therefore, the identified nesprin variants were named according
to their predicted molecular weights and the domains they
possessed. For example, p56CHNesp1 is a nesprin-1 variant of
56 kDa which has the N-terminal CH domains, p50Nesp1 is a
50 kDa nesprin-1 variant which lacks both the CH domains and
the KASH domain and is composed of SRs, while p53KASHNesp1
is a 53 kDa KASH containing variant lacking CH domains.
Variants that lack the KASH domain due to alternative splicing
events in and around the exons coding for the KASH domain have
been described as DKASH variants (See below).
Nesprin KASH Isoforms
So far a number of KASH variants including the nesprin-1 and
nesprin-2 a,b isoforms have been identified. In principle any of the
59UTRs identified in this study could be utilised with the 39UTR
of the nesprin-1 giant to make KASH containing NE localized
nesprin variants. Whilst most 59UTRs are too distant from the
KASH domain for PCR amplification we were able to verify
p53KASHNesp1 (Accession number JQ754366), the smallest
nesprin-1 KASH containing isoform identified to date, with a
molecular weight of 53 kDa. p53KASHNesp1 uses the N1-59E138
alternative start site which was detected in heart, spleen, lung,
brain, prostate, PBL, small intestine (SI), ovary and liver cDNA
(Figure 1C). Although full-length p53KASHNesp1 could not be
detected in a range of primary and transformed cell lines it was
detected in tissues including heart, spleen and peripheral blood
leukocytes (PBL) (Figure 4F). Flag-p53KASHNesp1 cloned from
heart cDNA confirmed NE localization when transfected into
U2OS cells (Figure 4A,B).
Nesprin Calponin Homology Domain containing Isoforms
Next we set out to identify the sub-cellular localizations of
KASH-less nesprin variants composed of SRs or CH domains.
p56CHNesp1 and p32CHNesp2 are two nesprin CH-domain
containing variants with a Mw suitable for PCR amplification
and cloning (Accession numbers JQ740783 and JQ754367
respectively) (Figures 4A,E). p56CHNesp1 initiates with the most
upstream nesprin-1 UTR utilised by the nesprin-1 giant and
terminates with N1-39E14, encoding a protein that possesses the
CH domains and the first SR of nesprin-1. p32CHNesp2 terminates
upstream of the first SR coding exon and is therefore the only
known nesprin variant to date which lacks any SRs. Interestingly
we observed differential sub-cellular localizations when
p56CHNesp1 was transfected into transformed and primary cell
lines. In U2OS cells p56CHNesp1 surprisingly localized to the
nucleolus while in HDFs it associated with actin stress fibres and
focal adhesions (Figure 4C,D). Whilst p56CHNesp1 expression was
ubiquitously detected in all cell lines examined, expression of
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p32CHNesp2 was limited to PBL, MBs and U2OS cells (Figure 4F).
Unlike p56CHNesp1, p32CHNesp2 localized to focal adhesions
when ectopically expressed in its native U2OS cells (Figure 4E).
Nesprin Central Rod Isoforms
Multiple 59 and 39 UTRs were identified in the nesprin-1 gene
between exons 83 and 90, suggesting that it is a region where
multiple variants are generated (Figure 5A). Using RACE we
identified a 59UTR where the first coding exon was exon 83 (N1-
59E83) and a 3‘UTR where the final coding exon was exon 90
(N1-39E90) (Figure 1A). Furthermore online databases revealed an
additional 59UTR associated with exon 84 (N1-59E84) and a
previously described Kazusa clone KIAA1262. The KIAA1262
sequence includes exons 77 to 87 and terminates in a 39UTR
where the final coding exon is exon 87 (N1-39E87). The
identification of these new UTRs together with the pre-existing
nesprin-1b1 and nesprin-1b2 59UTRs confirms that this is a region
of nesprin with the ability to generate multiple alternative
transcripts (Figure 5A).
Hypothetically these UTRs could generate 7 nesprin-1 splice
variants by alternative initiation and termination of the four
59UTRs with the three 39UTRs (Figure 5A). To test this, PCR
amplification from 59 to 39UTRs were carried out in multiple
tissue cDNA panels to see if any of the variant messages were
transcribed. p50Nesp1 (Accession number JQ740784) expression
was ubiquitous while expression of the p41Nesp1 (Accession
number JQ740786), p31Nesp1(Accession number JQ740785),
p23Nesp1 (Accession number JQ754364) and p12Nesp1 (Accession
Figure 1. Identification of novel nesprin UTRs. A) cDNA ends identified by 39 and 59 RACE from Brain, Skeletal Muscle (SkeMus) and HeLa cDNA
libraries. B) DNA sequencing results suggest that nesprin isoforms terminate with unique C-terminal ends absent from the giant isoforms as a result of
intron retention. For example, isoforms utilising the N1-39E90 UTR terminate with ‘AGAGYPHQ’ amino acids, giving it a unique fingerprint. Blue
sequences show the coding regions of exons 90 and 91, black sequences show intronic regions and red sequence indicates a stop codon. C)
Validation and tissue specificity of nesprin-1 UTRs identified on online databases and by RACE were confirmed by PCR amplification from a multiple
tissue cDNA panel and DNA sequencing. Nesprin-1 PCRs were carried out when UTRs were identified on cDNA panels available at the time and are
therefore organised into 3 separate sections. D) Validation and tissue specificity of nesprin-2 UTRs identified on online databases and by RACE were
confirmed by PCR amplification from a multiple tissue cDNA panel and DNA sequencing. Nesprin-2 PCRs were carried out when UTRs were identified
on cDNA panels available at the time and are therefore organised into 3 separate sections. Small Intestine and Peripheral Blood Lymphocytes have
been abbreviated as ‘SI’ and ‘PBL’ respectively for all cDNA panels.
doi:10.1371/journal.pone.0040098.g001
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number JQ754365) variants was restricted to certain tissues.
p30Nesp1 and p20Nesp1 failed to amplify and therefore are probably
not expressed (Figure 5A). When p50Nesp1 was expressed in U2OS
cells it localized to and polymerized microtubules while all the
other isoforms displayed a diffuse cytoplasmic and nuclear
localization (Figure 5B for Flag- p50Nesp1 and Flag- p31Nesp1).
All other isoforms are shown in Figure S1A). p23Nesp1 and
p12Nesp1 both localized to and disrupted nucleolar morphology
when expressed in HDFs, causing fibrillarin to redistribute into
peri-nucleolar caps, while the slightly larger p31Nesp1 localized
with fibrillarin without affecting its localization (Figure 5C). When
p41Nesp1 was expressed in HDFs, it displayed diffuse cytoplasmic
localization and also concentrated around the ER (Figure S1B).
Another central rod variant Nesprin-1 p55Nesp1, is composed of
a single SR and lacked both the CH and KASH domains
(Figure 5D). p55Nesp1 was detected in the kidney, spleen and PBL
by PCR and displayed diffuse cytoplasmic localization when
transfected into U2OS cells (Figure 5D).
Nesprin Isoform Expression is Highly Adaptable
To further confirm the validity of the novel variants and
because previous evidence indicates that nesprins have the ability
to self-compensate we decided to investigate how knocking down a
sub-set of transcripts would effect expression levels of variants
encoded by nearby transcripts [30]. By designing an siRNA
targeting exon 90 (si-90) we were able to monitor by qRT-PCR
the levels of transcripts terminating with N1-39E87 and N1-39E90
UTRs (Figure 6). In theory this siRNA should target all transcripts
terminating with N1-39E90 but have no effect on N1-39E87
terminating transcripts as this termination site is located to the 59
end on exon 87. As expected, si-90 significantly reduced levels of
N1-39E90 expression but more interestingly also significantly
knocked down levels of the transcripts terminating with N1-39E87.
Furthermore si-136, an siRNA designed towards the KASH
domain of nesprin-1 increased expression of N1-39E87 transcripts,
showing that perturbations in the expression of one transcript can
influence expression of other downstream transcripts. Conversely
no change in N1-39E90 was detected with si-136, however both
siRNAs knocked down levels of nesprin-1 KASH expressing
transcripts (Figure 6).
Nesprin and Alternative Splicing of Cassette Exons
Next we set out to determine whether any of the 100 plus exons
of the nesprin-1 and nesprin-2 genes have the ability to undergo
alternative splicing to increase further variant diversity. As a
starting point we used nesprin EST and nucleotide databases to
look for potential splicing events which identified cassette exons 69,
93 and 145 for nesprin-1 (Table 2). Exon 69 is a potential isoform
Table 1. UTRs identified through online databases.
Gene UTR 59 or 39 Location NCBI Accession
Verified by
PCR
Nesprin-1 N1-59I14/15 59 Intron 14–15/ DA151121, CR933676, AK055440, BG197747, DB324328 +
Nesprin-1 N1-39E18 39 Exon 18 BC028616, DB545136, DB540697, DB538738 +
Nesprin-1 N1-59I18/19 59 Intron 18–19 DA337073 2
Nesprin-1 N1-39E20 39 Exon 20 DB540697, DB545136, DB538738 2
Nesprin-1 N1-59I21/22 59 Intron 21–22 DA337073 +
Nesprin-1 N1-39E25 39 Exon 25 DA151121, CR933676, AK055440, BG197747, DB324328 +
Nesprin-1 N1-39E37 39 Exon 37 AL713682 +
Nesprin-1 N1-59E44 59 Exon 44 DB300122 2
Nesprin-1 N1-39E62 39 Exon 62 BC039121,CA425673,AW300380, BG203678, BG210617, DB516174,
CA441052, BX093712,CA312508, DB319424, AA227537,AI866946
+
Nesprin-1 N1-59E84 59 Exon 84 BU461222 2
Nesprin-1 N1-39E87 39 Exon 87 AB033088 2
Nesprin-1 N1-59E92 59 Exon 92 CJ462692, DA229059, DA227411, DA212433, DA509325, DB059554,
DA802484, EE366817, DA241105, DA338782, DB289567, DA116814,
DA493491
+
Nesprin-1 N1-59E97 59 Exon 97 BF740426, BF726175 2
Nesprin-1 N1-59I128/129 59 Intron 128–129 AK304825 +
Nesprin-1 N1-59I132/133 59 Intron 132–133 DA632075 2
Nesprin-1 N1-59E138 59 Exon 138 DA827648 +
Nesprin-2 N2-39E9 39 Exon 9 BC042134, BC071873 +
Nesprin-2 N2-39E46 39 Exon 46 BX648234 +
Nesprin-2 N2-59E49 59 Exon 49 BC036941, BI860943,AA247756 +
Nesprin-2 N2-59E63 59 Exon 63 CV571029 2
Nesprin-2 N2-59I 91/92 59 Intron 91–92 DA226447 +
Nesprin-2 N2-59I 99/100 59 Intron 99–100 DB089560, BM805144, DB088145, DA810994, DA725349, DA101036,
DB152052, DA196319, DA706514, DA186088, DA106538, DA093934,
DA334037, DA333629, DB063748, DA222451, DA230417, DA097798,
DA094004, DA522676
+
Table listing all potential UTRs identified through available online databases.
doi:10.1371/journal.pone.0040098.t001
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or tissue specific coding region located between exons 6 and 7 and
encodes a 7 amino acid peptide insert at the end of the first CH
domain of nesprin-1 (See Figure S2A for nesprin-1 genomic map
with cassette exon). Exon 93 contributes an additional 47 amino
acids to a SR of the central rod domain while exon 145 encodes a
peptide sequence at the C-terminal region of the KASH domain.
Several alternatively spliced exons, were also identified in
nesprin-2 using the same data mining procedure, including
cassette exons 1019, 1079 and 114 and 59 alternatively spliced
exons 110 to 113 (Table 2). Unlike nesprin-1, the identified exons
were all located near the C-terminal half of the nesprin-2 giant.
Splicing of exons 1019, 1079, 110 to 113 and 114 would alter the
length of the coiled-coil regions surrounding the two SR preceding
the KASH domain while removal of the first 31aa encoded by
exon 113 would eliminate the final SR before the KASH domain.
As with exon 69 of nesprin-1, exon 1019 and 1079 of nesprin-2
represent coding regions which maybe isoform or tissue specific
and are located between exons 101 to 102 and 107 to 108
respectively. (See Figure S2B for nesprin-2 genomic map with
cassette exons).
To identify whether these splicing events did indeed take place
we designed primers to exons either side of the cassette exons and
carried out PCR analysis from U2OS and VSMC cDNA libraries
(Figure 7A,B). For nesprin-1, two PCR products appeared from
U2OS and VSMC libraries when PCR amplification was carried
out across exon 93; the larger of the two bands included exon 93
and the smaller band with the exon excluded. Nesprin-2 splicing
showed more tissue specificity than nesprin-1, with PCR products
including and excluding cassette exon 1079 expressed in U2OS
cells at equal quantities while in VSMCs exon 1079 was exclusively
expressed with no band detected for transcripts with the exon
excluded expressed. Furthermore in VSMCs, transcripts with
exons 110–113 removed were detected as well as transcripts with
the exons included, although transcripts with the exons included
seem to be transcribed in greater abundance. U2OS cells only
expressed transcripts with the exons included.
Although splicing of cassette exons 69 of nesprin-1 and exon 28–
31, 1019 and 114 for nesprin-2 failed to be detected in this set of
PCRs, examination of a wider array of cells and tissues is required
to determine whether the splicing events listed in the databases
occur.
Nesprin DKASH Isoforms
The search for potential splicing events for nesprin also revealed
splice events that eliminate the KASH domain. Alternative
splicing of cassette exon 145 of nesprin-1, results in a frame shift
that removes the KASH domain to create Nesprin-1DKASH (N1-
DKASH) (Figure 8A). Though the same 39UTR adjacent to exon
146 is shared between KASH domain and N1-DKASH sequences,
the removal of exon 145 results in a change in the open reading
frame of N1-DKASH variants and therefore they terminate with a
novel 11aa tail: VHKRWLRFLPF rather than the RYTNGPPPL
sequence utilized by KASH containing variants. Expression of N1-
DKASH isoforms was detected in all tissue cDNA examined by
PCR, suggesting that this splicing and resultant variants are
ubiquitously expressed (Figure 8D). When the DKASH variant of
p53KASHNesp1 (p53DKASHNesp1) lacking exon 145 was trans-
fected into U2OS cells it no longer resided at the NE, but instead
displayed strong nuclear matrix localization and weak cytoplasmic
staining (Figure 8A).
Unlike N1-DKASH, nesprin-2 possesses two mechanisms for
creating DKASH variants (Figure 8B,C). Like nesprin-1, genera-
tion of N2-DKASH1 occurs via the removal of cassette exons 110
to 113 but uses the same 39UTR as the KASH variant. This
splicing event results in a change in the ORF and therefore N2-
DKASH1 terminates with a GIAGHSATPPA amino acid
sequence rather than the YPMLRYTNGPPPT sequence used
by KASH containing isoforms. N2-DKASH2 is created by a novel
39UTR immediately adjacent to the 39 end of exon 115. N2-
DKASH2 splicing truncates larger isoforms without generating a
novel C-terminal peptide. The N2-DKASH1 splicing was pre-
dominantly detected in the brain and kidney with smaller amounts
being amplified from the heart, where the lower band represents
the removal of the cassette exons promoting N2-DKASH1
formation (Figure 8D). The N2-DKASH2 termination was
detected in the heart and spleen only (Figure 8D).
Discussion
Nesprins as Adaptable, Tissue Specific, Intracellular
Scaffolds
This study has demonstrated that nesprins, by generating
variants via alternative transcriptional initiation and termination
show localizations and therefore functions independent of their
original description as NE linkers and scaffolds. Although nesprin-
1 has the potential to generate more isoforms than nesprin-2, with
more UTRs spread across the gene, the nesprin-2 isoforms are
primarily N-terminal truncations that would retain the KASH
domain. This suggests that nesprin-1 may have more functions
beyond the NE than nesprin-2 or that sequences near the highly
conserved C-terminus of nesprin-2 are important for cell function
[29]. To our knowledge, the potential combinations of UTRs and
exon splicing are unlimited. This combined with the ability of
nesprins to dynamically regulate variant expression would allow
cells to fine-tune their nesprin isoform repertoire as needed to
maintain and restore homeostasis following stress or to regulate
tissue-specific signalling pathways [31]. As a proof of principle we
were able to show that nesprin transcription appears to be highly
adaptable with a feedback loop regulating nesprin variant
expression. For example we demonstrate using siRNAs that by
knocking down a region of nesprin-1 near the KASH domain we
were able to upregulate expression of N1-39E87 UTR transcripts.
Furthermore nesprin-2 CH domain knockout mice display an
altered expression pattern for specific nesprin-2 C-terminal
isoforms in certain tissues to compensate for the loss of nesprin-2
giant or nesprin-2 actin binding domain isoforms [30]. These
observations suggest that nesprin alternative transcript generation
is highly flexible and more complex than a simplified tissue-specific
expression model.
Generation, Regulation and Function of Novel Tissue
Specific Nesprin Variants via Alternative Initiation and
Termination
Using 59 and 39RACE as well as sequences in the EST
database, followed by PCR amplification and DNA sequencing,
we identified multiple novel sequence variants for nesprin-1 and -
2. RT-PCR was used to establish the existence of mRNA
Figure 2. Potential nesprin-1 isoforms. A) Genomic map of the nesprin-1 gene highlighting the positions of the nesprin-1 UTRs identified to
date. B) Proposed nesprin-1 isoforms created by alternative transcription. SRs are numbered and shown according to the scheme of Simpson and
Roberts 2008 and are shown to scale.
doi:10.1371/journal.pone.0040098.g002
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Figure 3. Potential nesprin-2 isoforms. A) Genomic map of the nesprin-2 gene highlighting the positions of the nesprin-1 UTRs identified to
date. B) Proposed nesprin-2 isoforms created by alternative transcription. SRs are numbered and shown according to the scheme of Simpson and
Roberts 2008 and are shown to scale.
doi:10.1371/journal.pone.0040098.g003
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transcripts for full-length short isoforms or for the novel UTRs of
potentially larger variants. The multiple UTRs allow nesprins to
express a large number of sequence variants via alternate initiation
and termination and many of these were generated in a tissue
specific manner. Therefore, in addition to the novel UTR’s
verified in this study it is likely that by performing RACE in a
greater collection of cells/tissues we may be able to identify further
nesprin alternate initiation and termination sites.
To date, the mechanisms of tissue specific generation of nesprin
variants has not been studied. Analysis of the human transcrip-
tome shows a direct correlation between alternative promoter use
and alternative splicing [32]. Alternative promoters can produce
mRNAs with different 59UTRs that encode the same protein,
distinct N-termini, and even different proteins from the same locus
[33,34,35,36]. The identification of multiple, novel 59UTRs in
both nesprin-1 and -2 indicated the presence of several internal
alternative promoters. The existence and regulation of alternative
nesprin promoters has not yet been explored but this study
suggests that these promoters are utilised in a tissue specific
manner. Furthermore, because many individual variants have
unique pairs of 59 and 39UTRs, additional control and regulation
of variant expression can be maintained. The 59UTR is an
important regulator of mRNA translation and can contain
regulatory motifs/sequences which affect the rate of translation
as well as containing a kozak sequence upstream of the start codon
which plays a major role in determining the translational strength
of the transcript [37,38]. The 39UTR of mRNA transcripts can
play a role in mRNA localization, stability, and translation
[39,40,41,42]. For example, binding of miRNAs to partially
complementary sequences in the 39UTR can result in de-
adenylation and translational inhibition or destruction of the
target mRNA [43,44]. A RegRNA scan of both the nesprin 59 and
39UTRs for regulatory RNA motifs detected several potential
miRNA binding sites which were transcript specific and could
potentially regulate variant translation (data not shown).
Importantly, we showed that many of the variants generated
through retained introns had generated unique peptide sequences.
It is highly likely that these sequences expose new functional
domains that give the variants additional localization signals or
motifs that play an important role in their function. For example,
ELM analysis predicts a novel retinoblastoma (Rb) interacting
motif found in cell cycle regulatory proteins at the C-terminal end
of p220CHNesp2 while the N-terminus of p931KASHNesp1
contains a potential N-myristoylation site, a post-translational
modification which facilitates membrane anchoring [45,46,47].
ELM analysis also predicts multiple PKA, MAPK and CDK
phosphorylation sites in the unique sequences of p32CHNesp2,
p56CHNesp1 and p55Nesp1. To further explore this hypothesis
yeast-2-hybrid analyses or co-immunoprecipitation assays will be
required to identify binding partners for specific nesprin variants.
The ultimate validation for each proposed variant will be the
detection of their translation and expression by western blotting.
Post-translational modifications such as phosphorylation, sumoy-
lation, and enzymatic cleavage may be partially responsible for the
range of western bands often visualized using the currently
available anti-nesprin antibodies [1,17,48]. Designing isoform-
specific antibodies will help to distinguish between modifications
and splicing.
Alternative Splicing of Cassette Exons may Diversify
Nesprin Function and Localization
In addition to alternative initiation and termination, we showed
that some of the cassette exons located in the EST database are
indeed valid. It is unclear whether these splice events occur in
multiple variants or are isoform specific but they are likely to
substantially increase nesprin diversity, likely in a tissue specific
manner. This notion was supported by the observation that while
some splice events occurred in the majority of cell lines, some
events seemed to be cell type specific. For example unlike the
nesprin-1 DKASH which was detectable in all cells tested, the
splicing event of cassette exons which generate nesprin-2 DKASH
seem to be very tissue specific. Furthermore the ability for nesprin-
2 to generate DKASH variants via 2 different mechanisms, one by
the utilization of a unique 39UTR and another by the splicing of
exons 110–113 suggest that the C-terminal ends of the DKASH
variants may serve unique tissue specific functions at sites away
from the NE.
Although in this study we did not look specifically at the effects
of structure, function and localization of nesprin variants with and
without alternate splicing of the cassette exons we did show that
some of these splicing events also created unique peptides.
Nesprin-1 exon 93 encodes a unique 47 amino acid peptide
sequence and nesprin-2 exon 1079 encodes a unique 23 amino
acid peptide. Although these peptide sequences are not very large
they may be capable of encoding novel localization signals or
binding sites for interactions with other proteins. Our next aim will
be to create nesprin variants with and without these exons so we
can identify their putative roles in nesprin function.
However we were able to show that KASH-less nesprin
isoforms displayed subcellular localizations which varied depend-
ing on the cell lines they were expressed in. In U2OS cells
p56CHNesp1 localized to the nucleolus while the same protein
localized along actin cables and focal adhesions in HDFs.
Currently we do not understand what determines this differential
change in subcellular localizations but we speculate that the
presence of endogenous p32CHNesp2 at focal adhesions in U2OS
cells (p32CHNesp2 is not expressed in HDFs but is expressed in
U2OS) is enough for p56CHNesp1 function to become redundant
at focal adhesions in U2OS. Furthermore we suspect that
differences in the actin cytoskeleton may play a role in differential
localization of p56CHNesp1. The nesprin-1 CH domains contain
two nuclear localization signals which may be utilized in cells with
low actin levels such as U2OS cells but not in structural cells such
as HDFs where there is plenty of actin for the protein to bind to
[49]. Alternatively, potential p56CHNesp1 phosphorylation events
predicted by ELM analysis may occur in a tissue specific manner
which may contribute to the differences seen in localizations
between the two cell types. Similarly differential sub-cellular
localizations were seen when central rod isoforms p12Nesp1,
Figure 4. Cloning and expression of novel Nesprin KASH and CH isoforms. A) Schematic representation of p53KASHNesp1 (Accession
numberJQ754366) and p56CHNesp1 (Accession number JQ740783) relative to the nesprin-1 giant. B) p53KASHNesp1 localizes to the NE when
transfected into U2OS cells. C) Nesprin-1 Flag-p56CHNesp1 localized to the nucleolus when transfected into U2OS cells. D) Nesprin-1 Flag-p56CHNesp1
localizes to actin stress fibres and with Focal Adhesion Kinase (FAK) at focal adhesions when transfected into Human Dermal Fibroblasts (HDFs). E)
Nesprin-2 Flag-p32CHNesp2 (Accession numberJQ754367) co-localized with FAK at focal adhesions when transfected into U2OS cells. F) p53KASHNesp1
expression was not detected by PCR in U2OS, Human Dermal Fibroblasts (HDFs), Vascular Smooth Muscle Cells (VSMCs) or Myoblasts (MBs), however
it was detected in the heart, spleen and peripheral blood leukocytes (PBL). p56CHNesp1 was detected in all cells and tissues examined whereas
p32CHNesp2 was limited to U2OS cells, MBs and PBL.
doi:10.1371/journal.pone.0040098.g004
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p23Nesp1 and p31Nesp1, were transfected into U2OS and HDFs. In
U2OS cells all isoforms displayed diffuse cytoplasmic localization
while in HDFs nucleolar localization was observed. Differences in
post-translational modifications could vary between the two cell
lines or the proteins may have different binding partners in each
cell line which could contribute to differential localizations.
Ultimately the localization of these isoforms would have to be
monitored in cells that express the variant endogenously.
Isoforms and Disease
Multiple nesprin mutations have been identified in Emery
Dreifuss Muscular Dystrophy (EDMD), Dilated Cardiomyopathies
(DCM), autosomal recessive arthrogryposis (ARA) and autosomal
recessive cerebellar ataxia (ARCA1) [15,17,18,50,51]. The nesprin
mutations promoting EDMD and DCM presumably affect LINC
nesprin variants resulting in abnormal nuclear morphology and
function.
ARA is caused by an A to G mutation in a splice acceptor site,
resulting in retention of intron 136 of nesprin-1 [51]. This
mutation produces a premature stop codon and therefore the
nesprin-1 giant, nesprin-1b and nesprin-1a isoforms should lack
the KASH domain. Conversely these patients appeared to have no
defects in nuclear morphology or lamin and emerin localization,
suggesting other nesprin gene products or p53KASHNesp1 which
should not be effected by this mutation maybe enough to keep the
nucleus intact.
ARCA1 is a neurological disease characterized by irregular gait
and lack of limb coordination [18]. Five different mutations giving
rise to ARCA1 were identified within the central spectrin rod of
nesprin-1, upstream of the KASH variants identified so far. The
A310067G mutation which effects the invariant A of the AG splice
acceptor site at the junction of exon 85 and intron 84 results in the
formation of a pre-mature stop codon and therefore will effect
production of not only the p40, p50, p31 and p23 nesprin-1
proteins identified in this study but also other variants terminating
with the N1-39E87 and N1-39E90 ends in there native tissues/
cells. Although many diseases associated with nesprins so far
suggest that NE nesprins are involved, ARCA1 patients appear to
have no nuclear defects, suggesting that nesprin associated
signalling pathways beyond the NE may be significantly hindered
and potentially causative in the disease.
Materials and Methods
Identification of Novel UTRs
Rapid Amplification of cDNA Ends (RACE) on Brain, HeLa
and Skeletal muscle Marathon-Ready cDNA libraries using the
Advantage-2 PCR kit (Clontech) and gene specific primers was
performed (Table S3). Resultant PCR fragments were cloned into
pGEM-T easy vector (Promega) and sequenced (Gene Service).
These sequences were then BLASTED against the human genome
and novel cDNA ends were further analyzed.
Additional novel UTRs for nesprin-1 and nesprin-2 were
identified by screening the NCBI expressed sequence tag (EST)
database with consecutive, 500 bp-overlapping 1 kb Nesprin-1
and Nesprin-2 sequences covering the entirety of the giant isoform
cDNAs. Tissue specificity of novel UTRs was determined by
performing PCR amplification in a multiple tissue cDNA
collection (Clontech). 30 PCR cycles were performed on 0.5 ul
of cDNA followed by a further 15 cycles on 1 ul of the amplified
Figure 5. Nesprin-1 Central rod isoforms. A) Nesprin-1 isoforms p31Nesp1, p23 Nesp1, p12 Nesp1, p50 Nesp1, p41 Nesp1, p30 Nesp1 and p20 Nesp1 are
potential variants which could be generated through alternative initiation and termination using UTRs located between exons 83 and 90. All isoforms
except p30Nesp1 and p20Nesp1 PCR amplified from at least one tissue examined. B) p50Nesp1 localized to and polymerized microtubules in U2OS cells.
p31Nesp1 displayed a diffusive localization when transfected into U2OS cells. See Figure S1A for diffusive localization staining of p23Nesp1, p12Nesp1 and
p41Nesp1. C) p23Nesp1 and p12Nesp1 promoted nucleolar cap formation in HDFs while p31Nesp1 localized to the nucleolus without causing any nucleolar
disruption. D) p55Nesp1 localized diffusively around the cytosol when transfected into U2OS cells and was detected in the kidney, spleen and
peripheral blood leukocytes (PBL) by PCR.
doi:10.1371/journal.pone.0040098.g005
Figure 6. Nesprin-1 expression is highly adaptable. Expression levels of N1-39E87, N1-39E90 and nesprin-1 KASH domain were monitored post-
siRNA knockdown using siRNAs targeting exons 90 and 136 of the nesprin-1 gene. As demonstrated si-136 increased expression of N1-39E87 whereas
si-90 reduced it’s expression. *p,0.01, ANOVA analysis, 95% confidence interval.
doi:10.1371/journal.pone.0040098.g006
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product. Specificity of the PCR products were validated by DNA
sequencing. Primers used for UTR expression can be found in
Table S4. Primers used for cassette exon splicing and detection of
nesprin DKASH variants can be found in Tables S5 and S6
respectively.
Plasmids
Isoforms p53KASHNesp1, p56CHNesp1 and p50Nesp1 were Taq
PCR amplified from tissue cDNA and cloned into pGEM-T
Easy. The pGEM-T plasmids were subsequently used as
templates for Pfu amplification with primers containing restric-
tion sites and ligated into pCMV-Tag2 vector. p53DKASHNesp1
was cloned using inverse PCR with Pfu off the Flag-
p53KASHNesp1 vector while p50Nesp1 served as a template for
the inverse PCR and creation of p41Nesp1 and p30Nesp1. The
Kazusa cDNA clone KIAA1262 served as a template for PCR
amplification and cloning of p31Nesp1, p23Nesp1 and p12Nesp1
into a pCMV-Tag2 (Clontech). p32CHNesp2 was PCR amplified
from IMAGE clone 5478637 and cloned into pCMV-Tag2 as
described.
Tissue culture
Normal human dermal fibroblasts (HDF) and osteosarcoma
cells (U2OS) were obtained from American Tissue Culture
Table 2. Cassette exons identified through online databases.
Nesprin Exon Splicing Peptide Sequence Accession
Nesprin-1 Exon 69 Cassette SMHRGSP CF552114







Nesprin-1 Exon 145 Cassette VHKRWLRFLPF* BX647837
Nesprin-2 Exons 28–31 Cassette Premature stop codons AU185086
Nesprin-2 Exon 101’ Cassette PTHGVQQKYYLMMTKNAMFIREEVFQFFPMTMHFLFINVIFPKLGN
CITIIIKGQDSRDPTSLQATTALAGLYQLGRQGSTARY
CR749324








Nesprin-2 Exon 114 Cassette NPASPLPSFDEVDSGDQPPATSVPAPRAK BE795270
An online scan of the EST and nucleotide databases indicated that the nesprin-1 and nesprin-2 genes underwent extensive alternative splicing and this was verified
using PCR (Figure 7A,B).
*Represents a stop codon for nesprin-1 exon 145 and nesprin-2 exons 110–113.
doi:10.1371/journal.pone.0040098.t002
Figure 7. Identification of nesprin-1 and nesprin-2 splicing events. A) PCR amplification across splice sites was carried out from cDNA
isolated from U2OS cells. Splicing of exon 93 for nesprin-1 was observed as was the splicing for nesprin-2 exon 107’. B) PCR amplification across splice
sites was carried out from cDNA isolated from VSMCs. Splicing of exon 93 for nesprin-1 was observed. Exon 107’ was retained in all nesprin-2
transcripts while splicing of exons 110–113 was also observed in these cells. +Represents bands with exon(s) excluded.
doi:10.1371/journal.pone.0040098.g007
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Collection (ATCC). The cells were passaged after reaching 70%
confluency and maintained in DMEM complete media (Sigma)
supplemented with 10 units/mL penicillin, 10 mg/mL strepto-
mycin, 200 mM L-glutamine and 10% FBS.
Transfections
For Flag-tagged construct expression, 16106 HDFs or U2OS
cells were electroporated with 1 mg plasmid DNA using an Amaxa
Nucleofector and cultured on coverslips for 16 hours.
Immunofluorescence
Cells were fixed for 5 minutes in 3.7% paraformaldehyde in
PBS followed by 2 min permeabilization with 0.5% NP-40 in
PBS. The coverslips were incubated with blocking solution (1%
BSA) for 1 hour at RT. The primary antibodies were diluted in
blocking solution and applied to the coverslips for 1 hour at
RT, followed by a 1 hour RT incubation with fluorescent dye-
conjugated secondary antibodies (Invitrogen) diluted in blocking
solution. The coverslips were washed with PBS, mounted onto
Figure 8. Generation of nesprin-1 and nesprin-2 DKASH variants. A) Nesprin-1DKASH is generated through the removal of cassette exon 145,
resulting in disruption of the KASH domain. Ectopically expressed p53DKASHNesp1 fails to localize to the NE in U2OS cells and is strongly concentrated
within the nucleus and weakly in the cytosol. B) Nesprin-2DKASH1 is generated though the removal of exons 111–112 through the splicing event
described in the previous section (splicing shown in red). C) Nesprin-2DKASH2 is generated through utilization of an alternative 39UTR juxtaposed to
exon 115. D) PCR-based tissue screen for DKASH variants shows that the removal of exon 145 for Nesprin-1DKASH is detected in a wide array of
tissues. Nesprin-2DKASH1 splicing is detected pre-dominantly in the brain and kidney with small amounts also detected in the heart. +denotes the
spliced Nesprin-2DKASH1 product. Nesprin-2DKASH2 was detected in the heart and spleen only. Peripheral Blood Leukocytes (PBL).
doi:10.1371/journal.pone.0040098.g008
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slides with medium containing DAPI, and visualized using a
Leica SP5 confocal microscope or a Zeiss Axioskop microscope.
siRNA Knockdown and qRT-PCR
U2OS cells were transfected with siRNAs for nesprin-1 or
control siRNA using hiperfect transfection reagent (Quiagen) as
described by the manufacturer. Three days post-transfection total
RNA was obtained from cells using Triazole RNA STAT-60 and
phenol chloroform extraction. 2 mg of total RNA was reverse
transcribed using AMV Reverse Transcriptase (Promega) accord-
ing to the manufacturer’s instructions. qPCR was performed in a
20 ml reaction containing cDNA per 16 SYBR Green PCR
master mix (Eurogentec) and 0.1 mM of each primer. PCR
products were amplified, N1-39E87 primers (forward, 59-
TCTCCAAGCTCAATCAGGCAGCAT -39 and reverse, 59-
CACAGCCCTCTAAGTGTTGTGTCA -39), N1-39E90 primers
(forward, 59- AGTTGGACGTCTCAGTCTCAAGGA -39 and
reverse, 59- TTTGATGGCTGAGCCCACACAATG -39),
KASH primers (forward, 59-CGAGGCAAGTGTAGTCTCT-
CACAG-39 and reverse, 59-AGGGCCATTCGTGTATCTGAG-
CAT-39) and GAPDH primers (forward, 59-CGACCACTTTGT-
CAAGCTC-39 and reverse, 59-
CAAGGGTCTACATGGCAAC-39). The cycling parameters
were 94uC for 15 seconds followed by a single step annealing
and extension at 60uC for 60 seconds. Amplifications were
performed on RotorGene-3000 (Corbett). Fold changes between
samples were calculated by the delta-delta CT method.
Supporting Information
Figure S1 Localizations of p23Nesp1, p12Nesp1 and
p41Nesp1. A) p23Nesp1, p12Nesp1 and p41Nesp1 displayed diffusive
cytoplasmic localization when transfected into U2OS cells. B)
p41Nesp1 displayed diffusive localization and concentrated around
the ER when transfected into HDFs.
(TIF)
Figure S2 Schematics of nesprin-1 and nesprin-2 cas-
sette exons. A) Nesprin-1 genomic map showing the location of
nesprin-1 cassette exon 69 (Red box). B) Nesprin-2 genomic map
showing the location of nesprin-2 cassette exons 101’ (orange box)
and107’ (Purple box).
(TIF)
Table S1 UTR combinations used to generate potential
nesprin-1 variants. Nesprin-1 can generate multiple variants
through the use of alternative UTRs in a ‘mix-and-match’
approach. The tables highlight the UTR pairs used to generate
the potential isoforms described in Figures 2B.
(DOCX)
Table S2 UTR combinations used to generate potential
nesprin-2 variants. Nesprin-2 can generate multiple variants
through the use of alternative UTRs in a ‘mix-and-match’
approach. The tables highlight the UTR pairs used to generate
the potential isoforms described in Figures 3B.
(DOCX)
Table S3 Primers used for 59 and 39 RACE. Primers and
nested primers used for detection of novel nesprin-1 and nesprin-2
cDNA ends.
(DOCX)
Table S4 Primers used for UTR detection. Forward and
reverse primers used for detection of novel nesprin-1 and nesprin-2
UTRs. Forward and reverse primers were separated by at least 1
coding exon to control for genomic contamination.
(DOCX)
Table S5 Primers used for detection of cassette exons.
Forward and reverse primers used for detection of novel nesprin-1
and nesprin-2 cassette exons.
(DOCX)
Table S6 Primers used for the detection of DKASH
variants. Forward and reverse primers used for detection of
nesprin-1 and nesprin-2 DKASH variants.
(DOCX)
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      121 gtggtcccgg tataaaggct cgctgagcgg gtgggtcaca gcacagcttt gcagctgcgg
      181 agaaacgccc aaggccgtgc atctccagga gggcggctgg gctcccgcag tcctgcagac
      241 cgcgcccgat cccggcgaca gggcgggcgg acagccgcgc atccccgggg tcccgccgag
      301 cctgggcgca gagagccggg aggaagcgtt cgctcgcttc gccttgctgc tgggaaactg
      361 aacgaggccg agagagaagg ttcttgagtt catgtaagag gacagtctta aaacggaaga
      421 agaaaaagaa gcagttcagt ctttgggaga gctgcctcct tgttgagtgc tgcaaaggcc
      481 tggaattcat ttatgacaga atagatctag aaaagtccaa gcatgttttc tagagtggtg
      541 tagccctgtg ctgcctccag tgaagagtct cttggtgttg gcttcgtgct tccggaggga
      601 ccatggcaac ctccagaggg gcctcccggt gtcctcggga tatcgccaat gtgatgcaga
      661 ggctgcaaga tgagcaagag atagtacaaa aacgaacttt cacaaaatgg atcaactctc
      721 atctggccaa gcggaaacct ccaatggtgg tggacgatct ttttgaagac atgaaagatg
      781 gtgttaaact gcttgccctt ctggaggtcc tgtctgggca gaaactgcct tgtgaacaag
      841 gacgccggat gaagcgaatc catgctgtgg ctaacattgg cacggcactc aagttcctcg
      901 aaggaagaaa gtccatgcac agaggatcac cgattaaatt agtcaacatt aactccaccg
      961 atatagctga tggccgaccc tcaatagttc ttggattgat gtggaccatt attctatatt
     1021 tccagattga agagttgacc agcaacctgc cccagctcca gtctttgtcc agcagcgcat
     1081 cctccgtgga cagcatagtt agctctgaga ctcccagccc accaagtaaa cggaaggtga
     1141 ccaccaagat ccaaggaaat gctaagaagg ctttattaaa gtgggttcag tacacagctg
     1201 gcaagcagac tggaatagaa gtaaaagatt ttgggaagag ttggagaagc ggggttgcct
     1261 ttcattcagt tattcatgcc attcgaccgg aattggtgga cttggagaca gtgaaaggca
     1321 gatccaaccg agaaaatttg gaggatgctt tcactatcgc cgaaacagaa ctggggatcc
     1381 caagactgct agatcctgaa gacgttgatg tggataaacc agatgagaaa tctattatga
     1441 cctatgtagc ccagtttctg aaacattatc ctgacatcca caatgcaagc actgatgggc
     1501 aagaggatga tgaaatactt ccaggtttcc catcttttgc aaattctgta caaaatttta
     1561 agagagaaga cagagtaatt tttaaggaaa tgaaagtttg gatagaacaa tttgagagag
     1621 atttgacaag agcacagatg gtggaatcaa atttacagga taaatatcag tcatttaagc
     1681 acttcagagt tcaatatgaa atgaagagga aacagattga acatttaata caaccattac
     1741 acagagacgg taaattgtca cttgaccaag cattggtaaa acaatcttgg gatagagtga
     1801 cctccaggct ctttgactgg catatacagc ttgataaatc tcttcctgca cctctgggca
     1861 ccataggtgc ctggctgtac agagcggagg tggccctgag agaggaaata accgttcaac
     1921 aggtccacga ggaaacagca aacacgatac aacggaaact tgagcaacat aagaaaatag
     1981 aagcaatcag aaaagaattg ccaccagctc ccacggccac atcaacccac ctacgcaatt
     2041 gcatctgtgc ccgaatacac gctcttcact tctgttacta tgggtgaacc atctgtgctc
     2101 tgggccgagg ccaacctctc tatgtgtaca ttagatccca ccctctctcc aaaaggtaat
     2161 tcctgtcctt cctcccttct ctattttttt ctctttcttt ctttgttgga gtttactcat
     2221 ccacatacaa atatgctgcc attaactcat ctttaaaagt ctttttctta gccccacttc
     2281 ccctcccagc tactgtccaa ttttcttcct tccttttaca gcaaagctct ttgagagaat
     2341 tggctctttc ttctttctaa attctcttct ctcattcttt ctaaaatcca ttccaatcaa
     2401 gcttttatct tgccatctac catgtgaagt ttaccaggct ttgcctcatt cctcatccaa
     2461 tggccagttc tcagtcttct tacatcacct gtcacaaaca tttcacatag ttgtcccttt
     2521 acccttgaaa gactttcttt aaggcatggt ggctcatact tataatccca gcatgttgag
     2581 aagccaaggc aggaggagca catgagtcca gaagtttgag accaacctgg ccaacaaagc
     2641 gagactctgt ctctacaaaa aataaaaata aaaaattagg catagtggaa aaaaaaaaaa
     2701 aaaaaaaaaa aaaaaaaaaa
//
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                     /gene="SYNE1"
ORIGIN      
        1 tattggataa aatgttgcca agtattaggg ggttcctttc acttcacttc tgttttatcc
       61 ctgtaatgtt tctgaagcat gcaggagaaa gtgaagacta atggaaagtt ggtgaagcaa
      121 gagctgaagg accgagaaat ggtggagact cagatcaatt ctgtgaaatg ttgggttcag
      181 gaaacgaaag aatatttagg gaatccaaca atagaaatag atgctcaact tgaagaactt
      241 cagattctcc taacagaagc cacaaatcac cgacagaaca ttgaaaaaat ggcagaagaa
      301 cagaaggaga agtacttagg tctttatacc atattacctt ctgaactctc ccttcagttg
      361 gctgaagtgg cgttagatct aaagatccga gatcagatcc aagacaaaat aaaagaagtt
      421 gagcagagca aggccacgag ccaggaactc agccggcaaa ttcagaagtt agctaaagac
      481 ctcacaacta ttctaactaa gctgaaagcg aagacagata atgtagttca agctaaaact
      541 gaccaaaagg tgctgggaga ggaattagat ggctgtaatt caaagttaat ggaattagat
      601 gcagcagtac agaaattctt ggaacagaat ggccaactgg gtaagccact ggccaagaag
      661 ataggaaaac tgactgaact tcaccagcag accattagac aagctgagaa tcggctctcc
      721 aagctcaatc aggcagcatc acatttagaa gaatacaatg aaatgcttga attaattttg
      781 aagtggattg aaaaagctaa agtcttggct catggaacta ttgcatggaa ttctgcaagc
      841 cagcttcggg aacaatatat tttgcatcag accctgctag aagaatccaa agaaattgac
      901 agtgagctgg aagcaatgac tgagaaatta cagtacctca ctagcgtgta ctgtacagaa
      961 aaaatgtctc agcaagtggc agaactggga cgggagactg aggagttgcg acagatgatc
     1021 aaaattcgtt tgcagaacct ccaagatgca gctaaggata tgaaaaaatt tgaagcagag
     1081 ttgaaaaagt tacaagctgc cttggagcaa gcccaggcaa cactgacttc tccagaagtt
     1141 ggacgtctca gtctcaagga gcagctctct catcggcagc atttgttgtc tgagatggag
     1201 tcactgaagc cgaaggtgca agcagtgcag ctctgccaga gtgccctccg gatccccgag
     1261 gatgtggttg ccagcttacc tctctgtcat gctgctctgc ggctgcagga agaggccagc
     1321 cggctgcagc acaccgccat ccagcagtgt aacatcatgc aggcaggtgc agggtaccca
     1381 caccagtaga gcaattgctg atgaatcatg ggcttctttt cttagcattg tgtgggctca
     1441 gccatcaaaa cacatccagg gtgttgaatc tgacaggctg ttgtggtttt ataaaataag
     1501 gagattaaaa tgctgtcatt tggatcaccc acaaaagcct ggggaatgct atataaaaaa
     1561 tatccttggt gaaaattatc ttttagtgat atttttaaat aaataacttg taaagattaa
     1621 ttttctatga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa
//
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      301 agatcagatc caagacaaaa taaaagaagt tgagcagagc aaggccacga gccaggaact
      361 cagccggcaa attcagaagt tagctaaaga cctcacaact attctaacta agctgaaagc
      421 gaagacagat aatgtagttc aagctaaaac tgaccaaaag gtgctgggag aggaattaga
      481 tggctgtaat tcaaagttaa tggaattaga tgcagcagta cagaaattct tggaacagaa
      541 tggccaactg ggtaagccac tggccaagaa gataggaaaa ctgactgaac ttcaccagca
      601 gaccattaga caagctgaga atcggctctc caagctcaat caggcagcat cacatttaga
      661 agaatacaat gaaatgcttg aattaatttt gaagtggatt gaaaaagcta aagtcttggc
      721 tcatggaact attgcatgga attctgcaag ccagcttcgg gaacaatata ttttgcatca
      781 gaccctgcta gaagaatcca aagaaattga cagtgagctg gaagcaatga ctgagaaatt
      841 acagtacctc actagcgtgt actgtacaga aaaaatgtct cagcaagtgg cagaactggg
      901 acgggagact gaggagttgc gacagatgat caaaattcgt ttgcagaacc tccaagatgc
      961 agctaaggat atgaaaaaat ttgaagcaga gttgaaaaag ttacaagctg ccttggagca
     1021 agcccaggca acactgactt ctccagaagt tggacgtctc agtctcaagg agcagctctc
     1081 tcatcggcag catttgttgt ctgagatgga gtcactgaag ccgaaggtgc aagcagtgca
     1141 gctctgccag agtgccctcc ggatccccga ggatgtggtt gccagcttac ctctctgtca
     1201 tgctgctctg cggctgcagg aagaggccag ccggctgcag cacaccgcca tccagcagtg
     1261 taacatcatg caggcaggtg cagggtaccc acaccagtag agcaattgct gatgaatcat
     1321 gggcttcttt tcttagcatt gtgtgggctc agccatcaaa acacatccag ggtgttgaat
     1381 ctgacaggct gttgtggttt tataaaataa ggagattaaa atgctgtcat ttggatcacc
     1441 cacaaaagcc tggggaatgc tatataaaaa atatccttgg tgaaaattat cttttagtga
     1501 tatttttaaa taaataactt gtaaagatta attttctatg aaaaaaaaaa aaaaaaaaaa
     1561 aaaaaaaaaa aaaaaaaaaa aaa
//
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      121 gagctgaagg accgagaaat ggtggagact cagatcaatt ctgtgaaatg ttgggttcag
      181 gaaacgaaag aatatttagg gaatccaaca atagaaatag atgctcaact tgaagaactt
      241 cagattctcc taacagaagc cacaaatcac cgacagaaca ttgaaaaaat ggcagaagaa
      301 cagaaggaga agtacttagg tctttatacc atattacctt ctgaactctc ccttcagttg
      361 gctgaagtgg cgttagatct aaagatccga gatcagacat tggaagatct actgggaagg
      421 atgacttggc aagttcatgg tctttttata tttttgagac agagtctcgc tctgtccccc
      481 aggctggagt gcagtgaaac aatctcagct tactgcaacc tcctgggttt aagcagttct
      541 cgtgcctcag cctcccaagt agctgggatt ccaggcatgc accaccatac ccggctaatt
      601 ttttgtattt ttagtaaaaa gagacaaggt tttgccatgt tggccagcct ggtctcaaac
      661 tcctggcctc aagtgagctg cctgcctcag cctcccaaag tgctgggatt acagatccaa
      721 gacaaaataa aagaagttga gcagagcaag gccacgagcc aggaactcag ccggcaaatt
      781 cagaagttag ctaaagacct cacaactatt ctaactaagc tgaaagcgaa gacagataat
      841 gtagttcaag ctaaaactga ccaaaaggtg ctgggagagg aattagatgg ctgtaattca
      901 aagttaatgg aattagatgc agcagtacag aaattcttgg aacagaatgg ccaactgggt
      961 aagccactgg ccaagaagat aggaaaactg actgaacttc accagcagac cattagacaa
     1021 gctgagaatc ggctctccaa gctcaatcag gcagcatcac atttagaaga atacaatgaa
     1081 atgcttgaat taattttgaa gtggattgaa aaagctaaag tcttggctca tggaactatt
     1141 gcatggaatt ctgcaagcca gcttcgggaa caatatattt tgcatcaggt aaccttagga
     1201 aaaataatct ttaaaaagta accaagggca atttgattta actgggtaga ctgacacaac
     1261 acttagaggg ctgtg
//
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      661 agaatacaat gaaatgcttg aattaatttt gaagtggatt gaaaaagcta aagtcttggc
      721 tcatggaact attgcatgga attctgcaag ccagcttcgg gaacaatata ttttgcatca
      781 ggtaacctta ggaaaaataa tctttaaaaa gtaaccaagg gcaatttgat ttaactgggt
      841 agactgacac aacacttaga gggctgtg
//
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